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Scope of this thesis 
 
The congenital bleeding disorder haemophilia A is caused by a deficiency or functional 
defect of clotting factor VIII.1 The clinical picture of haemophilia has been recognised 
since historic times. Adequate treatment of this disease has only become available since 
half a century, when methods to prepare factor VIII concentrates from human plasma were 
developed. Intravenous administration of these concentrates made treatment of bleeding 
episodes possible, thus leading to a significant reduction in mortality and morbidity. In the 
last decades factor VIII concentrates have become purer and safer. Although this is of great 
benefit for most haemophiliacs, in about 25 % of the severely affected patients treatment is 
complicated by the formation of inhibiting antibodies (inhibitors) directed towards factor 
VIII. Clinically, these antibodies result in an increased bleeding tendency that does not 
respond to factor VIII replacement therapy. Patients that develop inhibitors suffer increased 
mortality and morbidity, although alternative (albeit expensive) haemostatic therapies are 
available. Gene therapy for haemophilia is currently under investigation. However, as with 
conventional therapy, this potential new treatment may give rise to an immune response 
against the transferred gene product, i.e. factor VIII.2 The development of inhibitory 
antibodies therefore remains one of the greatest challenges in the treatment of haemophilia 
A patients. Until now, limited attention has been directed at inhibitor development in 
patients mild haemophilia A. Inhibitor formation in mild haemophilia A is rare and this is 
most likely due to the presence of tolerizing amounts of endogenously synthesised factor 
VIII in these patients. It has been suggested that inhibitor formation in this group of patients 
is related to molecular defects in the factor VIII gene located in particular areas in the factor 
VIII molecule. At present, however, it is still unclear why some mild haemophilia A 
patients develop inhibitors while others do not. The aim of this thesis is to gain novel 
insight in the mechanism underlying inhibitor development in mild haemophilia A. We 
have studied the molecular properties of anti-factor VIII antibodies specific for different 
epitopes on factor VIII using phage display technology. We have also examined the role of 
HLA class II molecules in inhibitor formation in a large cohort of mild haemophilia A 
patients. To enable detailed studies of the immunological background of inhibitor 
formation, we have developed a new murine model for inhibitor development in 
haemophilia A. Before describing our own studies, we first review recent progress in the 
area of factor VIII inhibitors. 
 
Epitope mapping and mode of action of factor VIII inhibitors 
 
Inhibitory antibodies that develop in patients with haemophilia A are usually of mixed 
subclass with a dominant contribution of IgG4. Current evidence suggests that these 
antibodies recognise a restricted set of well-defined regions in factor VIII (see Figure 1). 
Major binding sites for factor VIII inhibitors have been assigned to residues Arg484-Ile508 in 
the A2 domain and residues Val2248-Ser2312 in the C2 domain.3,4 Results from two 
independent studies further suggest the presence of an antigenic site within residues 
Gln1778-Met1823 in the A3 domain of factor VIII.5,6 Functional studies performed with 
purified IgG derived from patient’s plasma have shown that anti-A2 and anti-A3 antibodies 
interfere with complex assembly between factor VIIIa and factor IXa.5,6,7 Antibodies 
directed against the C2 domain have been shown to limit binding of factor VIII to 
phospholipid membranes.8  
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Although there is general agreement on the presence of three major binding sites for 
inhibitory antibodies on factor VIII, a number of reports have challenged the simplicity of 
the scheme presented in Figure 1A. A new mechanism for inactivation of factor VIII by 
human antibodies has been proposed that is based on the capacity of human antibodies to 
proteolytically inactivate factor VIII.9 These so-called catalytic antibodies inactivate factor 
VIII by processing at different sites in both the heavy and the light chain. The reaction 
kinetics of these catalytic antibodies are slow compared to those of proteolytic enzymes like 
thrombin, factor Xa and activated protein C. Therefore, it remains to be determined to what 
extent catalytic antibodies contribute to factor VIII inactivation “in vivo”. Strikingly, 
several groups have been able to detect anti-factor VIII antibodies in plasma of healthy 
individuals.10,11 The clinical relevance of these anti-factor VIII antibodies is at present not 
entirely clear. A recent report suggested that factor VIII inhibitors occurring in patients 
with haemophilia A originate from the expansion of pre-existing B cell clones that produce 
low levels of “natural” anti-factor VIII antibodies.12  
So far, most studies on the properties and presence of factor VIII inhibitors have relied 
on heterogeneous mixtures of IgG molecules present in plasma of inhibitor patients. From a 
biochemical point of view the use of polyclonal populations of IgG presents an undesirable 
complexity that may interfere with proper characterisation of these antibodies. Two 
complementary approaches have been used to circumvent this potential problem. Epstein 
Barr virus immortalization has been used to isolate two human monoclonal antibodies 
directed against the light chain of factor VIII. The epitope of one of these antibodies 
designated 2C11 has been mapped to C2 domain of factor VIII. Antibody 2C11 has been 
shown to interfere with binding of factor VIII to phospholipids.13 Recently, the crystal 
structure of a Fab fragment of 2C11 in complex with the C2 domain has been obtained 14. 
Residues in the C2 domain that interact with monoclonal antibody 2C11 have been defined 
by both site-directed mutagenesis and co-crystallisation studies (see figure 1B).14,15 The 
side-chains of exposed hydrophobic amino acid residues of the factor VIII C2 domain 
interact with complementary sites in the variable part of 2C11 (Figure 1B). Electrostatic 
interactions mediated by residues Arg2210 and Arg2215 also contribute to binding of 2C11 to 
the C2 domain. This report elegantly illustrates that it is now possible to assess the 
contribution of individual amino acids to the antigenicity of factor VIII.  
Human monoclonal antibody LE2E9 has been isolated from a patient mild 
haemophilia A carrying a substitution of Arg2150 to His in factor VIII.16 Interestingly, 
binding of LE2E9 to factor VIII is critically dependent on Arg2150 since LE2E9 does not 
react with a factor VIII light chain molecule in which Arg2150 is replaced by a histidine. 
This observation suggests that LE2E9 selectively recognises exogenous factor VIII whereas 
no reactivity is observed with endogenous factor VIII. This pattern of reactivity is in 
agreement with the rise in (endogenous) factor VIII observed in inhibitor patients with an 
Arg2150 to His mutation following administration of DDAVP.17,18 A similar discrimination 
between self and non-self has been reported for a human antibody present in plasma of a 
mild haemophilia A patient with an Arg593 to Cys mutation.19 
In a complementary approach, phage display technology has been used to isolate a 
large number of different of human monoclonal antibodies from the immunoglobulin 
repertoire of patients with an inhibitor.20-24 Epitope mapping studies showed that the 
majority of these human antibodies bind to previously identified binding sites for factor 
VIII inhibitors (see Figure 1A). Within the total repertoire, however, individual antibodies 
exist that bind to areas on factor VIII that are not contained within these three binding sites. 
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A human monoclonal antibody generated by phage display binds within the acidic region 
that follows the A2 domain.21 Mutagenesis studies suggest that binding of this antibody 
depends on sulfation of tyrosine residues present in this part of factor VIII. Analysis of anti-
A3-C1 antibodies by phage display have shown that multiple binding sites for factor VIII 
inhibitors are present in the A3 domain of factor VIII.22 This observation is supported by 
two recent studies that demonstrate binding of factor VIII inhibitors to the a3-region and 
the binding site for APC in the factor VIII light chain.25,26 Further studies, preferably at the 
clonal level, are required to describe more adequately the characteristics of anti-factor VIII 
antibodies directed towards these and other sites in the light chain of factor VIII.  Similarly, 
more extensive characterisation of catalytic antibodies and human anti-factor VIII 
antibodies that appear in normal individuals seems warranted.  These studies may provide 
new insights into the complexity of the humoral response to factor VIII.  
 
 
 
 
Figure 1. (A) Factor VIII consists of a 
series of repeated domains (A1-A2-B-
A3-C1-C2). Spacer regions that are rich 
in negatively charged amino acids (a1, 
a2 and a3) are present adjacent to the 
A1, A2 and A3 domain. Epitopes for 
factor VIII inhibitors in the A2, A3 and 
C2 domain are indicated by closed 
arrowheads. Stretches of amino acid 
residues that contribute to the inhibitor 
epitopes in these domains are indicated. 
(B) Three dimensional structure of the 
C2 domain of factor VIII.  Side-chains of 
residues that contribute to binding of 
human inhibitory monoclonal antibody 
2C11 are depicted. Hydrophobic 
interactions are mediated by Val2223, 
Met2199, Phe2200, Leu2251 and Leu2252. 
Charged residues Arg2210 and Arg2215 
interact with aspartic acid residues 
present in the variable parts of 2C11. 
Amino acids involved in binding of 
2C11 are oriented towards the 
phospholipid surface. This is consistent 
with the inhibitory effect of 2C11 on 
binding of factor VIII to phospholipids. 
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Immunological aspects of inhibitor formation  
 
Whereas considerable progress has been made at the level of epitope specificity and mode 
of action of factor VIII inhibitors, it still not clear why some patients do develop inhibitors 
and others do not. Inhibitors occur much more frequently in patients affected by the severe 
form of haemophilia than in patients with moderate or mild haemophilia.27 This is not 
surprising since moderately or mildly affected patients do have low levels of circulating, 
endogenous factor VIII, whereas in most severely affected haemophiliacs no factor VIII can 
be detected in the circulation.1 In general, patients with intron 22 inversions, nonsense 
mutations and large deletions are more prone to develop inhibitors than patients with 
missense mutations and small deletions.28-30 It is likely that the association between 
genotype and inhibitor development is related to the presence of tolerizing amounts of 
factor VIII in the circulation. Besides factor VIII genotype other yet unidentified 
determinants contribute to inhibitor development in patients with haemophilia A. 
The immunological mechanisms leading to inhibitor development are now slowly 
being unravelled. T cells play an important role in the humoral response to protein antigens 
and several observations demonstrate that inhibitor formation in haemophilia patients is T 
cell dependent. Analyses performed on peripheral blood mononuclear cells that were 
depleted for B cells revealed that factor VIII-reactive T cells were present in the circulation 
of haemophilia A patients with an inhibitor.31 The extent of the T cell proliferative 
responses varied between individual patients and appeared to be related to the inhibitor titre 
of the patient.31 Surprisingly, factor VIII-dependent proliferation of T cells was also 
observed in patients without an inhibitor and in normal individuals. The responses in these 
groups were significantly lower than in the inhibitor positive group. In a recent study 
Reding and co-workers also observed factor VIII-dependent T cell responses in healthy 
subjects.32 Longitudinal analysis revealed that T cell responses in healthy subjects were 
lower than in haemophiliacs and transient in nature, whereas they persisted at fluctuating 
levels in haemophilia A patients. The extent of T cell proliferative responses differed 
slightly for peptide pools derived from the different domains of factor VIII. These findings 
suggest that multiple T cell epitopes are present scattered over the A, B and C domains of 
factor VIII. The above mentioned studies provide an initial view on the complexity of the 
immune response against factor VIII at the T cell level. It is likely that differences in factor 
VIII genotype, (immuno) genetic background and treatment regime results in considerable 
heterogeneity of T cell responses in patients with haemophilia A.  
Much of our current knowledge on the role of T cells in inhibitor development stems 
from studies performed in mouse models for haemophilia A. Two similar strains of  
haemophilia A mice have been developed by targeted disruption of the murine factor VIII 
gene by insertion of the neomycin phosphotransferase gene into exon 16 (E16KO) or exon 
17 (E17KO).33 Phenotypic analysis showed that these mice bleed to death following 
clipping of the tail.33,34 Consistent with their haemophilic phenotype no factor VIII activity 
is present in plasma of these mice. Unexpectedly, factor VIII heavy chain has been detected 
in the circulation of KO mice.35 Apparently, insertion of a neomycine-cassette in exon 16 or 
17 of the murine factor VIII gene does not affect biosynthesis of factor VIII heavy chain.  
These murine models of haemophilia A offer an opportunity to study the 
immunological aspects of inhibitor development after administration of human factor VIII. 
After two to three intravenous injections with human factor VIII inhibitory antibodies 
develop in haemophilic mice.36 Epitope mapping studies revealed that in addition to the 
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factor VIII light chain both the A2 and B domain were recognised by antibodies developing 
in this model.37 Concurrent with the appearance of antibodies in plasma, anti factor VIII 
antibody-secreting cells are detected by Elispot assay in the spleen after two doses of factor 
VIII and in the bone marrow after three doses of factor VIII.38 The antibody-secreting cells 
in the bone marrow probably originate from the spleen. Persistence of this population of 
antibody-secreting cells does not require continuous exposure to factor VIII since these 
cells remain detectable for up to 22 weeks after intravenous administration of factor VIII.  
Factor VIII specific T cell proliferative responses could be measured using CD4+ T 
cells derived from the spleen in haemophilia A mice injected intravenously with factor 
VIII.37,39 Classically, cytokine release patterns are used to subdivide CD4+ (helper) T cells 
into two subpopulations; IFN-γ and IL-2 are secreted by the Th1 subset that is responsible 
for many cell-mediated functions.  IL-4 and IL-10 are secreted by Th2 cells, which mediate 
humoral immunity and provide help to B cells. Regulation of the antibody response towards 
factor VIII in haemophilic mice is very complex and involves both Th1 and Th2 type T 
cells. In one study, factor VIII specific T cells secreted IL-10, whereas in a few mice also 
IFN-γ, and IL-4 were detected. No IL-2 was secreted.39 A factor VIII-specific T cell clone 
isolated from haemophilic mice injected with factor VIII was able to produce both IFN-γ 
and IL-4.39 Another study reported on the production of significant amounts of IL-2, IL-4, 
IFN-γ and IL-10.40 Although small differences exist between the studies, the above findings 
suggest that a mixed Th1 and Th2 response is elicited following a challenge with factor 
VIII. Kinetic studies of cytokine production demonstrated that concurrent with the 
appearance of antibodies in plasma, IFN-γ producing T cells, already arising after the first 
injection in some experiments, were the most prominent type of factor VIII-specific T 
cells.41  IL-10 producing T cells were the second most dominant type. Furthermore, IL-2 
was produced in all experiments and IL-4 in some experiments. Cytokine co-expression 
studies identified a subgroup of factor VIII specific T cells producing both IL-10 and IFN-
γ.41  
Cytokines secreted by Th2 cells are involved in class switching of immunoglobulins 
to IgG4 in humans. Since most anti-factor VIII antibodies in human plasma are of subclass 
IgG4 it is likely that Th2 cytokines participate in an immune response elicited by factor 
VIII. In the mouse Th2 cytokines result in class switching from IgG2a to IgG1, a subclass 
that is indeed prominently observed in haemophilic mice following injection of factor 
VIII.36,37,39 The presence of T cells secreting Th2 cytokines in factor VIII-KO mice is 
consistent with the strong humoral response induced by factor VIII.  At present it is more 
difficult to explain the co-existence of T cells that secrete Th1 cytokines. Since Th1 
cytokines, in particular IFN-γ, inhibit Th2 responses, it is possible that Th1 cytokines have 
a modulating role during the humoral response to factor VIII. The observation that specific 
T cells can produce both Th1 and Th2 cytokines emphasises that our current understanding 
of the dynamics between these subpopulations of T cells is still limited.  
For optimal T cell activation at least two signals are needed. Signal one requires the 
interaction of the antigen specific T cell receptor (TCR) with a peptide bound to the major 
histocompatibility complex. The peptide (T cell epitope) is obtained after proteolytic 
degradation of factor VIII by the antigen presenting cell. Signal two is delivered through the 
interaction of co-stimulatory molecules, present on the T cell and the antigen presenting 
cell.42,43 At present multiple co-stimulatory interactions have been identified that may 
promote or down-regulate proliferation of T cells. CD28, a surface molecule that is 
constitutively expressed on T cells, interacts with CD80 (B7-1) and/or CD86 (B7-2) present 
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on activated professional antigen presenting cells (Figure 2A). The ligands for B7 are CD28 
and cytotoxic T lymphocyte antigen 4 (CTLA4), which act antagonistically. Signalling 
through CD28 delivers a positive co-stimulatory signal to the T cell, but signalling through 
CTLA4 is inhibitory and down regulates T cell activation. Synthesis of CTLA4 by T cells 
is upregulated following TCR engagement. Activation of T cells also upregulates a number 
of molecules like CD40L (CD154). This molecule acts as a ligand for the co-stimulatory 
molecule CD40 that is expressed on B cells. The interaction between T and B cells 
facilitated by CD40-ligation results in production of antibodies by B cells (Figure 2C).  
Based on our current knowledge of the regulation of immune responses by co-
stimulatory molecules a number of reagents have been evaluated for their suppressing 
effect on the immune response. A fusion protein consisting of soluble CTLA4 and part of 
the heavy chain of IgG1, designated CTLA4-Ig, has been shown to interfere with B7-CD28 
cross-linking in vivo (Figure 2B).44 Recently, the effect of CTLA4-Ig on inhibitor 
formation in factor VIII knock out mice was evaluated.45 When CTLA4-Ig was 
administrated on the day before and the day after factor VIII administration inhibitor 
formation in haemophilia A mice was delayed after additional administration of three doses 
of factor VIII. Moreover, inhibitor formation could be blocked completely by co-
administration of CTLA4-Ig with each of six doses of factor VIII. In mice with a pre-
existing low titre inhibitor the secondary immune response to factor VIII is suppressed. In 
the same study it was shown that haemophilic mice lacking the co-stimulatory molecule 
B7-2 did not develop an immune response to intravenously infused factor VIII whereas 
inhibitor development did occur in B7-1 deficient mice.45 Apparently, B7-2 serves an 
essential role in humoral responses to infused factor VIII in this animal model for 
haemophilia A. These results suggest that it may be worthwhile to evaluate the effect of 
monoclonal antibodies that block the activity of the co-stimulatory molecule B7-2 on 
inhibitor development.  
Blockade of the CD40-CD40L interaction has been successful in the prevention of 
renal allograft rejection.46 This method for the suppression of inhibitor formation has been 
evaluated in several studies using different treatment regimens (Figure 2D). In haemophilic 
mice that had developed high titre inhibitors anti-CD40L treatment reduced the inhibitor 
titre, whereas little effect was seen in mice with low titre inhibitors.47 Two other studies 
confirmed the modulating role of anti-CD40L on inhibitor development.40,48 Surprisingly, 
in one of these studies, in about half of the animals treated with anti-CD40L long term 
tolerance (150 days) was achieved whereas in the other half inhibitory antibodies did 
develop after repeated challenges with factor VIII.40 In the non-tolerant mice factor VIII 
reactive T cells were mainly of the Th2 type whereas in control mice, receiving only factor 
VIII, also T cells secreting cytokines characteristic of a Th1 response were observed. As yet 
no explanation is provided for the fact that only half of the mice has become tolerant to 
factor VIII. Possibly, under conditions of co-stimulatory blockade of the CD40 pathway, 
inhibitor formation becomes critically dependent on the expression of other co-stimulatory 
molecules like B7.2. The narrow and tightly regulated window of B7.2 expression on 
antigen presenting cells may explain why inhibitor development is not initiated in all 
treated animals.43 In another study inhibitor formation could be prevented by co-
administration of anti-CD40L with factor VIII, but contrary to the former study, no lasting 
effect was noted. Flow cytometric analysis and analysis of spleen cell supernatants 
demonstrated that prior treatment with anti-CD40L did not influence Th1/Th2 polarization, 
nor did it alter subclass distribution of the formed antibodies.48 
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A few years ago, a humanised monoclonal antibody directed against CD40L has been 
assessed for its efficacy of reducing the inhibitor titre in four haemophilia A patients.49 The 
results of this study did not show a strong reduction in inhibitor titres in the treated patients, 
although preliminary results suggest anti-CD40L treatment prevented an anamnestic 
response to the infused factor VIII in some patients. Due to thrombo-embolic complications 
associated with the use of anti-CD40L in patients with autoimmune diseases, clinical trials 
with anti-CD40L were discontinued.50 Nevertheless, investigation of blocking co-
stimulatory interactions in animal models for haemophilia A can yield new insights in the 
immunobiology of inhibitor development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Co-stimulatory blockade using CTLA4-Ig and anti-CD40L antibodies. (A) Activation of T cells by 
antigen presenting cells (APC) requires multiple contacts between these two cell types. The first signal (indicated 
by 1) is mediated by the T cell receptor (TCR) that binds to a peptide (indicated in black) present in the groove of 
major histocompability complex (MHC) class II molecules on APCs. In case of an immune response against factor 
VIII the peptide originates from factor VIII which is taken up and proteolytically degraded into small fragments by 
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APCs. For optimal activation of T cells a second co-stimulatory signal (indicated by 2) is required which involves 
the interaction between CD28 on T cells with B7.1 or B7.2 molecules expressed on APCs. T cells can now 
proliferate and exert their biological function. Excessive proliferation of T cells is prevented by cytotoxic T 
lymphocyte antigen 4 (CTLA4) which is upregulated following activation of T cells. CTLA4 competes with CD28 
for binding to B7.1 and B7.2 on APCs. CTLA4-B7.1/7.2 ligation delivers result in the onset of signalling 
pathways that prevent proliferation of T cells. (B) The modulating role of CTLA4 during initiation of an immune 
response has been exploited by construction of a recombinant soluble variant of this molecule designated CTLA4-
Ig. Binding of CTLA4-Ig to B7.1/7.2 interferes with co-stimulation of T cells by CD28/B7.1/7.2 ligation. As a 
result activation of T cells is halted and they lose their ability to proliferate in response to the  presented antigen. 
(C) Co-stimulatory interactions also play a role in the interaction between antigen specific B and T cells. Also here 
signal 1 is delivered via the T cell receptor and peptide containing MHC class II molecules. The peptide is derived 
from antigen which has been internalized via the B cell receptor (BCR). Following intracellular processing antigen 
derived peptides are loaded on MHC class II molecules. An important co-stimulatory signal for a productive 
interaction between B and T cells is mediated by CD40 ligation (indicated by 2). Interaction of CD40 on the B cell 
with CD40L on the T cell provides a strong activating signal to B cells that ultimately results in the production of 
high affinity antibodies. (D) Administration of monoclonal antibodies directed towards CD40L provides a co-
stimulatory blockade which prevents stimulation of antigen specific B cells. During the last years several 
additional co-stimulatory molecules have been identified that regulate the interaction between T cells and APCs40. 
These newly identified co-stimulatory molecules have not been included in this figure. 
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Abstract 
 
Most plasmas from patients with inhibitors contain antibodies that are reactive with the C2 
domain of factor VIII. Previously, we have shown that the variable heavy (VH) chain 
regions of antibodies to the C2 domain are encoded by the closely related germline gene 
segments DP-10, DP-14 and DP-88 which all belong to the VH1 gene family. Here, we 
report on the isolation and characterization of additional anti-C2 antibodies that are derived 
from variable heavy chain gene segments DP-88 and DP-5. Competition experiments using 
murine monoclonal antibodies CLB-CAg 117 and ESH4 demonstrated that antibodies 
derived from DP-5 and DP-88 bound to different sites within the C2 domain. Epitope 
mapping studies using a series of factor VIII/factor V hybrids revealed that residues 2223-
2332 of factor VIII are required for binding of the DP-10, DP-14, and DP-88 encoded 
antibodies. In contrast, binding of the DP-5 encoded antibodies required residues in both 
the amino- and carboxy-terminus of the C2 domain. Inspection of the reactivity of the 
antibodies with a series of human/porcine hybrids yielded similar data. Binding of 
antibodies derived from germline gene segments DP-10, DP-14, and DP-88 was unaffected 
by replacement of residues 2181-2243 of human factor VIII for the porcine sequence 
whereas binding of the DP-5 encoded antibodies was abrogated by this replacement. 
Together these data indicate that antibodies assembled from VH gene segments DP-5 and 
the closely related germline gene segments DP-10, DP-14 and DP-88 target two distinct 
antigenic sites in the C2 domain of factor VIII. 
 
 
Introduction 
 
Haemophilia A is an X-linked bleeding disorder that is characterized by the absence or 
dysfunction of blood coagulation factor VIII. Current treatment of haemophilia A consists 
of infusion of therapeutic amounts of factor VIII that can evoke an immune response in 
some patients. The presence of neutralizing antibodies to factor VIII, commonly termed 
factor VIII inhibitors, presents a serious complication of haemophilia care1. The 
biochemical properties of factor VIII inhibitors have been extensively studied with 
emphasis on the epitope specificity and mode of action of these antibodies. Binding sites 
for inhibitors have been identified within the A2, A3 and C2 domains of factor VIII.2-6  In 
general, heterogeneous mixtures of anti-factor VIII antibodies are present in plasma from 
patients with factor VIII inhibitors and in more than 80% of inhibitor plasmas antibodies 
directed against the C2 domain are present.7 Epitope mapping of anti-C2 domain antibodies 
revealed the presence of an inhibitor binding site comprising amino acid residues Val2248-
Ser2312 of the C2 domain.3 A second inhibitor epitope in the C2 domain has been attributed 
to region Glu2181-Val2243.6 Antibodies reactive with the C2 domain prevent factor VIII from 
binding to phospholipid surfaces and von Willebrand factor.8,9 Both findings are in 
agreement with the presence of binding sites for phospholipids and von Willebrand factor 
in the C2 domain.10,11 An additional mechanism of factor VIII inhibition has been described 
for less common human antibodies directed to the C2 domain.12 These antibodies did not 
block the binding of factor VIII to von Willebrand factor but reduced the release of 
activated factor VIII from von Willebrand factor. Although both the factor VIII inhibitory 
mechanism and epitope specificity of C2-inhibitors are well understood, knowledge about 
their primary structure of these antibodies is limited. 
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Recently, anti-C2 antibodies have been studied at the clonal level using phage display 
technology.13 The variable heavy chain (VH) domains of these antibodies were encoded by 
VH germline gene segments DP-10, DP-14, and DP-88 derived from the VH1 gene family. 
Furthermore, these VH domains contain hypervariable CDR3 loops that were relatively 
large (20-23 residues) compared to the average CDR3 length of 14 residues.14,15 Another 
human anti-C2 antibody has been isolated from a haemophilia A patient with an inhibitor 
using classical Epstein-Barr virus immortalization.16 The VH domain of this antibody was 
encoded by germline gene segment DP-5, which is also derived from the VH1 gene family. 
This antibody inhibited factor VIII activity by preventing binding of factor VIII to von 
Willebrand factor and phospholipid surfaces. Interestingly, the anti-C2 antibodies expressed 
as single-chain variable domain antibody fragments (scFv) composed of DP-10, DP-14 and 
DP-88-encoded VH domains did not inhibit factor VIII activity.13 In the present study, 
additional antibodies were isolated from the immunoglobulin repertoire of a mild 
haemophilia A patient with anti-C2 antibodies. The isolated antibodies were encoded by 
heavy chain germline gene segments DP-5 and DP-88. Epitope mapping studies revealed 
that antibodies encoded by these two classes of variable heavy chain gene segments bind to 
distinct antigenic sites within the C2 domain.  
 
 
Materials and Methods 
 
Materials 
DNA modifying enzymes were purchased from Life Technologies (Breda, The 
Netherlands) and New England Biolabs (Beverly, MA). Immunotubes and microtitre plates 
were purchased from Nunc (Life Technologies, Breda, The Netherlands). Plasma-derived 
factor VIII light chain was purified as described.17 Monoclonal antibodies (mAbs) CLB-
CAg 12 and 117 have been characterized previously 4,17; mAb ESH418 was purchased from 
American Diagnostica Inc. (Greenwich, CT).  
 
Factor VIII assays 
Factor VIII activity was measured by a one-stage clotting assay.19 Factor VIII inhibitor 
titres were determined by the Bethesda assay.20 Neutralization experiments and 
immunoprecipitation assays were performed as described previously.4,13,21. 
  
Phage display library construction, selection and characterization of selected clones 
In this study plasma and peripheral blood mononuclear cells were used from a mild 
haemophilia A patient with an Arg2163→His mutation who developed a factor VIII 
inhibitor.22 The patient's IgG4-specific VH gene repertoire was amplified and combined 
with a VL gene repertoire of nonimmune origin in pHEN-1-VLrep and displayed as scFv on 
the surface of filamentous phage.13 Phages from the library were selected on factor VIII 
light chain immobilized via antibody CLB-CAg 12-coated microtitre wells as described 
previously.13 After 3 rounds of selection for binding to the factor VIII light chain, the factor 
VIII domain specificity of phages obtained from single infected colonies was determined. 
Phages were tested for reactivity with factor VIII light chain immobilized to CLB-CAg 12 
as described previously.13 Phages corresponding to clones reactive with factor VIII light 
chain were selected for further study. VH and VL genes were sequenced on an Applied 
Biosystems 377XL automated DNA sequencer (Foster City, CA) using the BigDye 
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Terminator sequencing kit. Nucleotide sequences were aligned to their most homologous 
germline sequences as present in the V-BASE sequence directory.23 The selected clones 
were subsequently tested for reactivity with the C2 domain of factor VIII in the following 
manner. Monoclonal antibodies ESH4 or CLB-Cag117 were immobilized on microtitre 
wells overnight at 4°C. Subsequently, wells were incubated for 1.5 hour with recombinant 
C2 domain (3.5 nM in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2% (wt/vol) HSA and 
0.1% (vol/vol) Tween-20). Wells were washed three times with 50 mM Tris-HCl, pH 7.4, 
150 mM NaCl and 0.1% Tween-20. Recombinant phages derived of single infected clones 
were then added in 150 mM NaCl, 50 mM Tris, pH 7.4, 3% (wt/vol) human serum 
albumin, 0.5% (vol/vol) Tween-20 and incubated for 2 hours at room temperature. Wells 
were washed three times with 50 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.1% Tween-
20. Bound phages were detected following a 2 hour incubation at room temperature with  
peroxidase labelled anti-M13 antibody (Pharmacia-LKB, Woerden, the Netherlands) 
diluted 2000-fold in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2% (wt/vol) HSA and 0.05% 
(vol/vol) Tween-20.  
Production and purification of single-chain variable domain antibody fragments 
(scFv) was performed as described previously.13 Purified scFv were analysed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and protein 
concentrations were measured spectrophotometrically at A280. Reactivity of scFv with 
recombinant factor VIII and factor V hybrid molecules was evaluated by 
immunoprecipitation analysis. Construction and expression of hybrid human factor VIII 
molecules containing porcine C2 domain substitutions and hybrid human factor V 
molecules containing factor VIII C2 domain substitutions have been described 
previously.6,24,25.  Immunoprecipitation of metabolically labelled factor VIII fragments by 
scFv/Ni-NTA agarose (Qiagen, Hilden, Germany) complexes was performed as described  
previously.13 
 
Surface plasmon resonance  
The kinetics of the interaction between scFv and factor VIII light chain were determined by 
surface plasmon resonance, using a BIAcoreTM 2000 biosensor system (Biacore AB, 
Uppsala, Sweden). Factor VIII light chain was covalently coupled to the dextran surface of 
an activated CM5-sensor chip at a density of 88.5 fmol/mm2, using the amine-coupling kit 
according to the manufacturer's instructions (Biacore AB, Uppsala, Sweden). As a control, 
one of the four channels on a chip was activated and blocked in the absence of protein. 
Binding to coated channels was corrected for binding to non-coated channels (< 5% of 
binding to coated channels). Binding (association) of scFv was assessed in 100 mM NaCl, 
100 mM imidazole, and 50 mM sodium phosphate, pH 7.5 at 25°C for 2 minutes at a flow 
rate of 20 µL/min. Dissociation was allowed for 2 minutes in the same buffer flow. 
Association (kon) and dissociation (koff) rate constants were calculated from data sets using 
the BIAevaluation 3.1 software. Binding data were corrected for bulk refractive index 
changes and fitted according to a one-site model. Equilibrium dissociation constants (Kd) 
were calculated from the measured values of koff and kon. 
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Results 
 
Isolation of anti-factor VIII antibodies using phage display. 
The domain specificity of antibodies present in the plasma of an inhibitor patient with mild 
haemophilia A was determined by immunoprecipitation analysis. The patient's antibodies 
reacted with metabolically labelled factor VIII light chain and the C2 domain. 
Approximately 80% of the inhibitory activity originated from anti-C2 antibodies as was 
determined by neutralization assays (data not shown). These data indicate that the C2 
domain is the major target for factor VIII inhibitors present in plasma of this patient. To 
further examine the patient's anti-C2 domain antibodies we used phage display to isolate 
factor VIII-reactive antibodies from the patient's immunoglobulin repertoire. Therefore, a 
phage display library derived from the patient's IgG4-specific VH gene repertoire and a VL 
gene repertoire of nonimmune source was constructed. The library, which consisted of 1.9 
× 107 clones was subsequently selected for binding to plasma-derived factor VIII light 
chain immobilized via antibody CLB-CAg 12. After 3 rounds of selection, phages derived 
from 19 out of 20 clones were found to react with factor VIII light chain. Nucleotide 
sequences of the VH and VL domains of the 19 clones were determined and aligned to their 
most homologous germline genes in the V-BASE directory.23 The VH domains of 5 clones 
were encoded by germline gene segment DP-5. Germline gene segment DP-88 could be 
identified as the most homologous gene segment encoding the VH domains of the other 14 
clones. Both gene segments belong to the VH1 gene family. In total, 3 unique VH domains 
encoded by germline gene segment DP-5 were identified (Figure 1). The VH domains of 
WR1 and WR17 are highly homologous, varying in only 2 amino acid residues. At the 
nucleotide level, 4 substitutions were observed, which makes it unlikely that the observed 
differences resulted from PCR artefacts. The VH domains of WR1/17 and WR16 were 
generated by VDJ-recombination using JH gene segments JH4b and JH3b, respectively. 
Rearrangement of particular D gene segments could not be determined as a consequence of 
limited sequence homology with known D genes. CDR3 sequences of WR1/17 and WR16 
consisted of 11 and 9 amino acids, respectively. 
 Of 14 VH domains encoded by the DP-88 germline gene segment, 8 unique VH 
domains were identified (Figure 1). All VH domains were heavily hypermutated compared 
to the DP-88 germline. Seven of 8 VH domains shared homologous patterns of somatic 
hypermutation suggesting that these VH domains share an identical B-cell precursor. It 
should be noted that amino acid replacements in WR3, WR7, WR11 and WR15 were 
caused by single nucleotide substitutions. Consequently, it cannot be excluded that the 
nucleotide substitutions in these VH domains were introduced during amplification of the 
patient's VH gene repertoire. All VH domains, except that of WR10, have a similar CDR3, 
which is partially encoded by the largest known JH gene segment, JH6b. The VH domain of 
WR10 has a different pattern of somatic mutation compared to the other DP-88-encoded VH 
domains (Figure 1). Furthermore, the CDR3 of WR10, which comprises 20 amino acid 
residues, has been assembled using gene segments D3-10 and JH3b. Different VL domains 
encoded by germline gene segments of Vκ and Vλ gene families were paired with single VH 
domains derived from DP-5 and DP-88 germline gene segments (Table 1). 
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Figure 1. Deduced protein sequences of scFv that bind to the C2 domain. Sequence numbering is according to 
Kabat et al.31  Sequences are available from Genbank under accession numbers:AY050689 (VHWR1); AY050690 
(VHWR10); AY050691 (VLWR10); AY050692 (WR11); AY050693 (VLWR11); AY050694 (VHWR13); 
AY050695 (VHWR14); AY050696 (VHWR15); AY050697 (VLWR15); AY050698 (VHWR16); AY050699 
(VLWR16); AY050700 (VHWR17); AY050701 (VLWR17); AY050702 (VHWR19); AY050703 (VLWR1); 
AY050704 (VHWR2); AY050705 (VHWR20); AY050706 (VHWR3); AY050707 (VLWR3); AY050708 
(VHWR7); AY050709 (VHWR8); AY050710 (VLWR10); AY050711 (VHWR9); AY050712 (VLWR9). FR, 
framework region; CDR, complementarity determining region. Dashes indicate sequence identity to germline. 
Amino acid substitutions that are most likely introduced by the use of VH gene family-specific oligonucleotide 
primers during amplification of VH repertoires are indicated in lowercase. 
 
 
                       FR1               CDR1       FR2             CDR2          
           
          ------------------------------ ----- -------------- ----------------- 
                                                                                    
                  1         2         3           4          5          6         
          123456789012345678901234567890 12345 67890123456789 012a3456789012345  
    
    
DP-5      QVQLVQSGAEVKKPGASVKVSCKVSGYTLT ELSMH WVRQAPGKGLEWMG GFDPEDGETIYAQKFQG 
WR1       ----q----------S-------------- ----- -------------- -SN-----I-----L--  
WR17      ----q------------------------- ----- -------------- -SN-----I-----L-- 
WR16      e----e----MQ------------P-HSV- -I-F- -------------- --A-----P-------- 
 
DP-88     QVQLVQSGAEVKKPGSSVKVSCKASGGTFS SYAIS WVRQAPGQGLEWMG GIIPIFGTANYAQKFQG 
WR10      e----e----------------R---D--- -S--- -------------- -V-----A------L--   
WR13      -----------------------T---D-- --GVT -------------- ------NA-T-------   
WR2       e----e-----------------T---D-- --GV- -------------- V---V----S-T----- 
WR3       -----------------------T---D-- --GV- -------------- ----V----S-T----- 
WR7       -----------R-----------T---D-- --GV- -------------- V---V----S-T----- 
WR8       -----------------------T---D-- --GV- -------R------ V---V----S-T----- 
WR11      -----------------------T---D-- --GV- -------------- V---V----S-T----- 
WR15      ----q------------------T---D-- --GV- -------------- V---V----S-T----- 
 
 
                         FR3                       CDR3             FR4 
           
          -------------------------------- -------------------- ---------- 
                                                1                      1 
              7         8            9          0                      1   
          67890123456789012abc345678901234 567890abcdefghijkl12 3456789012 
  
DP-5      RVTMTEDTSTDTAYMELSSLRSEDTAVYYCAT 
WR1       -----A------------------------T- GDLEVTGAY.........DF WGQGTLVTVSS 
WR17      -----A------V-----------------T- GDLEVTGAY.........DF WGQGTLVTVSS 
WR16      -----------------R--------M----- SDIGNGL...........DI WGQGTMVTVSS 
 
DP-88     RVTITADKSTSTAYMELSSLRSEDTAVYYCAR 
WR10      --S---------------N-T-D--G------ GSEGALRYSDGFLPTDAFAI WGQGTMVTVSS 
WR13      --S---------I----TG-----A---F--S ASKPNYYGSTDFYS..DMDV WGQGTTVTVSS 
WR2       --S---------V----TG-----A---F--S ASKPNYYGSTDFYS..DMDV WGQGTTVTVSS 
WR3       --S---------V----TG-----A---F--S ASKPNYYGSTDFYS..DMDV WGQGTTVTVSS 
WR7       --S---------V----TG-----A---F--S ASKPNYYGSTDFYS..DMDV WGQGTTVTVSS 
WR8       --S---------V----TG-----A---F--S TSKPNYYGSTDFYS..DMDV WGQGTTVTVSS 
WR11      --S---------V----TG-----A---F--S ASKPNYYGSTDFYS..DMDV WGQGTTVTVSS 
WR15      --S---------V----TG-----A---F--S ASKPNYYGSTDFYS..DMDV WGQGTTVTVSS 
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Table 1. Most homologous germline genes segments used by human 
antibodies directed against the C2 domain.  
VH and VL germline gene use and nomenclature according to V-BASE.23 All observed VH germline 
genes belong to the VH1 gene family. ND (not determined). 
 
Clone VH domain VL domain  Reference 
 germline germline family  
WR1 DP-5 (1-24) DPK8 (L8) VκI This study 
WR17  DPL5 (V1-19) Vλ1 This study 
WR16  DPK3 (L11) VκI This study 
BO2C11  DPK22 (A27) VκIII 16 
YK3-3-38       - - 27 
YK3-3-40       - - 27 
YK3-3-50       - - 27 
EL-14 DP-10 (1-69) DPK5 (L5) VκI 13 
EL-5 DP-14 (1-18) L12a VκI 13 
EL16  DPK8 (L8) VκI 13 
EL-25  DPK7 (L15) VκI 13 
EL-9 DP-88 (1-e) DPK8 (L8) VκI 13 
WR10  DPL11 (V1-4) Vλ2 This study 
WR2/7/13  ND ND This study 
WR3  DPK3 (L11) VκI This study 
WR8  DPK24 (B3) VκIV This study 
WR9  V1-2 (V1-2) Vλ2 This study 
WR11  DPL11 (V1-4) Vλ2 This study 
WR15  DPL16 (V2-13) Vλ3 This study 
 
 
 
 
Epitope specificity of scFv reactive with the C2 domain. 
Similar to clones WR2, 3, 7, 8, 10, 11, 13, and 15, the VH domain of the previously 
described scFv EL-9 is also derived from germline gene DP-88 (Table 1). Competition 
experiments have shown that the binding site for EL-9 in the C2 domain overlapped with 
that of monoclonal antibody CLB-CAg 117.13 Therefore, phages derived from the newly 
isolated clones were tested whether they also competed with CLB-CAg 117 for binding to 
the C2 domain. Phages bearing a VH domain derived from germline gene segment DP-88 
did not bind to the C2 domain that was immobilized via CLB-CAg 117 (Figure 2). 
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Interestingly, phages corresponding to clones consisting of a DP-5-encoded VH domain 
bound readily to the C2 domain that was immobilized via CLB-CAg 117. We also tested 
reactivity of phages with C2 domain immobilized via ESH4. Previously, we have shown 
that ESH4 and CLB-CAg 117 bind nonoverlapping epitopes in the C2 domain of factor 
VIII.4 Phages derived from clones using germline gene segment DP-5 did not bind to 
ESH4-immobilized C2 domain. In contrast, the C2 domain immobilized via ESH4 
exclusively allowed for binding of phages derived from clones consisting of a DP-88-
encoded VH domain (Figure 2). These data suggest that DP-5 and DP-88 germline gene 
segments generate antibodies with distinct binding sites in the C2 domain of factor VIII. 
 Previously, we have shown that scFv EL-5, 9 and 14 did not inhibit factor VIII 
activity.13 The capacity of scFv isolated in this study to inhibit factor VIII activity was 
assessed in a Bethesda assay. None of the scFv significantly inhibited factor VIII activity 
(titre < 15 BU/mg scFv). Subsequently, we determined the affinity of the scFv for the factor 
VIII light chain using surface plasmon resonance. All scFv readily associated with factor 
VIII light chain and for all but three scFv the rate of dissociation was extremely slow 
(Table 2). The relative high dissociation rate observed for EL-5, EL-9, and WR16 results in 
a reduced affinity for factor VIII light chain when compared to the other scFv (Table 2).  
 To further explore the epitope specificity of the isolated scFv, their reactivity with 
labelled hybrid factor VIII/factor V molecules was evaluated by immunoprecipitation 
analysis. Three previously isolated scFv EL-5, EL-9 and EL-14 (encoded by VH germline 
gene segments DP-14, DP-88 and DP-10) were also included in this analysis.13 Factor 
VIII/factor V hybrids in which (part of) the C2 domain of factor V was replaced by factor 
VIII did not react with scFv VK-34 that is directed to the A2 domain of factor VIII. (Figure 
3A, lane 1).28 All scFv tested reacted with the factor VIII/factor V hybrid in which the C2 
domain of factor V was replaced by that of factor VIII (panel 3A). The scFv composed of 
VH domains derived from germline gene segments DP-10, DP-14, and DP-88 (scFv EL-5, 
EL-9, EL-14, WR8, WR10, WR11, and WR13) reacted with the factor V hybrid 2A, which 
indicates that the epitope for these scFv is located within residues 2223-2332 of factor VIII. 
This group of scFv did not react with factor VIII/V hybrids in which residues 2223-2281 or 
2282-2332 of factor VIII were present. Binding of scFv containing VH domains encoded 
by germline gene segment DP-5 solely react with a hybrid that contained residues 2173-
2222 and 2282-2232 of factor VIII (lane 8A). Apparently, residues contained in both these 
regions contribute to the epitope of this class of scFv (panel 8A). Taken together these 
results suggest that DP-5 encoded scFv and DP-10, DP-14, and DP-88 encoded scFv bind 
to distinct antigenic sites within the C2 domain.  
 We also evaluated the reactivity of the scFv with a series of human-porcine hybrids 
that have been described previously.6 All scFv reacted with B domain deleted factor VIII 
whereas no reactivity was observed with hybrid HP20 in which the human C2 domain was 
replaced by the corresponding part of porcine factor VIII (figure 3B). Based on the lack of 
reactivity with HP28, residues within amino acid sequence 2207-2321 are likely to 
contribute to the epitopes of scFv derived from heavy chain germline gene segments DP-
10, DP-14, and DP-88 (Figure 3). Interestingly, both hybrids HP23 and HP25 are not 
recognized by scFv EL-5, 9 and WR10 suggesting that residues 2253-2311 contain amino 
acids crucial for binding of these scFv. The pattern observed for scFv derived of germline 
gene segment DP-5 is clearly different. Hybrid HP24 and HP26 are not recognized by WR1 
and WR16 suggesting that residues located between 2181 and 2199 are crucial for binding 
of these scFv to the C2 domain of factor VIII. Overall the data suggest that the amino-
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terminal portion of the C2 domain is involved in binding of DP-5 encoded scFv. Binding of 
scFv derived from heavy chain segments DP-10, DP-14 and DP-88 requires the presence of 
residues contained within the central and/or carboxy-terminal part of the C2 domain.  
 
 
 
Figure 2. Specificity of phages isolated 
by selection on plasma-derived factor 
VIII light chain for the C2 domain. 
Binding of phages to recombinant C2 
domain that was immobilized via 
monoclonal antibodies CLB-CAg 117 or 
ESH4 was determined by ELISA. The 
results were corrected for binding to both 
antibodies in the absence of C2 domain. 
Clones were divided in 2 groups, DP-5 and 
DP88 respectively, based on the variable 
heavy gene segment that encode the VH 
domain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Binding kinetics of isolated single-chain variable domain antibody fragments. 
Kd, kon, and koff were determined by surface plasmon resonance as described in "Materials and methods". 
 
ScFv kon(M-1s-1) koff(s-1) Kd (nM) 
EL5 1.6 x 104 3.6 x 10-3 226 
EL9 3.1 x 104 1.3 x 10-3 42 
EL14 3.7 x 104 4.2 x 10-5 1.1 
WR1 2.7 x 104 3.9 x 10-4 14 
WR8 1.2 x 104 5.3 x 10-5 4.2 
WR10 4.1 x 104 4.9 x 10-4 12 
WR11 8.8 x 103 4.2 x 10-5 4.8 
WR13 3.0 x 105 6.4 x 10-4 2.1 
WR16 1.6 x 104 1.9 x 10-3 115 
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Figure 3. Reactivity of isolated scFv with factor V/factorVIII and human/porcine factorVIII hybrids. 
Binding of scFv to recombinant factor V/VIII (panel A) and porcine/human factor VIII (panel B) hybrids was 
assessed by immunoprecipitation. (Lane 1) positive control (34, anti-A2 scFv VK34); (lanes 2-10) 5, 9, 14, 8, 10, 
11, 13, 1, and 16; scFv corresponding to clones EL-5, EL-9, EL-14, WR8, WR10, WR11, WR13, WR1, and 
WR16; (lane 11) negative (-) control. On the right, the fragments used are indicated. Sequences corresponding to 
human factor VIII are depicted as white boxes. At the top of the figure the two classes of variable heavy chain 
gene segments that encode the different clones are given. Clone EL-5, EL-9, EL-14, WR8, WR10, WR11 and WR 
13 are derived from VH gene segments DP-10, DP-14 and DP-88 whereas clone WR1 and WR16 are derived from 
VH gene segment DP-5.  
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Figure 4. Phylogeny of the VH1 family germline gene family. Dendrogram of all human VH1 family germline 
genes shows relatedness of DP-10, DP-88 and DP-14. The nucleotide sequences were aligned using the 
CLUSTAL alignment of the DNAstar MegALIGN application. The evolutionary distance between the different 
gene segments correlates with the length of the closed lines (-).  
 
 
Discussion 
 
Antibodies directed to the C2 domain of factor VIII are frequently found in plasma of 
haemophilia A patients with an inhibitor.7 In this study, we defined the primary structure of 
human C2 domain-specific antibodies. Two classes of anti-C2 antibodies directed to 
distinct epitopes were isolated from the immunoglobulin repertoire of a mild haemophilia A 
patient with an inhibitor. The isolated antibodies consisted of VH domains encoded by 
germline gene segments DP-5 and DP-88 from the VH1 gene family. Previously, we 
reported on the isolation of a panel of anti-C2 domain antibodies encoded by germline gene 
segments DP-10, DP-14 and DP-88. 13 The nonmutated germline genes DP-10 and DP-88 
are highly homologous and vary by only 1 nucleotide. The DP-14 and DP-88 genes are 
more distantly related and vary by 29 nucleotides, which lead to 17 amino acid 
substitutions. In two recent studies anti-C2 antibodies derived from VH gene segment DP-5 
were isolated (Table 1) 16,27. The nonmutated germline gene DP-5 differs substantially from 
DP-10, DP-14, and DP-88 (46-47 nucleotides which results in 21-22 amino acid 
substitutions), although all these genes belong to the VH1 gene family. Phylogenetic 
analysis of germline gene segments of the VH1 family confirms the close relation between 
germline genes DP-10, DP-14, and DP-88 (Figure 4). In contrast, DP-5 appears to be 
present in a different branch of the phylogenetic tree of the VH1 family. Interestingly, the 
VH domains encoded by DP-10, DP-14 and DP-88 all contain a large CDR3 consisting of 
18-23 residues whereas the CDR3-length of DP-5 derived VH domains ranges between 8-11 
amino acids .13,16 It cannot be excluded that antibody fragments selected by phage display 
are not fully representative of the complete spectrum of antibodies present in patient’s 
plasma. Additional anti-C2 antibodies with different characteristics then reported in this 
study may exist. The common features of human anti-C2 antibodies described in this and 
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other studies however suggest that these antibodies are derived from a limited proportion of 
the human immunoglobulin repertoire 
Both epitope mapping studies and competition experiments suggest that scFv derived 
from DP-10, DP-14, DP-88 and DP-5 germline genes bind to distinct antigenic sites within 
the C2 domain of factor VIII. Based on the results with human/porcine hybrids it is likely 
that residues 2181-2243 contribute to binding of DP-5 encoded antibodies. This observation 
is consistent with the identification of a major epitope for factor VIII inhibitors in this part 
of factor VIII.6,29 Based on their reactivity with factor VIII/V hybrid 8A, it is likely that 
residues contained within the carboxy-terminus of the C2 domain also contribute to binding 
of DP-5 encoded scFv (see Figure 3). Recently, the three-dimensional structure of DP-5 
encoded human monoclonal antibody BO2C11 in complex with the C2 domain has been 
determined.30 A number of amino acid residues within 2181-2243 has been implicated in 
binding of BO2C11 to the C2 domain. However, also residues His2315 and Gln2316 present at 
the carboxy-terminus of the C2 domain have been shown to interact with BO2C11. From 
the three-dimensional structure, it appears that the interactive surface of BO2C11 is acidic 
whereas the antigenic surface of the C2 epitope contains a number of basic residues. In 
contrast to other germlines, the CDR1 and CDR2 of DP-5 harbour 5 negatively charged Glu 
(E) and Asp (D) amino acid residues (Figure 1). These residues contribute to the net 
negative charge of VH domains encoded by this particular germline gene segment. The 
average calculated isoelectric point (pI) of nonmutated germline VH segments is 8.74 ± 
1.06. In a previous study the average pI of rearranged VH domains of 39 randomly picked 
clones was 9.24 ± 0.8.31 Conversely, germline DP-5, being one of the 3 VH segments with a 
net negative charge, has a predicted pI of 4.84. It can be anticipated that surface Ig 
molecules on immature B cells carrying a DP-5-encoded VH domains may more readily 
interact with a complementary positively charged site in the C2 domain. This may result in 
selective amplification of these B cell clones and explain the presence of the DP-5 gene 
segment in a subset of human antibodies directed against the C2 domain.  
Human anti-C2 antibodies encoded by VH gene segments DP-10, DP-14, and DP-88 
compete with binding of CLB-CAg 117 but not ESH4 for binding to the C2 domain. In 
contrast DP-5 encoded clones compete with binding of ESH4 to the C2 domain. This 
observation suggests that DP-10, DP-14, and DP-88 encoded clones bind to an antigenic 
site within the C2 domain that does not overlap with the epitope of the DP-5 encoded scFv. 
Epitope mapping studies support this notion and clearly indicate that the C2 domain 
contains at least two antigenic sites. DP-10, DP-14, and DP-88 encoded scFv bind to HP24 
whereas DP-5 encoded scFv do not bind to this hybrid molecule. These data are in 
agreement with the results obtained for factor V/VIII hybrid 2A and suggest that residues 
contained within 2243-2332 contribute to binding of DP-10, DP-14 and DP-88 encoded 
scFv to the C2 domain of factor VIII. More detailed information on the epitope specificity 
of this group of scFv can be derived from the results obtained with hybrids HP23 and 
HP25. ScFv EL-5, EL-9, and WR10 most likely bind to an epitope contained within 
residues 2253-2311 since these scFv do not react with human porcine hybrid HP23 (Figure 
3). Interestingly, the related scFv EL-14, WR8, WR11 and WR13 do bind to hybrid HP23. 
Only when the replaced region was extended from residues 2207-2321 reduced binding of 
these scFv was observed (see hybrid HP28; Figure 3). The results obtained with hybrid 
HP23 and 25 suggest that within amino acid sequence 2207-2321 different amino acid 
residues may contribute to binding of human antibodies to the C2 domain of factor VIII. 
Inspection of the primary sequence of DP-10, DP-14, and DP-88 derived scFv does not 
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reveal characteristics that may explain different reactivity of the scFv with hybrids HP23 
and HP25. Since the overall structure of the heavy chain of the scFv is likely to be similar, 
the observed differences may reflect a modulating role of the CDR3-region on the epitope 
specificity. Alternatively, amino acid changes introduced by somatic hypermutation may 
result in the formation of additional contacts between antibodies and the C2 domain. At 
present, we cannot discriminate between these two possibilities. Future studies aim at 
defining amino acid residues within 2207-2321 that contribute to binding of DP-10, DP-14 
and DP-88 encoded human antibodies to the C2 domain of factor VIII.  
In a previous study we have shown that scFv encoded by germline gene segments DP-
10, DP-14 and DP-88 do not inhibit factor VIII in a Bethesda assay (Van den Brink et al., 
2000). Here, we have isolated additional scFv encoded by germline gene segment DP-88 
(Table 1). In accordance with previous data these scFv do not inhibit factor VIII activity. 
The lack of inhibition may be explained by the epitope of this subset of human antibodies, 
which may not overlap with a functional site within the C2 domain. Alternatively, the 
affinity of the scFv may be too low to compete for binding of factor VIII to phospholipids. 
In this study we also show that DP-5 encoded scFv do not inhibit factor VIII activity. At 
first sight these findings do not correspond with the properties of human monoclonal 
BO2C11, a DP-5 encoded antibody that does inhibit factor VIII with a specific activity of 
7000 BU/mg (Jacquemin et al., 1998). However, the affinity of BO2C11 for factor VIII is 
1000-10000 fold higher then observed for the DP-5 encoded scFv WR1 and 16 (0.014 nM 
versus 14, respectively, 115 nM). Apparently, high affinity binding is required for human 
antibodies to inhibit the interaction of factor VIII with phospholipid membranes. Therefore, 
we favour the view that the inability of the isolated scFv to inhibit factor VIII is primarily 
due to their reduced affinity for the C2 domain compared to that of complete antibody 
molecules. 
  Our data show the presence of two distinct antigenic sites within the C2 domain of 
factor VIII that are recognized by two classes of human antibodies. The first class of 
antibodies is encoded by VH gene segments DP-10, DP-14, and DP-88 whereas the second 
class of antibodies is encoded by VH gene segment DP-5. As argued previously, the 
preferential use of VH gene segment DP-5 for the assembly of anti-C2 antibodies may be 
explained by its overall negative charge, which can complement positively charged residues 
in the C2 domain. Yet, we do not have an explanation for the presence of DP-10, DP-14, 
and DP-88 gene segments in human antibodies that target the C2 domain. A common 
property of this class of human antibodies is their exceptionally large CDR3, which ranges 
from 20-23 amino acids. Selection of the DP-10, DP-14, and DP-88 for the assembly of 
anti-C2 antibodies can be related to their ability to incorporate a large CDR3 segment. In 
addition, other common structural elements shared between these closely related VH gene 
segments might explain their presence in anti-C2 antibodies. Collectively, our data suggest 
that two classes of antibodies recognize two distinct sites in the C2 domain of factor VIII. 
Identification and subsequent modification of the interactive surfaces in the C2 domain that 
reacts with these two classes of scFv can potentially reduce both the antigenicity and 
immunogenicity of this portion of factor VIII.  
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Abstract 
 
Inhibitory antibodies that develop in patients with haemophilia A bind to restricted regions 
in the A2, A3 and C2 domain of factor VIII. Functional studies have shown that anti-A2 
and anti-A3 antibodies interfere with assembly of the factor VIIIa-factor IXa complex. 
Binding of inhibitors to the C2 domain precludes binding of factor VIII to phospholipids. 
We have used phage display to isolate a large number of human monoclonal antibodies 
from the immunoglobulin repertoire of haemophilia A patients with an inhibitor. Epitope 
mapping studies suggest that the majority of human monoclonal antibodies bind to 
previously identified epitopes on factor VIII. Inspection of the amino acid sequence of the 
variable heavy chain (VH) domains of human anti-factor VIII antibodies reveals some 
striking features. Anti-A2 and anti-A3-C1 antibodies incorporate VH gene segments that 
are frequently used for assembly of human IgG molecules. This may explain the presence 
of antibodies with this specificity in a large number of inhibitor patients. Anti-C2 
antibodies are derived from two classes of VH gene segments both belonging to the VH1 
family that bind to two distinct antigenic sites in the C2 domain. Our findings suggest that 
B cells expressing immunoglobulin molecules that comprise VH gene segments with the 
above-mentioned characteristics are selectively amplified from the total repertoire 
following exposure to antigenic determinants in the C2 domain of factor VIII.  
 
 
Introduction 
 
Factor VIII participates in the intrinsic pathway of blood coagulation. The physiological 
importance of factor VIII is illustrated by the X-linked bleeding disorder haemophilia A 
which is due to functional absence of factor VIII. The bleeding tendency in patients with 
haemophilia A can be corrected by the administration of factor VIII concentrates. In 
approximately 20-40% of patients with severe haemophilia A inhibitory antibodies develop 
usually after 5-12 exposure days.1 Inhibitor formation hampers further treatment of patients 
with factor VIII. Activated prothrombin complexes concentrates and activated factor VII 
are used for treatment of bleeding episodes in inhibitor patients.1 Based on internal 
sequence homology factor VIII is divided in a series of homologous domains which are 
interspersed by short spacer regions that are rich in acidic amino acids.2 In plasma factor 
VIII circulates as a metal-ion linked heterodimer. The heavy chain consists of the domains 
A1-a1-A2-a2-B whereas the light chain is composed of the domains a3-A3-C1-C2. Due to 
proteolysis at various sites in the B domain the size of factor VIII heavy chain ranges 
between 90 and 220 kDa. In plasma factor VIII is bound to von Willebrand factor (VWF) 
which protects factor VIII from proteolytic degradation.2 Upon activation by thrombin or 
factor Xa, factor VIII dissociates from VWF and assembly of the factor VIIIa-factor IXa 
complex on phospholipid surfaces can occur.2 Activation of factor X by factor IXa is 
significantly enhanced by the non-enzymatic cofactor factor VIII. Functional sites on factor 
VIII involved in binding to factor IXa and phospholipids have been defined in considerable 
detail.3 Concomitantly, knowledge on the binding sites for factor VIII inhibitors on factor 
VIII has grown rapidly during the last five years.4 Based on different experimental 
approaches three major epitopes have been defined on factor VIII. In the A3 domain of 
factor VIII a binding site for factor VIII inhibitors has been localized to residues Gln1778-
Met1823.5,6 Binding of inhibitory antibodies to this site in the A3 domain interferes with 
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complex assembly of the factor IXa-factor VIIIa which is mediated by this part of the factor 
VIII light chain.5-7 Residues Arg484-Ile508 comprise a major determinant of a binding site for 
factor VIII inhibitors in the A2 domain.8 Single alanine replacements in this part of the A2 
domain suggested that Tyr487 is a residue critical for binding of inhibitory antibodies to this 
part of the A2 domain of factor VIII.9 Antibodies directed toward residues Arg484-Ile508 
prevent the stimulatory effect of isolated A2 domain on the catalytic activity of factor 
IXa.10 The inhibitory properties of anti-A3 and anti-A2 antibodies are in agreement with 
our current model of the assembly of the factor VIIIa-IXa complex. Initial high affinity 
binding is mediated by interaction of the factor VIII light chain with residues present in the 
EGF1-and EGF2 domains of factor IXa whereas stimulation of factor VIII cofactor activity 
results from interaction of the A2 domain with the protease moiety of factor IXa.3 
Apparently, factor VIII inhibitory antibodies can block the interaction of factor VIIIa with 
factor IXa via two distinct mechanisms.  
Conflicting data have been reported on the epitope for factor VIII inhibitors in the C2 
domain. Recombinant factor VIII fragments expressed in Escherischia coli revealed the 
presence of a binding site within region Val2248-Ser2312.11 Evaluation of the functional 
inhibition of a panel of anti-C2 inhibitors against a series of human/porcine hybrids 
suggested that residues Glu2181-Val2243 are involved in binding of factor VIII inhibitors.12 
The apparent discrepancies between the two studies may be explained by the different 
approaches that have been used to characterize factor VIII inhibitors. Antibodies directed 
toward the C2 domain interfere with binding of factor VIII to phospholipids.11,13 Current 
data suggest that a restricted number of 3-4 major binding sites for inhibitory antibodies are 
present on factor VIII. At present it is not clear why only a limited number of sites on factor 
VIII is targeted by the immune system. This may be explained by the use of only a selected 
portion of the total available immunoglobulin repertoire for the generation of antibodies 
that interact with immunodominant regions on factor VIII. To explore this issue we have 
analyzed the anti-factor VIII repertoire of a number of well-characterized inhibitor patients 
by phage display.  
 
 
Assembly of human immunoglobulin repertoires 
 
Immunoglobulins are composed of a light and a heavy chain that contain both variable and 
constant regions. The variable or V-regions are encoded by two and  three gene segments 
for the light and heavy chain respectively. The heavy chain locus is present on chromosome 
14 whereas loci encoding κ and λ light chains are present on chromosome 2 and 22, 
respectively. The individual loci contain large numbers of different gene segments that are 
assembled into functional antibody molecules during maturation of B cells. The heavy 
chain locus consists of over 120 variable heavy chain gene segments, 27 diversity (D) 
segments and 6 joining (J) segments which are followed by gene segments that encode 
constant parts of immunoglobulin heavy chains (µ, δ, γ3, γ1, α1, γ2, γ4, ε, α2).14,15 The κ 
light chain locus on chromosome 2 comprises 91 variable light (VL) chain gene segments 
and 5 J segments. The λ light chain on chromosome 22 contains >45 variable light chain 
and four J segments. Not all variable heavy and light chain segments are used for assembly 
of human antibodies. Approximately 50-75% of VH and VL segments are non-functional. 
This may be due to the absence of an open reading frame or lack of recombination sites 
flanking the variable segments.16 Assembly of immunoglobulin molecules proceeds in a 
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highly regulated manner. The first event that occurs is the joining of a D segment with a J 
segments in the variable region of the immunoglobulin locus. Subsequently, a VH gene 
segment and a µ constant region is added giving rise to a functional heavy chain which is 
co-expressed together with a surrogate light chain on a B cell precursor in the bone 
marrow.17 Next, a VL segment is fused with a JL segment resulting in a functional light 
chain segment that replaces the surrogate light chain. Following negative selection of self 
reactive B cells in the bone marrow, immature B cells are transported to the periphery 
where they express both IgM and IgD.17 Internalization of antigen via surface 
immunoglobulins on B cells is followed by proteolytic processing of antigens into peptides 
that are amenable for presentation by MHC class II molecules on the surface of B cells. T 
helper cells specifically recognizing the presented peptide then help B cells to proliferate. 
Proliferating B cells migrate to the lymph nodes where germinal centres arise that provide 
an environment for adequate T cell help for the generation of high affinity antibodies. 
Affinity maturation proceeds via amino acid replacements in the variable parts of the 
antibody, a process termed somatic hypermutation. Additionally, class switching from IgM 
to IgA, IgG or IgE occurs at this stage. Following affinity maturation, B cells develop into 
plasma cells that produce antibodies that are present in plasma. Alternatively, B cells 
develop into memory B cells, which are present for extended periods in the periphery 
thereby facilitating secondary responses to incoming antigens.  
 
 
Analysis of factor VIII inhibitors by phage display; general outline 
 
Using peripheral B lymphocytes as a source of RNA we have isolated immunoglobulin 
repertoires of patients with an inhibitor using a series of PCR reactions that target the 
variable domains of the immunoglobulin heavy chain.18 Several restrictions have been 
applied to preferentially amplify the anti-factor VIII repertoire of these patients. The 
majority of factor VIII inhibitors are of subclass IgG4 therefore an IgG4 specific 
amplification step was introduced in our experimental protocol. The concentration of IgG4 
is approximately 5% of the total quantity of IgG in human serum. Although this number 
does not necessarily correspond to the percentage of IgG4 positive B cells in the peripheral 
blood, it is anticipated that the resulting immunoglobulin repertoires are enriched for anti-
factor VIII antibodies. A further simplification involves the use of a immunoglobulin light 
chain repertoire that has been amplified from peripheral blood lymphocytes of healthy 
individuals.19,20 Different immunoglobulin light chains can pair to a single heavy chain and 
therefor it is anticipated that VH domains derived from patients with haemophilia A will 
pair with a suitable light chain from the available non-immune repertoire. Because of our 
focus on the variable part of the heavy chain we can only determine the characteristics of 
this part of immunoglobulin molecules that bind to factor VIII. The variable heavy chain 
locus encodes 51 functional variable heavy chain segments that can be classified into seven 
families (see Figure 1). Some families like VH2, 5, 6 and 7 contain only one or a few 
members whereas others (VH1, VH3 and VH4) harbour more then 10 members. Usage of 
the different families of VH germline gene segments in the peripheral repertoire roughly 
corresponds to the number of VH gene segments present within a single family (see Figure 
1; data based on data in ref. n. 21). It has been shown that the variable heavy chain gene 
segments contribute to the overall fold of the VH domain of immunoglobulins.22 Fusion of 
a VH gene with a D and a J segment, a process that involves addition and deletion of 
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nucleotides at the sites of junction, creates antigen-independent diversity on this initial fold. 
Suitably assembled IgG molecules make up the naïve B cell repertoire. The presence of 
antigen then stimulates selective outgrowth and maturation of B cells that express surface 
immunoglobulins that can interact with antigen. We have assessed the characteristics of the 
variable heavy chain domains of human antibodies directed against factor VIII. At present 
we have isolated human antibodies directed against major inhibitor epitopes in the A2, A3-
C1 and C2 domain of factor VIII.23-27 In the following paragraphs an initial analysis of the 
characteristics of the variable heavy chain (VH) domains of these antibodies will be 
presented. 
 
 
 
 
  A                    B    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. (A) Schematic representation of phylogenetic tree of human variable heavy (VH) gene segments. 
Based on sequence homology human VH gene segments can be divided into seven families. The number of 
individual gene segments present within each family is given in brackets (adapted from ref. n.16). (B) Variable 
heavy chain segments found in peripheral IgG-positive B cells. VH gene segments are classified into seven 
families (x-axis). On the y-axis the percentage of IgG-positive B cells expressing an IgG with a VH gene segments 
from one of these families is depicted (data based on ref. n. 21).  
 
 
Characteristics of anti-A2 and anti-A3-C1 antibodies obtained by phage 
display 
 
Since the characteristics of anti-A2 and anti-A3 antibodies display some common features 
we will first discuss this subset of human anti-factor VIII antibodies. Four different human 
antibodies directed against the A2 domain have been isolated of which three bind to the 
residues Arg484-Ile508 an immunodominant region on factor VIII.24,27 One anti-A2 antibody, 
designated VK41, bound to the acidic region that follows the A2 domain. Two out of four 
antibodies were derived from VH segments DP-47 (3-23) whereas the other ones were 
encoded by DP-10 (1-69) and DP-58 (gene segment not yet mapped). Among the six 
human antibodies directed against the A3-C1 domains of factor VIII that have been isolated 
5 were directed against residues Gln1778-Met1823, a major binding site for factor VIII 
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inhibitors in the A3 domain of factor VIII.5,6,25 All isolated antibodies were derived from 
germline gene segments of the VH1 and VH3 family. Two of the anti-A3-C1 antibodies 
were derived from germline gene segment DP-49 (3-30), two of DP-77 (3-21), one of DP-
14 (1-18) and one of DP-15 (1-8). At first sight there is little to be learned from the origin 
of variable heavy chain of the anti-A2 and anti-A3 antibodies. Germline gene segments 
used are derived from both the VH1 and VH3 family which does not come as a surprise 
since these VH segments from this families are used by 70% of peripheral IgG+ B cells 
(see Figure 1). Closer inspection of the occurrence of the different VH gene segments in the 
normal repertoire yields some remarkable features (see Figure 2). About 25% of the human 
IgG+ repertoire is derived from VH gene segments DP-47 (3-23), DP-49 (3-30) and DP-77 
(3-21). These findings show that anti-A2 and anti-A3 antibodies use VH gene segments that 
are preferentially expressed in IgG molecules in the normal repertoire. The observed 
preference suggests that epitopes present in the A2 and A3-C1 domain of factor VIII are 
accessible for surface immunoglobulins that have incorporated VH segments DP-47 (3-23), 
DP-49 (3-30) and DP-77 (3-21). The high concentration of IgG+ B cells in the periphery 
that are derived from these VH gene segments may be due to some inherent flexibility of 
IgG molecules with these VH gene segments to bind to antigenic sites on a variety of 
proteins. Alternatively, IgG molecules containing these VH gene segments may more 
efficiently cope with selective processes that occur during maturation of B cells. A 
relatively large number of immature B cells containing surface IgG derived from these VH 
gene segments is then available for incoming antigen. Independent of the underlying 
mechanism the presence of DP-47 (3-23), DP-49 (3-30) and DP-77 (3-21) gene segments in 
anti-A2 and anti-A3-C1 antibodies suggests that antibodies with this specificity are 
frequently observed in plasma of inhibitor patients. Indeed a large study concluded that 
anti-A2 or anti-A3 antibodies are present in virtually all patients with factor VIII 
inhibitors.28 The above analysis provides an attractively simple explanation for the frequent 
occurrence of anti-A2 and anti-A3 antibodies in inhibitor patients. However, some caution 
is warranted. Sofar only a limited number of patients has been included in our analysis. 
Also, our studies suggest that the epitopes in the A2 and A3-C1 domain are more complex 
then previously anticipated.24,25 More detailed studies on epitope specificity and VH gene 
usage are required to unequivocally determine whether a particular VH gene segment is 
preferentially incorporated into an IgG molecule binding to an antigenic site in the A2 or 
A3-C1 domain of factor VIII.  
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       VH3 gene family 
 
Figure 2. Variable heavy chain gene segments of the VH3 family present in peripheral IgG-positive B cells. 
On the x-axis the 22 gene segments belonging to the VH3 family are listed. On the y-axis the percentage of IgG-
positive B cells expressing an IgG containing one of these gene segments is depicted (data based on ref. n. 21). 
Anti-A2 and anti-A3-C1 antibodies are derived from gene segments 3-21, 3-23 and 3.30 which are commonly 
expressed in peripheral IgG positive B cells. 
 
 
Characteristics of anti-C2 antibodies obtained by phage display 
 
The plasma of most inhibitor patients contains antibodies that react with the C2 domain of 
factor VIII.28 At present we have isolated 16 different scFv reactive with this domain from 
the repertoire of patients with mild and acquired haemophilia A.23,26 Independently, Arai 
and co-workers have isolated 3 human antibodies from a phage library of an unrelated 
patient.29 Epstein Barr immortalization of peripheral B lymphocytes was used to isolate a 
human monoclonal antibody directed against the C2 domain of factor VIII.30 Sequence 
analysis of the VH domain of these clones reveals some interesting features. Germline gene 
segment DP-5 (1-24) of the VH1 family is used by about half of the anti-C2 antibodies that 
have been isolated sofar.23,26,29,30 The VH domain of the remainder of human antibodies 
directed against the C2 domain is derived from germline gene segments DP-10 (1-69), DP-
14 (1-18) and DP-88 (1-e).23,26 Phylogenetic analysis of gene segments belonging to the 
VH1 family shows that DP-10 (1-69), DP-14 (1-18) and DP-88 (1-e) are present within one 
branch of this family.26 Consistent with the more extensive differences in nucleotide 
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sequence, DP-5 (1-24) is present within a distinct branch of the VH1 family (see Figure 3). 
The available data suggest that based on the characteristics of their VH domains, anti-C2 
antibodies can be subdivided in two different classes. In a previous section it was proposed 
that anti-A2 and anti-A3 antibodies are derived from VH gene segments that are commonly 
used in the immunoglobulin repertoire. Both DP-10 (1-69) and DP-14  (1-18) are used in 
approximately 3-5% of peripheral IgG+ B cells whereas DP-5 (1-24) and DP-88 (1-e) occur 
in less then 1% the total IgG+ repertoire (data extracted from ref. n. 21). These percentages 
indicate that these germline gene segments are not dominantly expressed in IgG+ peripheral 
B cells. The restricted usage of VH gene segments DP-5 (1-24), DP-10 (1-69), DP-14 (1-
18) and DP-88 (1-e) for assembly of anti-C2 antibodies suggests that B cells expressing 
human antibodies with these VH gene segments are positively selected following exposure 
of naïve B cells to factor VIII.  
Structural elements present within these VH gene families may facilitate interaction of 
antibodies containing these gene segments with the C2 domain. Based on the three-
dimensional structure of a large collection of antibodies an overall topology of antigen 
binding sites has been proposed by Chothia and co-workers.22 Six antigen binding loops 
derived from both heavy (H1, H2, H3) and light chains (L1, L2, L3) have been defined that 
partially overlap with the hypervariable complementary determining regions (CDR’s) 
(Figure 4A).15,31 Both the H1 and H2 region are contained within the VH gene segment of 
an antibody. For region H1 three so-called “canonical structures” have been defined that 
differ in the number of amino acids contained within the H1 region. Similarly, the existence 
of four different canonical structures for the H2 region has been proposed.22 Interestingly, 
both germline gene segments DP-10 (1-69), DP-14 (1-18) and DP-88 (1-e) possess the H1-
H2 canonical structure 1-2. This combination of canonical structures is observed in only 7 
out of 51 VH gene segments. Four of them [DP-3 (1-f), DP-10 (1-69), DP-14 (1-18) and 
DP-88 (1-e)] belong to the VH1 family whereas DP-73 (5-51), 5-a and DP-21 (7-4.1) 
belong to the VH5 and VH7 family.15 Although region H1 and H2 determine only part of 
the architecture of an antigen binding site the presence of canonical structure 1-2 may 
facilitate interactions of VH domains with antigenic determinants present in the C2 domain. 
A canonical structure for the H2 region of germline gene segment DP-5 (1-24) could not be 
defined due to the presence of an aspartic acid instead of the more usual threonine, alanine 
or leucine at position 71.22,32 Interestingly, in three of out of four human antibodies that are 
encoded by the germline gene segment DP-5 (1-24) amino acid substitutions have taken 
place at this position (Figure 4A).26,30 Replacement of the glutamic acid for an alanine at 
position 71 may affect the canonical structure of the VH domains of the DP-5 (1-24) 
encoded antibodies which now becomes identical to that of the VH domains of the other 
anti-C2 antibodies (i.e. 1-2). The above analysis suggests that restricted usage of VH 
segments may endow anti-C2 antibodies with unique structural features that may play a role 
in creating an appropriate paratope.  
In the previous section evidence has been obtained for the existence of two classes of 
human antibodies that bind to the C2 domain of factor VIII. The first class contains VH 
domains that are derived from the closely related VH gene segments DP-10 (1-69), DP-14 
(1-18) and DP-88 (1-e) whereas the second class of human antibodies is characterized by 
the presence of germline gene segment DP-5 (1-24).26 Epitope mapping studies using a 
series of human/porcine and factor V/VIII hybrids reveals that these two classes of 
antibodies bind to distinct sites within the C2 domain of factor VIII. Residues contributing 
to the epitope of human antibodies encoded by VH segments DP-10 (1-69), DP-14 (1-18) 
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and DP-88 (1-e) resides in the carboxyl terminal part of the C2 domain (residues 2243-
2332).  In contrast human antibodies containing VH segment DP-5 (1-24) interact with 
residues at the amino- and carboxyl terminal part of the C2 domain. Recently, the three-
dimensional structure of the C2 domain of factor VIII has been determined.33 Based on the 
structure it was proposed that three loops containing hydrophobic residues intersect the 
phospholipid bilayer whereas a layer of positively charged residues can interact with 
negatively charged phosphate moieties of phosphatidylserine.33 In a follow-up study the 
three dimensional structure of a complex of the human monoclonal antibody BO2C11 and 
the C2 domain was determined at 2.0Å (Figure 4B).34 The VH domain of BO2C11 is 
encoded by VH gene segment DP-5.30 Figure 4A shows an alignment of the amino acid 
sequence of BO2C11 with the DP-5 (1-24) encoded antibodies we have recently isolated.26 
All four DP-5 (1-24) encoded antibodies have a relatively small CDR3 which comprises 8-
11 amino acids. The pattern of somatic hypermutation varies considerably between 
BO2C11 and the clones isolated by phage display, which is not surprising, since these 
antibodies have been derived from different patients. A common replacement between 3 of 
the 4 antibodies is a replacement of glutamic acid at position 71 for an alanine. This 
suggests that clones harbouring this amino acid replacement are preferentially selected from 
the total pool of C2 domain reactive B cells. A possible structural basis for this selective 
enrichment has been discussed in a previous paragraph. Based on the three dimensional 
structure of BO2C11 and the C2 domain multiple atomic contacts have been detected 
between the heavy chain of BO2C11 and the C2 domain (Figure 4A/4B).34 Comparison of 
the amino acid sequence of the WR clones with that of BO2C11 reveals that the majority of 
contact residues are conserved in the sequence of the WR clones (see Figure 4A). This 
suggests that the interactive surface of the complex between BO2C11 and the C2 domain is 
representative for other DP-5 (1-24) encoded anti-C2 antibodies. Small differences between 
binding of individual DP-5 (1-24) encoded antibodies to the C2 domain can however occur. 
The DP-5 (1-24) encoded residue Asp52 of BO2C11 that interacts with Arg2215 in the C2 
domain has been substituted for an asparagine or alanine in the VH domains of the WR 
clones (see Figure 4A). Also residue Asp99 present in the CDR3 of BO2C11 (indicated by 
an arrow; Figure 4A) is not conserved among the WR clones. Since several additional 
negatively charged amino acids are present in both CDR2 and CDR3 of WR1, WR16 and 
WR17, the effect of these substitutions on the overall architecture of the interactive surface 
is most likely limited.  Single amino acid substitutions in the C2 domain have recently been 
evaluated for their reactivity with factor VIII inhibitors.35 A reduction in functional 
inhibition of human antibodies was observed when residues Met2199/Phe2200 (Loop I; Figure 
4B) and Leu2252 (Loop II; Figure 4B) were substituted for an Ile, Leu and Phe, 
respectively.35 Combination of these substitutions resulted in a further decrease in the 
antigenicity of the C2 domain. The significance of electrostatic interactions mediated by 
Arg2210 and Arg2215 for binding to factor VIII inhibitors has not yet been assessed. Residues 
Arg2210 and Arg2215 are not critical for binding of factor VIII to phospholipids.36 Factor VIII 
variants harbouring substitutions at these sites may therefore display a reduced antigenicity 
while maintaining their phospholipid binding properties.  
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Figure 3. Phylogenetic tree of the VH1 family. Anti-C2 antibodies are derived from two classes of VH gene 
segments. The first class comprises VH gene segments DP-10 (1-69), DP-14 (1-18) and DP-88 (1-e). The second 
class of anti-C2 antibodies incorporates VH gene segment DP-5 (1-24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 (A). Deduced amino acid sequences of variable heavy chain domains of DP-5 (1-24) encoded 
human anti-C2 antibodies. FR, framework region; CDR, complementary-determining region; H1, H2 and H3, 
antigen binding loops defined based on structural homology of immunoglobulins.22 Dashes indicate sequence 
identity to germline gene segments. Lower case letters indicate amino acid substitutions originating from the PCR 
primer. The crystal structure of a complex of BO2C11 in contact with the C2 domain has been resolved.34 
Residues in BO2C11 in contact with the C2 domain are underlined. 
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   Figure 4.  (B) Three-dimensional model of a 
complex between BO2C11 and the C2 
domain of factor VIII. At the left site part of 
the VH domain (residues 1-113) of BO2C11 
is depicted, the C2 domain is positioned at 
the right. The light chain of BO2C11 is not 
included in this figure. Multiple contacts 
exist between BO2C11 and the C2 domain.34 
Loop I represent contacts between residues 
Met2199/Phe2200 of the C2 domain with 
residues Ser50/Ile59 of BO2C11. Loop II 
represents contacts between Leu2251/2252 of C2 
with residues Val2/Tyr98 of BO2C11. 
Highlighted are residues Arg2215 and Arg2220 
of C2 that interact with negatively charged 
residues Asp52 and Asp99  in BO2C11. 
 
 
 
 
Conclusions and implications 
 
Overall, our data show that phage display is a useful technology to isolate large numbers of 
human monoclonal antibodies from the repertoire of patients with inhibitors. Inspection of 
the primary amino acid sequence of these antibodies suggest that only a restricted number 
of variable heavy chain segments is used for the assembly of human antibodies that react 
with the C2 domain. In contrast, less restriction is observed for anti-A2 and anti-A3 
antibodies at least at the level of VH gene segments. The availability of a large panel of 
human antibodies derived from different patients is likely to increase our knowledge on the 
number and complexity of B cell epitopes on factor VIII. Subsequent modification of 
antigenic sites within the A2, A3 and C2 domain may provide a basis for the reduction of 
the antigenicity and perhaps also immunogenicity of factor VIII.4 Alternatively, it may be 
possible to develop antibody-based reagents that interfere with binding of inhibitory 
antibodies to factor VIII. In this respect it is noteworthy to mention that the majority of 
variable domain antibody fragments do not interfere with factor VIII cofactor activity. We 
have previously shown that the non-inhibitory single chain variable domain antibody 
fragment EL-14 can partially neutralize factor VIII inhibitors in an in vitro assay.18 Further 
study is required to establish whether the concept of masking of antigenic sites on factor 
VIII by antibody-derived reagents can be translated into a new therapeutic option for 
treatment of patients with inhibitors. 
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Abstract 
 
We report on the isolation of two antibodies from a phage library of a patient with mild 
haemophilia A. Inspection of the sequence of these two antibodies designated VK29 and 
VK33 reveals that they are derived from VH germline gene segments DP-25 (1-03) and 
DP-79 (4-39). ScFv corresponding to clone VK29 and VK33 were isolated and the affinity 
for factor VIII light chain was determined. ScFv VK29 bound with high affinity to factor 
VIII (Kd 3.6 nM). ScFv VK33 displayed a somewhat lower affinity (Kd 28.7 nM) due to its 
relatively large dissociation rate. Epitope specificity of ScFv’s VK29 and VK33 was 
determined by immunoprecipitation with a series of metabolically labelled fragments 
corresponding to the light chain of factor VIII. ScFv VK29 and VK33 recognized both 
factor VIII light chain and C2 domain. Binding of scFv VK29 and VK33 to factor VIII was 
not abolished by replacement of amino acid residues 1778-1823 (in the A3 domain) for the 
corresponding region of factor V. These findings indicate that the epitope of these scFv is 
contained within the C2 domain and not within residues 1778-1823 of the A3 domain. 
Interestingly, the VH segments of the two isolated scFv do not adhere to previously 
established criteria for anti-C2 antibodies. To obtain more insight into the epitope of these 
scFv we performed binding experiments with monoclonal antibodies CLB-CAg 117 and 
ESH4. These murine monoclonal antibodies have previously been shown to bind to two 
distinct non-overlapping epitopes within the C2 domain. Clone VK29 and VK33 only 
reacted with factor VIII light chain that had been immobilized via ESH4. No reactivity was 
observed when binding to factor VIII light chain immobilized via CLB-CAg 117 was 
evaluated. These data show that VK29 and VK33 bind to an antigenic site within the C2 
domain that overlap with the epitope of CLB-CAg 117. Previously, we have shown that this 
epitope is recognized by scFv derived of VH gene segments DP-10 (1-69), DP-14 (1-18) 
and DP-88 (1-e). Our results show that the VH gene usage of antibodies binding to the 
epitope defined by CLB-CAg 117 is less restricted then previously anticipated.  
 
 
Introduction 
 
Haemophilia A is an X-linked bleeding disorder that results from a deficiency or 
dysfunction of blood coagulation factor VIII.1 Treatment of the bleeding tendency in 
patients with haemophilia A is accomplished by intravenous administration of factor VIII. 
Treatment is complicated by the development of immune responses to the transfused 
product in some patients. This complication results in development of antibodies that limit 
the functional activity of factor VIII. Extensive characterization of panels of human 
antibodies present in patient’s plasma have been performed.2,3 At present multiple binding 
sites for these antibodies, that are commonly termed factor VIII inhibitors, are described in 
the A2, A3 and C2 domain of factor VIII. In addition, the presence of binding sites in the B 
domain of factor VIII has been suggested by several studies.4,5 Inspection of the domain 
structure of factor VIII (A1-a1-A2-a2-B-a3-A3-C1-C2) reveals that the A domains of 
factor VIII are interspersed by areas that comprise 35-40 amino acids that have been 
designated a1, a2 and a3.6 These areas contain a relatively large number of negatively 
charged amino acids that together constitute a consensus sequence for tyrosine sulfation.7  
Human antibodies that react with these so-called acidic regions have been identified in a 
number of haemophilia A patients with inhibitors.5,8-10 Together these data suggest that 
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different surface-exposed areas may account for the immunogenicity of factor VIII. 
Analysis of the dispersion of epitopes on factor VIII has suggested that several immuno-
dominant regions are present.9 An immunodominant epitope corresponds to residues 
Arg484-Ile508 that accommodates binding of most anti-A2 antibodies.11 Also inhibitory 
antibodies binding to the A3 and C2 domains are observed in plasma of the majority of 
inhibitor patients.9,12 At present detailed epitope mapping studies on epitopes present in the 
A3 domain have only been performed for a limited number of samples. Data from these 
studies suggests that residues 1778-1823 comprise an immunodominant region in the A3 
domain.13,14 Within the C2 domain residues 2181-2243 have been assigned to contribute to 
binding of inhibitory antibodies15,16. Taken together, epitope mapping studies performed 
with heterogeneous mixtures of factor VIII reactive IgG point at the presence of a limited 
number of immuno-dominant antigenic surfaces on factor VIII.  
 Comparison of the antigenicity of factor VIII with model antigens like hen egg 
lysozyme reveals some interesting differences. Hen egg lysozyme is a relatively small 
protein with a molecular mass similar to one of the C domains of factor VIII. The surface 
area on lysozyme covered following binding of an antibody ranges from 500 to 900 Å2.17  
Modelling studies based on the known three-dimensional structure of hen egg lysozyme 
suggests that only half of the accessible surface area of lysozyme is covered following 
binding of four antibodies with different epitope specificity.17 These data illustrate that 
multiple epitopes can be presence within a relatively small antigen such as hen egg 
lysozyme. Thus, it is anticipated that multiple binding sites for antibodies can bind to the 
C1 and C2 domains of factor VIII that have similar dimensions as hen egg lysozyme. 
Furthermore, the even larger A1, A2 and A3 domains should be able to accommodate 
binding of human antibodies to multiple surface exposed areas. Nevertheless, as described 
above only restricted portions areas within the A2, A3 and C2 domains factor VIII are 
involved in binding of human antibodies derived from plasma of patients with haemophilia 
A.  The restricted epitope specificity of factor VIII inhibitors suggests that human 
antibodies with a preference for immuno-dominant sites are selected from the total 
repertoire that is generated from recombination events at the heavy and light chain 
immunoglobulin locus.18 Previously, we have described the characteristics of human 
monoclonal antibodies directed to factor VIII that were isolated by phage display.8,19-22 This 
analysis revealed that anti-A2 and anti-A3 antibodies utilize variable immunoglobulin 
heavy chain (VH) gene segments that are commonly expressed within the normal 
repertoire.8,20 Apparently, these VH segments can participate in creation of appropriate 
paratopes that preferentially interact with antigenic sites within the A2 and A3 domain. The 
primary structure of human antibodies directed towards the C2 domains reveals some 
interesting features19,21 Based on the amino acid sequence of their VH domains, anti-C2 
antibodies can be arranged in two different classes. The first class of antibodies is encoded 
by VH segment DP-5 (1-24) and these antibodies have a relatively short CDR3 region in 
the heavy chain of around 8 amino acids. Human antibodies belonging to the second class 
of anti-C2 antibodies are derived from the closely related VH gene segments DP-10 (1-69), 
DP-14 (1-18) and DP-88 (1-e). In addition, this second class of human antibodies contain 
an exceptionally large CDR3 that ranges from 18-23 amino acids. Functional importance of 
the observed differences in primary sequence is suggested by epitope mapping studies that 
reveal that the two classes of human antibodies can bind to distinct antigenic sites within 
the C2 domain of factor VIII.21  
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 To further assess the proportion of the human immunoglobulin repertoire that is 
utilized for assembly of factor VIII inhibitors we screened a phage display library for the 
presence of light chain antibodies. Two novel human antibodies were isolated that bound 
with high affinity to the C2 domain. Inspection of their primary structure revealed some 
striking differences with respect to the characteristics of previously characterized anti-C2 
antibodies that argue for a modification in the current classification of anti-C2 antibodies.  
 
 
Materials and Methods 
 
Materials 
Factor VIII light chain was prepared from factor VIII concentrates as described 
previously.23  Monoclonal antibodies CLB-CAg 12, CLB-CAg A and CLB-CAg 117 have 
been described previously.23,24 CLB-CAg 117 reacts with the C2 domain of factor VIII.13 
CLB-CAg 12 recognizes an epitope in the A3-C1 domains of factor VIII whereas residues 
1804-1818 in the A3 domain are required for binding of CLB-CAg A.20 Monoclonal 
antibody ESH4 was purchased from American Diagnostica (Greenwich, CT).  
 
Selection of phage library 
Construction of a phage library of peripheral blood lymphocytes of patient AMC-67 has 
been described previously.8 In a previous manuscript we have described the epitope 
specificity of inhibitory antibodies that develop in this mild haemophilia A patient with an 
Arg593 to Cys mutation.25 Neutralization experiments revealed that the majority of 
inhibitory antibodies were directed against the A2 domain. Also, antibodies reactive with 
factor VIII light chain and C2 domain were present in plasma of this patient at the time of 
library construction. The library consisted of 1.9 x 107 independent clones.8 Recombinant 
phages corresponding to the patient’s immunoglobulin repertoire were prepared by 
infection of a portion of the phage display library with 8 x 109 VSCM13 helper phage. 
Recombinant phages were collected and selected for binding to factor VIII light chain using 
three different selection strategies. Factor VIII light chain was directly immobilized on 
immunotubes at a concentration of 10 µg/ml dissolved in 50 mM NaHCO3 (pH 9,5). 
Alternatively, factor VIII light chain was immobilized via monoclonal antibodies CLB-
CAg 117 and ESH4 in microtitre plates. Selection of phage binding to factor VIII was 
performed as described previously.8 After three rounds of selection recombinant phage 
prepared from single colonies were screened for binding to factor VIII light chain that was 
immobilized via monoclonal antibody CLB-CAg 12. Bound phages were detected using a 
peroxidase-labelled polyclonal antibody directed against the filamentous phage M13 
(Pharmacia-LKB, Woerden, The Netherlands).  Selection on factor VIII light chain 
immobilized via CLB-CAg 117 and ESH4 did not yield factor VIII reactive clones. Two 
positive clones were isolated following three rounds of selection on factor VIII light chain 
directly immobilized on immunotubes. The nucleotide sequence of the VH and VL segment 
of the two positive clones was determined on an Applied Biosystems 377 XL automated 
DNA sequencer (Foster City, CA). The obtained nucleotide sequences were aligned to the 
V-BASE database of variable heavy and light chain immunoglobulin gene segments.  
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Characterization of scFv 
Two clones designated VK29 and VK33 that express phages that interact with the light 
chain of factor VIII were selected for further study. The Nco1-NotI inserts encoding the 
single chain variable antibody domains (scFv) were transferred to plasmid pUC119-
Sfi/Not-His6. In the resulting plasmids the scFv are expressed with a carboxy-terminal His 
tag which allows for purification of scFv by immobilized metal chelate-affinity 
chromatography (Qiagen, Hilden, Germany). ScFv’s VK29 and VK33 were purified 
essentially as described previously. ScFv were eluted in 20 mM HEPES (pH 7.4), 150 mM 
NaCl and 100 mM Imidazole. Eluted scFv were free of contaminating proteins as assessed 
by SDS-PAGE.  
 The affinity for factor VIII light chain was determined using surface plasmon 
resonance using a BIAcore 2000 biosensor system (Biacore, Uppsala, Sweden). Factor VIII 
light chain was covalently coupled to the dextran surface of an activated CM5 sensor chip 
at a density of 88.5 fmol/mm2. Binding of different concentrations of scFv was evaluated in 
20 mM HEPES (pH 7.5), 150 mM NaCl and 100 mM Imidazole for 2 minutes at a flow of 
20 µl/min at 25°C. At 2 minutes, channels were incubated with the same buffer in the 
absence of added scFv. Under these conditions, part of the bound scFv dissociates from the 
immobilized factor VIII light chain. Dissociation (koff) and association constants (kon) were 
calculated as described previously. Equilibrium binding constants (Kd) were calculated 
from experimentally determined kon and koff values.  
 Immunoprecipitation analysis was performed using metabolically labelled factor VIII 
fragments corresponding to the light chain and C2 domain of factor VIII. In addition, a 
factor VIII light chain in which an immunodominant epitope at residues 1778-1823 was 
replaced by the corresponding sequence of factor V (HV1778-1823) was used in these 
studies.20 Immunoprecipitation analysis was performed as follows. Conditioned medium 
containing metabolically labelled fragments were first precleared by incubation with gelatin 
Sepharose 4B and Ni-NTA agarose. Preformed complexes of scFv with Ni-NTA agarose 
were then incubated with metabolically labelled fragments overnight at 4°C. Following 
extensive washing with immunoprecipatation buffer samples were incubated for 5 min at 
95°C in SDS-PAGE sample buffer. Eluted material was analysed under non-reducing 
conditions by 12.5% SDS-PAGE.  
 
 
Results 
 
Isolation and sequence characteristics of factor VIII light chain specific antibodies from a 
phage display library  
Previously, we reported on the epitope specificity of an inhibitor in a mild haemophilia A 
patient with an Arg593 to Cys mutation.25 The majority of inhibitory antibodies in this 
patient are directed towards residues 484-508 in the A2 domain. Screening of a phage 
display library for antibodies reactive with the A2 domain yielded two scFv, VK34 and 
VK41.8 Clone VK34 reacted with residues 484-508 of the A2 domain whereas clone VK41 
was directed against residues 712-736 in the acidic region following the A2 domain. 
Besides anti-A2 antibodies in plasma of this patient significant levels of anti-factor VIII 
light chain antibodies have been found.25 Therefore, we screened a phage library of this 
patient for antibodies that reacted with factor VIII light chain. Different protocols were 
employed using factor VIII light chain immobilized directly on immunotubes or indirectly 
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via monoclonal antibodies CLB-CAg117 and ESH4.23,24 Two positive clones were obtained 
following three rounds of selection on factor VIII light chain immobilized on immunotubes. 
Selection on factor VIII light chain immobilized via CLB-Cag117 and ESH4 did not yield 
phage reactive with factor VIII. The nucleotide sequence of the two clones was determined 
and compared to the most homologous immunoglobulin heavy and light chain segments 
using the V-BASE sequence directory (Figure 1).26 Clone VK29 was derived from variable 
heavy chain gene segment DP-25 (1-03). The amino acid sequence of clone VK29 differed 
at 9 amino acid positions from that of the VH gene segment DP-25 (1-03). The variable 
light chain of clone VK29 was derived from VL segment DPK22, a member of the VKIII 
family. Clone VK33 was derived from variable heavy chain segment DP-79 (4-39). Only 
four amino acid substitutions were observed when compared to germline gene segment DP-
79 (4-39). The variable light chain of clone VK33 was most homologous to variable light 
chain gene segment DPK24, a member of the VKIV family. The variable heavy chain 
fragments of both clones contained relatively large CDR3 regions of 18 and 21 amino 
acids, respectively. The joining segments of the variable heavy chain were most likely 
derived of segments JH4b (VK29) and JH3b (VK33).  
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Figure 1. Amino acid sequence of variable heavy and light chain of scFV VK29 and VK33. Sequences are 
aligned against the most homologous VH and VL gene segments using the V base directory. Lower case indicates 
amino acid substitutions encoded by the PCR primer. Dashes indicate sequence identity to germline gene 
segments. Gaps introduced for optimal alignment are indicated by dots. FR, indicates framework regions.  
 
 
Heavy chains 
                     FR1                  CDR1       FR2             CDR2          
          ------------------------------ ----- -------------- ----------------- 
                                                                                       
                  1         2         3             4          5          6         
          123456789012345678901234567890 1ab2345 67890123456789 012a3456789012345  
    
    
DP-25     QVQLVQSGAEVKKPGASVKVSCKASGYTFT S..YAMH WVRQAPGQRLEWMG WINAGNGNTKYSQKFQG  
VK29      ----Q------R-----------------S N..HV-- -------------- ---------E-------  
    
DP-79     QLQLQESGPGLVKPSETLSLTCTVSGGSIS SSSYYWG WIRQPPGKGLEWIG SIY.YSGSTYYNPSLKS  
VK33      -v---------------------------- ------- -------------- ---.-----S-----E-  
 
 
                          FR3                       CDR3              FR4 
          -------------------------------- --------------------- ------------ 
                                                1                       1 
              7         8            9          0                       1   
          67890123456789012abc345678901234 567890abcdefghijklm12 345678901234 
  
DP-25     RVTITRDTSASTAYMELSSLRSEDTAVYYCAR 
VK29      --IM------------F--------------- GMLSDYDSSGYYFDYF...DY WGQGTLVTVSSG  
 
DP-79     RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR  
VK33      ---M-----Q---------------------- RSRSFPLRYFDWLPDGGAFDI WGQGTMVTVSSG 
 
  
Light chains 
 
                    FR1                  CDR1             FR2         CDR2          
          ----------------------- ----------------- --------------- ------- 
                                                                                        
                  1         2          3                4          5         
          12345678901234567890123 45678901abcdef234 567890123456789 0123456  
    
DPK22     EIVLTQSPGTLSLSPGERATLSC RASQSVSSS-----YLA WYQQKPGQAPRLLIY GASSRAT  
VK29      --------S---A-L-D-V-IT- -----I---.....H-- ---------L----- -T----P  
 
DPK24     DIVMTQSPDSLAVSLGERATINC KSSQSVLYSSNNKNYLA WYQQKPGQPPKLLIY WASTRES  
VK33      --Q-------------------- ----------------- ----------R---Y -------  
 
 
                          FR3                 CDR3             FR4 
          -------------------------------- --------- -------------------- 
                                                       1         1 
             6         7         8          9          0         1   
          78901234567890123456789012345678 901234567 89012345678901234567 
DPK22     GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSP  
VK29      -------------------------------- -------RT FGQGTKVEIKRAAAEQKLIS  
 
DPK24     GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQYYSTP  
VK33      -------------------N------------ -H---Y-LT FGQGTKLEIKRAAAEQKLIS 
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Binding characteristics of scFv VK29 and VK33. 
Variable antibody domain fragments VK29 and VK33 were expressed as scFv in E. coli 
and purified to homogeneity by immobilized metal chelate-affinity chromatography by 
virtue of a carboxy-terminely inserted 6 x His-tag.8 The resulting scFv were tested for their 
ability to inhibitor procoagulant activity of factor VIII in a one-stage clotting assay. 
Addition of increasing amounts of scFv did not result in inhibition of factor VIII activity (< 
10 BU/mg). Subsequently, we determined the affinity of clone VK29 and VK33 for 
immobilized factor VIII light chains using surface plasmon resonance, using a 
BIAcore2000 biosensor system. Increasing concentrations of scFv were incubated with 
immobilized factor VIII. Both scFv VK29 and scFv VK33 rapidly associate with factor 
VIII light chain (Figure 2). Fitting of this part of the curve yielded a kon of 9.2 x 104 for 
scFv VK29 and 5.7 x 104 for scFv VK33 (Table I). Dissociation of scFv was initiated after 
2 minutes. The rate of dissociation of scFv VK29 was extremely low whereas scFv VK33 
dissociates more rapidly from immobilized factor VIII light chain. A dissociation constant 
Kd of 3.6 nM was derived from the experimentally determined values of kon and koff for 
scFv VK29. Largely due to its increased koff ScFv VK33 bound to factor VIII light chain 
with a much lower affinity compared to scFv VK29 (Kd = 28.7 nM).  The affinity for factor 
VIII light chain is similar to that of other scFv directed against factor VIII light chain.20,21 
 
 
A                                                                                              B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Kinetic analysis of the interaction of scFv VK29 and VK33 with factor VIII light chain. Binding of 
different concentrations of scFv VK29 (A) and VK33 (B) to factor VIII light chain was determined by surface 
plasmon resonance.  Response is depicted in response units and is corrected for non-specific binding. On the x–
axis time is depicted in seconds. Association of scFv with factor VIII light chain was followed for 2 minutes; 
dissociation was also allowed for 2 minutes. Concentration of scFv added were 10, 20, 40, 80 and 120 nM. 
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Table I. Binding kinetics of scFv VK29 and VK33.  
Values for kon, koff and Kd were determined as outlined in Materials and Methods. 
 
 
 
Epitope mapping of scFv VK29 and VK33.   
To determine the epitope specificity of scFv VK29 and VK33 we determined their 
reactivity with a set of metabolically labelled fragment derived of factor VIII light chain. 
Monoclonal antibody CLB-CAg 117, directed against the C2 domain and CLB-CAg A, 
directed against residues 1803-1818 were included in these studies. First, reactivity of scFv 
VK29 and VK33 with intact factor VIII light chain was assessed. Similar to CLB-CAg A 
and 117, both scFv VK29 and VK33 interact with metabolically labelled factor VIII light 
chain (Figure 3). Replacement of residues 1778-1821 by the corresponding residues of 
factor V did not abrogate binding of scFv VK29 and VK33 to factor VIII light chain 
(Figure 3). In contrast, CLB-CAg A does not react with this hybrid molecule. In agreement 
with previous findings, CLB-CAg 117 retains its ability to interact with hybrid factor VIII 
molecule HV1778-1821. These data indicate that the epitope of scFv VK29 and VK33 is 
not contained within residues 1778-1821 of the A3 domain. Subsequently, we evaluated 
reactivity of different antibodies with metabolically labelled C2 domain. CLB-CAg A did 
not react with metabolically labelled C2 domain whereas binding of CLB-CAg 117 to this 
fragment is observed. Both scFv VK29 and VK33 are able to interact with the C2 domain. 
These results indicate that scFv VK29 and VK33 are directed towards the C2 domain of 
factor VIII. Previous results have shown that two distinct antigenic sites are present within 
the C2 domain.21 This classification is based on competition experiments with monoclonal 
antibodies ESH4 and CLB-CAg 117 that bind to two non-overlapping sites in the C2 
domain. To obtain information on the epitope specificity of scFv VK29 and VK33 we 
evaluated the binding of phage expressing scFv VK29 and VK33 to factor VIII light chain 
immobilized via ESH4 and CLB-CAg 117. As a control, we utilized the A3-C1 specific 
antibody CLB-CAg 12. Phage expressing scFv VK29 and VK34 both interact with factor 
VIII light chain immobilized via CLB-CAg 12 (Figure 4). Also, binding to factor VIII light 
chain immobilized via ESH4 was observed under these conditions. In contrast, phage 
expressing scFv VK29 and VK33 were not capable of binding to factor VIII light chain 
immobilized via CLB-CAg 117. These data show that scFv VK29 and VK33 bind to an 
epitope in the C2 domain that overlaps with that of CLB-CAg 117.  
 
 
 
 
 
 
 
scFv 
 
koff (s-1) kon (M-1s-1) Kd (nM) 
VK33 1.6 (± 0.2) x 10-3 5.7 (± 0.7) x 104 28.7  ± 5.1 
      
VK29 3.3 (± 0.6) x 10-4 9.2 (± 1.4) x 104 3.6 ± 0.8 
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Figure 3. Reactivity of scFv VK29 and VK33 with different factor VIII light chain variants. Reactivity of 
scFv VK29, VK33, MoAb CLB-CAg117 and CLB-CAgA with factor VIII light chain (LCh), HV1778-1823, in 
which residues 1778-1823 have been replaced by the corresponding residues of factor V (HV1778-1823) and C2 
domain (C2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Competition between scFv and murine monoclonal antibodies for binding to factor VIII light 
chain. Factor VIII light chain was immobilized via monoclonal antibody CLB-CAg12 (white bars), CLB-CAg117 
(black bars) and ESH4 (grey bars). Subsequently, it was determined whether VK29 and VK33 could still interact 
with immobilized factor VIII light chain. On the x-axis absorbance at 540-450 nm is indicated.   
 
117 A 29 33
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Table II. Characteristics of anti-C2 scFv's specific for the epitope defined by 
monoclonal antibody CLB-CAg 117.  
The most homologous VH germline gene segments, total number of somatic hypermutations in the heavy chain 
and the length of the CDR3 region of the heavy chain (H-CDR3) are listed. Canonical structures for the first (H1) 
and second (H2) antigen binding loop as defined by Chotchia et al and the affinity for factor VIII light chain (Kd in 
nM) are shown.32 SvFv's were isolated from three different patients by phage display analysis; 1) This study, 2) van 
den Brink et al Blood 2000, 3) van den Brink et al Blood 2002.19,21 
 
 
 
 
Discussion 
 
One of the initial steps during an immune response requires the functional interaction of a 
naive B cell expressing surface Ig molecules with a foreign antigen. Several factors may 
contribute to whether productive binding of antigen to immunoglobulin receptors on naive 
B cells will occur. On the antigen the number and density of antigenic determinants is 
important for eliciting an appropriate immune response. Equally relevant is the generation 
of a broad repertoire of immunoglobulin receptors with a high propensity to interact with 
surface exposed areas on an antigen. Diversification is created by recombination of 
different gene segments of the variable heavy and light chain locus.18 These recombination 
events generate diversity at the level of the hypervariable antigenic binding loops in the 
heavy and light chain. Generation of a functional immunoglobulin then requires productive 
pairing of heavy and light chain, a process that can further modify antigen binding 
properties of immunoglobulin surface receptors. Additional diversity is provided by 
ongoing processes as somatic hypermutation, receptor editing and receptor revision.27-29 
Thus a broad antibody repertoire is created which can potentially interact with a virtually 
unlimited number of foreign antigens.  
 Recognition of antigen by B cell receptors is driven by the presence of antigenic 
surfaces that are recognized by the antigen binding loops present on surface 
ScFv VH domain 
germline  
Som. 
hyperm. 
H-CDR3 
length   
Canonical 
structure 
LCh affinity 
(Kd in nM) 
VK29 1) DP-25 (1-03) 9 18 1-3 3.6 
VK33 1) DP-79 (4-39) 4 21 3-1 28.7 
EL-14 2) DP-10 (1-69) 12 21 1-2 1.1 
EL-5 2) DP-14 (1-18) 10 23 1-2 226 
EL-16 2) DP-14 (1-18) 11 23 1-2 nd 
EL-25 2) DP-14 (1-18) 8 23 1-2 nd 
WR2 3) DP-88 (1-e) 15 18 1-2 nd 
WR3 3) DP-88 (1-e) 14 18 1-2 nd 
WR7 3) DP-88 (1-e) 16 18 1-2 nd 
WR8 3) DP-88 (1-e) 16 18 1-2 4.2 
WR10 3)  DP-88 (1-e) 11 20 1-2 12 
WR11 3) DP-88 (1-e) 15 18 1-2 4.8 
WR13 3) DP-88 (1-e) 15 18 1-2 2.1 
WR15 3) DP-88 (1-e) 15 18 1-2 nd 
EL-9 2) DP-88 (1-e) 16 20 1-2 42 
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immunoglobulins. Previously, we have shown that antigenic sites present within the C2 
domain of factor VIII, are recognized by immunoglobulin molecules that incorporate a 
selective group of VH gene segments that are derived from the VH1 family.19,21 Antigenic 
sites contained within the amino terminus and carboxy terminus of the C2 domain 
contribute to binding to human antibodies that have incorporated the VH gene segment DP-
5 (1-24). ScFv that incorporate this VH segment compete with monoclonal antibody ESH4 
for binding to factor VIII. The epitope of DP-5 (1-24) derived antibodies has been mapped 
to residues 2181-2199.21 Additional data concerning the epitope specificity of DP-5 (1-24) 
encoded human anti-C2 antibodies are derived from co-crystallization and epitope mapping 
studies of the human monoclonal antibody BO2C11.30,31 Multiple contacts exist between 
BO2C11 and the C2 domain. Mutagenesis studies reveal an important role for residues 
Met2199 and Phe2200 present in one of the phospholipid binding loops of the C2 domain.31 
These amino acids are in close proximity to residues 2181-2199 that are required for 
binding of DP-5 (1-24) derived scFv's to the C2 domain. 21  
 A second class of human anti-C2 antibodies that has been isolated by phage display is 
characterized by competition with murine monoclonal antibody CLB-CAg 117.21 Residues 
contained within the carboxy-terminal part of the C2 domain are involved in binding to 
scFv belonging to this second class of anti-C2 antibodies. VH domains of this class of scFv 
are derived from closely related germline gene segments DP-10 (1-96), DP-14 (1-18) and 
DP-88 (1-e) (Table II). In this report we describe two scFv VK29 and VK33 that are not 
derived from these germline gene segments. ScFv VK29 is most homologous to germline 
gene segment DP-25 (1-03), a germline gene segment belonging to the VH1 family. 
Inspection of a family tree of the VH1 family shows that segment DP-25 (1-03) is present 
in another branch of the VH1 family as DP-10 (1-96), DP-14 (1-18) and DP-88 (1-e) (see 
Figure 4, Chapter 2). Remarkably, scFv VK33 is derived from germline gene segment DP-
79 (4-39) belonging to a different VH family (VH4). Based on collection of data from a 
large number of antibody structures, canonical structures have been defined that describe 
the main-chain fold of antigen binding loops in the CDR1 and CDR2 region (H1 and H2).32 
VH germline gene segments DP-10 (1-96), DP-14 (1-18) and DP-88 (1-e) display canonical 
structure 1-2 for H1 and H2 (see chapter 3). The variable heavy chain segment DP-25 (1-
03) renders scFv VK29 with a different canonical structure (1-3). The observed differences 
predict a different presentation of the second antigen binding loop between scFv VK29 and 
the previously identified scFv's. Even more pronounced differences are observed for scFv 
VK33 that displays canonical structure 3-1 (Table II). Competition experiments with 
monoclonal antibodies CLB-CAg 117 and ESH4 showed that scFv VK29 and VK33 bind 
to the same epitope as scFv encoded by DP-10 (1-96), DP-14 (1-18) and DP-88 (1-e). Our 
results indicate that VH gene segment and predicted canonical structures of the anti-C2 
antibodies competing with CLB-CAg 117 can not entirely account for the observed binding 
specificity of this class of anti-C2 antibodies. Remarkably, all scFv's that compete with 
CLB-CAg 117 for binding to the C2 domain contain an unusually large CDR3. The CDR3 
region of fifteen scFv's isolated from the repertoire of three different patients ranges from 
18 to 23 amino acids (Table II). The hypervariable CDR3 region of the heavy chain 
provides a major contribution to the creation of appropriate paratope.32 Previously, it has 
been suggested that long CDR3 loops are relatively flexible and are prone to so-called 
“conformational isomerism”.33-35 Support for this notion is gained from the molecular 
properties of polyreactive human antibodies that contain a relatively long CDR3.36,37 These 
findings raise the possibility that human antibodies directed against the C2 domain 
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originate from a pool of polyreactive antibodies that can interact with multiple antigens by 
virtue of their unusually large CDR3. Subsequent exposure to factor VIII provides a 
platform for affinity maturation yielding anti-C2 antibodies that can bind specifically and 
with high affinity to an epitope that is defined by its interaction with the murine monoclonal 
antibody CLB-CAg 117.  
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Abstract 
 
We have characterized anti-factor VIII antibodies in a mild haemophilia A patient with an 
Arg593 to Cys mutation in the A2 domain using V gene phage display technology. All 
isolated single-chain variable domain antibody fragments were directed against residues 
Arg484-Ile508, a binding site for factor VIII inhibitors in the A2 domain. After a further 
period of replacement therapy, a transient rise in inhbitor  was observed. These antibodies 
were directed against the A2 domain. Activation of a pre-existing pool of B cells, which 
express antibodies directed towards residues Arg484-Ile508, could explain the rapid 
anamnestic response.  
 
 
Introduction 
 
A serious complication in haemophilia A treatment is the development of antibodies that 
neutralise factor VIII activity (inhibitors). The prevalence of factor VIII inhibitors in 
patients with severe haemophilia A is approximately 25 %.1 Factor VIII inhibitors are 
infrequently observed in patients with mild or moderate haemophilia A.2 The lower risk of 
inhibitor formation in this group of patients can be explained by the presence of tolerising 
amounts of circulating endogenous factor VIII. Inhibitor development in these patients 
commonly arises after intensive factor VIII replacement therapy and is usually a transient 
event.3 
Interestingly, some genetic defects are frequently observed in patients with mild 
haemophilia A who developed inhibitors. Amino acid substitutions located at the junction 
between the C1 and C2 domain or located in the A2 domain of factor VIII may predispose 
towards the development of factor VIII inhibitors.3 We have previously reported on the 
presence of human alloantibodies in a patient with an Arg593 to Cys mutation.4 In this 
patient (AMC-92), the anti-factor VIII antibodies are directed to wild-type A2 domain and 
not to the A2 domain containing the Arg593 to Cys mutation when analysed at a late stage of 
inhibitor formation. These findings indicate that the missense mutation Arg593 to Cys is 
related to antibody development.  
In the present study, phage display technology is used for the characterisation of anti-
factor VIII antibodies in patient AMC-92.  Our findings show that peripheral IgG+ B cells 
can express human antibodies reactive with residues Arg484-Ile508. These antibodies are 
distinct from the alloantibodies found in plasma. Following a period of intensive treatment 
with FVIII concentrate after a surgical intervention, the patient developed a transient low  
inhibitor that cross-reacts with endogenous factor VIII. We propose that activation of pre-
existing factor VIII-specific B cells underlies the rapid appearance of cross-reactive 
antibodies.  
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Materials and Methods 
 
Expression, metabolic labelling and immunoprecipitation of A2 domain variants. 
Wild-type factor VIII A2 domain, A2 domain containing the Arg593 to Cys mutation (A2-
R593C) and A2 domain in which the residues Arg484-Ile508 were replaced by the 
corresponding sequence of factor V (A2-FV484-508) have been described previously.4,5 
Recombinant factor VIII fragments were expressed and metabolically labelled in insect 
cells and immunoprecipitation was performed as described.4 
 
Phage display library construction, selection and characterisation of selected clones. 
Peripheral blood mononuclear cells were used from a mild haemophilia A patient (patient 
AMC-92) with a factor VIII inhibitor. Approximately half of the anti-factor VIII antibodies 
in plasma of this patient are of subclass IgG4.4 RNA was isolated from the peripheral blood 
cells and used for the construction of a phage display library as described previously.5 The 
patient’s IgG4-specific VH gene repertoire was amplified and combined with a VL gene 
repertoire of nonimmune origin in pHEN-1-VLrep and displayed as scFv on the surface of 
filamentous phage. 
Phages from the library were selected for binding to the factor VIII heavy chain 
essentially as described previously.5  VH and VL genes of clones reactive with factor VIII 
heavy chain were sequenced and compared with non-mutated germline V genes in the V-
BASE sequence database.6 To produce scFv’s, V genes were subcloned into the vector 
pUC119-Sfi/Not-His6. ScFv's were expressed and subsequently purified by immobilised 
metal chelate-affinity chromatography as described before.5 Inhibition of factor VIII 
activity by scFv was measured in the one-stage clotting assay.  
 
 
Results and Discussion 
 
Longitudinal analysis of factor VIII inhibitors in patient AMC-92. 
Mild haemophilia A patient AMC-92 with an Arg593 to Cys substitution in factor VIII had a 
baseline factor VIII activity of  0.20 IU/ml. He developed an inhibitor after a period of peri-
operative replacement therapy in 1980.4 At that time an inhibitor  of 22 BU/ml was 
observed and the patient's endogenous factor VIII level dropped below 0.01 IU/ml. The 
inhibitor  gradually declined. A low level (< 1 BU/ml) of inhibitor persisted for fifteen 
years. Epitope mapping studies revealed that antibodies present in plasma samples of 1992 
and 1995 bind exclusively to wild-type A2 domain and not to A2 containing the Arg593 to 
Cys mutation (A2-R593C) (Fig. 1B; lane 1 and 2). These findings suggest that antibodies 
are present that solely react with exogenous, administered factor VIII. In 1999 the patient 
underwent vasectomy under the protection of factor VIII and DDAVP. Following surgery, 
he developed a transient rise in inhibitor , which resulted in a decrease of plasma levels of 
factor VIII. Initially, the patient's factor VIII level decreased below 0.02 IU/ml and an 
inhibitor  of 2.6 BU/ml was measured. Within three months the inhibitor  gradually 
decreased and the circulating factor VIII level returned to a value of 0.15 IU/mL (Fig. 1A). 
The transient decline in factor VIII suggests cross reactivity of the inhibitor with 
endogenous factor VIII. To address this issue we evaluated the reactivity of the inhibitor 
with recombinant fragments corresponding to A2 and variant A2-R593C domain. Epitope 
mapping studies were performed using plasma samples collected at different time points 
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during inhibitor development. Five days following surgery an increase in reactivity of the 
inhibitor towards the A2 domain could be detected (Fig. 1B; lane 3, 4), this persisted for 6 
months. At later time points lower reactivity was observed (Fig. 1B; lane 13-15). 
Immediately following peri-operative treatment binding of antibodies to A2-R593C was 
observed (Fig. 1B; lane 3, 4). Concomitantly, the factor VIII plasma level of the patient 
decreased. After 10 weeks, factor VIII plasma levels returned to 0.15 IU/ml, which 
coincided with a decrease in antibodies directed against A2-R593C (Fig. 1B; lane 11-13).  
Our data indicate the existence of two populations of antibodies directed against the 
A2 domain in this patient. The first class of antibodies binds to a B cell epitope that 
overlaps with Arg593 and persists for an extended period of time. These antibodies do not 
bind to endogenous factor VIII and consequently plasma factor VIII levels are not affected. 
Following peri-operative factor VIII replacement therapy, a transient rise in a second class 
of antibodies is observed that cross react with endogenous factor VIII. Cross reactive 
antibodies directed towards residues Arg484-Ile508, a major binding site for factor VIII 
inhibitors in the A2 domain, have been described in two other unrelated inhibitor patients 
with the same genetic defect.7,8 In these patients antibodies reactive with Arg593 have not 
been observed. These data suggest that the region Arg484-Ile508 constitutes an 
immunodominant epitope in patients with the Arg593 to Cys mutation. 
 
Chapter 5 
 70
 
 
 
 
Figure 1. Longitudinal analysis of factor VIII inhibitors in patient AMC-92. (A) On the left y-axis the 
inhibitor  is given in BU/mL (grey bars). On the right y-axis factor VIII activity is depicted in IU/mL (). The 
numbers at the top of the figures represent plasma samples that are obtained at different time point of inhibitor 
development. At the bottom of this panel the dates at which these samples were taken is indicated. On 28-09-1999 
the patient underwent a surgical intervention under the protection of factor VIII and DDAVP. From 04-10-1999 
till 11-10-1999 the patient was treated with Novoseven®. A lymphocyte sample of 1993 was used for the 
construction of the phage display library (indicated by the arrow). (B) Binding of anti-factor VIII antibodies 
present in the patient's plasma to recombinant wild-type A2 domain, A2 domain containing the Arg593 to Cys 
mutation (A2-R593C) was assessed by immunoprecipitation (arrowheads). A non-specific band is present below 
the A2-R593C fragment (indicated by ) The numbers at the bottom correspond to plasma samples obtained at 
different time-points of inhibitor development (see panel A).  
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Figure 2. Characteristics of scFv’s binding to the A2 domain of factor VIII. (A) Comparison of deduced 
protein sequence of the heavy chains of isolated human antibodies with variable heavy chain germline gene 
segments. FR, framework region; CDR, complementarity-determining region. Dashes indicate sequence identity to 
variable heavy chain germline gene segments. Lower case indicates amino acid substitution encoded by the PCR 
primers. Sequences are available from Genbank under accession numbers: AY052530 (VH 92-102); AY052531 
(VL 92-102); AY052532 (VH 92-137); AY052533 (VL 92-137). (B) Binding of phage expressing 92-102 (black 
bars) or 92-137 (grey bars) to the A2 domain of factor VIII, A2-R593C and A2-FV484-508 was assessed as 
described in Materials and Methods.  
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Isolation and characterisation of antibodies specific for the heavy chain of factor VIII 
employing phage display. 
Complementary to the characterisation of factor VIII inhibitors from plasma we have 
analysed the anti-factor VIII repertoire of patient AMC-92 by phage display. A V gene 
phage display library was constructed with a blood sample taken from patient AMC-92 in 
1993 (see Fig. 1). The patient's IgG4-specific VH gene repertoire was combined with a VL 
gene repertoire of nonimmune source.5 The resulting library consisted of 4.7 x 106 clones 
and was used to isolate antibodies binding to the factor VIII heavy chain. After four rounds 
of selection, phages derived from 23 of 45 clones were specific for factor VIII (data not 
shown). The nucleotide sequences of VH and VL genes of the 23 clones were analysed and 
it appeared that the sequences of 22 clones were completely identical. The VH domain of 
these clones was encoded by germline gene segment DP-47, a member of the VH3 family. 
The deduced protein sequence of the heavy chain of one of these clones (92-102) is shown 
in Fig 2A. One clone (92-137) isolated from the library was encoded by the VH germline 
gene segment DP-58 belonging to the VH3 family as well (Fig 2A). Phages expressing scFv 
92-102 and 92-137 were tested for binding to variant and wild type factor VIII A2 domain. 
Both clones bind to wild-type A2 domain as well as to mutated A2-R593C domain. Phages 
92-102 and 92-137 do not react with the A2-FV484-508 (Fig. 2B). Similar results were 
obtained when epitope mapping studies were performed using purified scFv (data not 
shown). The inhibitory capacity of scFv 92-102 and 92-137 was evaluated in a Bethesda 
assay. Only slight inhibition of factor VIII was observed at elevated levels of scFv (specific 
activity < 5 BU/mg). 
Our analysis of patient AMC-92 reveals that B cells express antibodies directed 
against Arg484-Ile508 at a time when antibodies with this specificity are not observed in 
plasma. Phage display provides information on the immunoglobulin repertoire expressed by 
peripheral B lymphocytes whereas antibodies in plasma are derived from antibody-
secreting plasma cells present in bone marrow and spleen. Only a limited number of plasma 
cells circulates in the periphery. Virtually all peripheral blood B lymphocytes can be 
phenotypicaly divided into naive and memory B cells.9 In view of the large number of 
somatic hypermutation present in the scFv’s it is likely that these antibody fragments 
originate from the memory B cell pool. Long-living memory B cells differentiate into 
plasma cells upon stimulation with antigen.10,11 The rapid anamnestic response observed in 
patient AMC-92 may be due to stimulation of factor VIII specific memory B cells. 
Alternatively, antibodies may originate from anergic self-reactive B cells that are activated 
following a strong immunogenic stimulus during peri-operative treatment.12 Future studies 
should address whether human antibodies isolated from peripheral blood lymphocytes by 
phage display originate from the memory B cell pool.  
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Abstract 
 
Inhibitory antibodies to factor VIII develop as a consequence of replacement therapy in  
patients with haemophilia A. In this study, we evaluated inhibitor formation in a large 
group of patients with mild haemophilia A caused by an Arg593 to Cys mutation. A 
remarkably high cumulative inhibitor incidence of 14% over 20 years was observed. Three 
out of 42 patients developed transient, low titre inhibitors which remained below 2.0 
BU/ml. Four patients with the Arg593 to Cys mutation developed high titre inhibitors (> 2.0 
BU/ml). Three of these four patients have been described previously. In this study, we 
characterized the anti-factor VIII antibodies in the fourth patient with high titre inhibitors. 
This patient developed a high titre inhibitor following peri-operative treatment. Epitope 
mapping studies showed that antibodies were predominantly directed to the A2 domain of 
factor VIII. In previous studies, similar antibody specificities were found in patients with 
the Arg593 to Cys mutation. We evaluated the role of HLA class II alleles in inhibitor 
development in patients with the Arg593 to Cys mutation by HLA genotyping. We observed 
raised frequencies of HLA-DQB1*05 and DRB1*01 in the low responder group and a weak 
association of HLA-DQB1*06 and DRB1*11 or DRB1*13 in the group of patients which 
developed high titre inhibitors. Overall, our data did not reveal a strong association between 
inhibitor development and HLA class II alleles in patients with an Arg593 to Cys mutation.  
 
 
Introduction 
 
The X-linked bleeding disorder haemophilia A is caused by a decrease or dysfunction in 
circulating levels of blood coagulation factor VIII. Treatment of haemorrhages in patients 
with haemophilia A consists of protein replacement therapy using plasma derived or 
recombinant factor VIII. An immune response to transfused factor VIII is observed in a 
significant number of patients with severe haemophilia A. The development of anti-factor 
VIII antibodies (factor VIII inhibitors) complicates treatment of haemorrhages resulting in 
an increased mortality and morbidity.1  
Recent studies have explored the relation between factor VIII genotype and the 
development of factor VIII inhibitors. Severely affected haemophilia A patients with large 
deletions, non-sense mutations and inversions in the factor VIII gene showed an inhibitor 
incidence of 20-35%, whereas patients with missense mutations or small deletions showed 
a lower incidence.2,3  Inhibitor formation in mildly or moderately affected patients is 
relatively rare. The low incidence can be explained by the fact that these patients have 
tolerizing amounts of circulating factor VIII in their plasma. However, some mild/moderate 
haemophilia A patients develop anti-factor VIII antibodies after replacement therapy.  
It has been suggested that certain missense mutations in factor VIII predispose to 
inhibitor development in mild/moderate haemophilia A.4 Mutations in the A2 domain or in 
the border of the C1 and the C2 domain are frequently observed in patients, who develop an 
inhibitor. We have studied the properties of inhibitors in a mild haemophilia A patients with 
an Arg593 to Cys mutation in the A2 domain of factor VIII one.5-7 Previously we 
demonstrated that  antibodies present in one of  the patient's plasma were exclusively 
directed towards wild-type A2 domain and did not bind to A2 domain with the Arg593 to 
Cys mutation.5 However, when the antibody repertoire of peripheral lymphocytes of  this 
patient was studied using phage display technology, an antibody specific for residues  
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Arg484-Ile508, a major inhibitor epitope in the A2 domain, was detected.7 In plasma of 
another patient antibodies specific for both  the A2 domain and the factor VIII light chain 
were detected.6 These antibodies did not discriminate between wild type and variant  A2 
domain with the Arg593 to Cys mutation. Thompson et al. have observed antibodies specific 
for residues  Arg484-Ile508 in the A2 domain  in another patient with the same gene.8 
Inhibitor development has also been reported in another family with the Arg593 to Cys 
mutation.9 Not all patients with an Arg593 to Cys mutation develop factor VIII inhibitors. At 
present, it is not clear why some patients with this genetic defect do develop inhibitors 
whereas others do not.  
In this study, we evaluated inhibitor development in 42 patients with mild 
haemophilia A with the Arg593 to Cys mutation. Seven of these patients developed 
inhibitory antibodies to factor VIII. In three patients inhibitor titres remained below 2.0 
BU/ml. High titre inhibitors occurring in three patients have been described.5-7 Inhibitory 
antibodies present in plasma of one additional patient with a high inhibitor titre were 
characterized. Furthermore, we also investigated whether the presence of a particular HLA 
class II allele is related to inhibitor formation in patients with the Arg593 to Cys mutation.  
 
 
Materials and Methods 
 
Patients 
All non-severely affected haemophilia A patients treated at the Academic Medical Center 
Haemophilia Treatment Center in Amsterdam were screened for the Arg593 to Cys 
mutation. This genetic defect was found in 56 patients. Seven patients had not yet received 
factor VIII treatment and seven patients were not available for HLA analysis, resulting in a 
study group of 42 previously treated patients. The 42 patients belonged to 12 different 
families and all patients were Caucasians of Dutch origin. Seven patients developed an 
inhibitor after replacement therapy. Four patients were high responders and three patients 
developed a low or transient inhibitor. Patient files and laboratory results were checked 
retrospectively for inhibitor development over a period of  20 years. A high titre inhibitor 
was defined as an inhibitor titre  >5 BU/ml, whereas a low titre inhibitor  was defined as an 
inhibitor titre between 0.1-5 BU/ml concomitant with either an increase in clinical bleeding 
symptoms or a significant decrease in circulating factor VIII levels. Three high titre 
inhibitor patients have been described previously.5-7   
 
Functional assays  
Blood was collected by venapuncture in tubes containing 9 volumes of blood and one 
volume of 3.2% (w/v) trisodium citrate. Citrated plasma samples were collected as 
described and stored in aliquots at -70˚C. Factor VIII activity was measured using a one 
stage clotting assay. Inhibitor titres were determined using the Nijmegen modification of 
the Bethesda assay.10  
 
Immunoprecipiation and neutralization experiments 
Expression and metabolic labelling in insect cells of recombinant factor VIII fragments 
have been described previously.5 Immunoprecipitation of factor VIII light chain, C2 
domain, A2 domain and A2 domain containing the Arg593 to Cys mutation (A2-R593C) by 
anti-factor VIII antibodies was performed using 40 µl of patient's plasma. Binding of 
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antibodies from the patient's plasma to the 35S-radiolabelled factor VIII fragments was 
analysed by immunoprecipitation essentially as described previously.5 Radiolabelled 
proteins interacting with immobilized IgG derived from patient’s plasma were visualized 
following SDS polyacrylamide gelelectrophoresis under reducing conditions. A mixture of 
monoclonal antibodies CLB-CAg 9 and CLB-CAg 117 was used as a positive control in 
these experiments.11 A pool of normal plasma was used as a negative control. Inhibitor 
neutralization assays were performed as described using recombinant factor VIII fragments 
corresponding to the A2 domain, A2-R593C  and factor VIII light.6  
 
Molecular genetic studies  
Peripheral blood lymphocytes were isolated by density gradient centrifugation (Ficoll-
Paque, Amersham Pharmacia Biotech BA, Uppsala, Sweden). Genomic DNA was isolated 
from the lymphocytes using the QIAamp Blood Kit (Qiagen Westburg, Leusden. The 
Netherlands). Exon 12 was amplified using primer pairs that have been described 
previously. The presence of the Arg593 to Cys mutation was determined using sequence 
analysis of exon 12 of the factor VIII gene. HLA-DRB1 typing was performed by PCR 
analysis using the Dynal PCR-SSP DRB1* kit (Dynal, Oslo, Norway). HLA-DQA1 and 
HLA-DQB1 typing were performed using the Dynal PCR-SSP DQA1* and DQB1* kit 
(Dynal, Oslo, Norway).  
 
Statistical analysis 
Relative risks were calculated and when zero was encountered, we used Haldane's 
modification of Woolf's formula of relative risk.12,13 An relative risk was considered to be 
significant if the value of the lower 95% confidence interval did not fall below 1.00. The 
significance of an association between HLA allele and inhibitor formation was calculated 
using Fisher's exact test (two-tailed). A relative risk was considered to be significant when 
the p-value <0.05. 
 
 
Results 
 
Seven out of forty-nine previously treated patients carrying the Arg593 to Cys mutation 
developed an inhibitor after factor VIII replacement therapy over the last twenty years, 
resulting in a cumulative incidence of 14%. Four patients were high responders and three 
patients developed a low or transient inhibitor. Inhibitor titres were below 2.0 BU/ml in the 
three patients with low or transient inhibitors. The presence of an inhibitor was further 
suggested by a decline in endogenous factor VIII levels (Table 1B). In one of the three 
patients, inhibitor formation resulted in mild clinical symptoms. The characteristics of three 
high titre inhibitor patients  have been described previously (Table I).5-7 Two of the high 
responders were monozygotic twins.5,7 In the present study, the inhibitor of one of these 
patients (patient D) is characterised. Patient D, aged 70, developed a high titre inhibitor 
following intensive factor VIII replacement therapy for a surgical procedure. Before 
undergoing surgery, he had received treatment with factor VIII concentrate on 11 
occasions. An inhibitor titre of 62 BU/ml was measured and the patient's endogenous factor 
VIII activity level dropped below 1%. The inhibitor titre reached a maximum level of 90 
BU/ml.  Immunosuppression therapy with endoxan was instituted for two months to 
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suppress the antibody response. One month after endoxan treatment was stopped the patient 
died from urosepsis. In the present study the characteristics of  the inhibitor are evaluated. 
Epitope specificities of anti-factor VIII antibodies were evaluated by 
immunoprecipitation analysis (Fig.1). Antibodies present in the patient's plasma reacted 
with the light chain and the A2 domain of factor VIII, no binding to the C2 domain of 
factor VIII was observed. To investigate whether antibody binding to the A2 domain was 
dependent on the Arg593 residue in patient D, immunoprecipitation analysis was performed 
using A2 domain harbouring the Arg593 to Cys mutation. As can been seen in figure 1, 
antibodies in the patient's plasma reacted both with the A2 domain  and with the variant 
A2-R593C fragment. 
Neutralization experiments were performed to assess the contribution of different 
domain-specific antibodies to the total inhibitor titre. Addition of recombinant A2 domain 
resulted in almost complete neutralization of inhibitory antibodies (see Figure 2). In 
contrast, factor VIII light chain could not neutralise the inhibitor. Consistent with the results 
from the immunoprecipitation experiments, similar levels of neutralization were observed 
for A2-R593C and A2 domain. Taken together, these data indicate that the majority of 
inhibitory antibodies are directed towards the A2 domain of factor VIII.  
Inspection of the epitope specificity of the four patients with high titre factor VIII 
inhibitors reveals that the majority of inhibitory antibodies are directed towards residues in 
the A2 domain (Table 1A). The similar epitope specificity suggests that inhibitor formation 
proceeds via a common mechanism in these patients. Previously, we hypothesized that 
inhibitor formation in patients with an Arg593 to Cys mutation is dependent on adequate 
presentation of a peptide overlapping residue Arg593 on an appropriate HLA class II 
molecule.6 In this model, HLA class II profile potentially influences inhibitor development. 
Therefore, we determined the HLA class II profile of both inhibitor and non-inhibitor 
patients. All patients were genotyped for HLA-DQB1 and HLA-DRB1/3/4/5 (see Appendix 
Table III). Table IIa shows the frequencies of HLA-DQB1 and HLA-DRB1/3/4/5 alleles in 
inhibitor and non-inhibitor patients. Overall, no strong association between inhibitor 
development and an HLA-DQB1 or HLA-DRB1/3/4/5 alleles was observed. However, the 
frequency of HLA-DQB1*05 is raised in the group of inhibitor patients (57.1%) compared 
to non-inhibitor patients (34.3%). HLA-DRB1*01 was also raised in inhibitor patients 
(57.1%) compared to non-inhibitor patients (22.9%). HLA-DQB1*05 and HLA-DRB1*01 
are known to be in linkage disequilibrium (haplotype HLA-DQB1*0501, DRB1*0101).The 
increased frequency of this haplotype in inhibitor patients, however, did not reached 
statistical significance. The group of inhibitor patients can be divided in four patients with a 
high inhibitor titre and three patients with a low inhibitor titre. In the high responder group 
the frequency of haplotypes HLA-DQB1*0602/04/09, DRB1*1302 and HLA-
DQB1*0602/04/09, DRB1*1101 were raised but the group of patients is too small to reach 
statistical significance (Table IIb). Remarkably, the frequencies of HLA-DQB1*05 and 
DRB1*01 are not raised in the group of patient that developed a high inhibitor titre while 
both alleles are raised in the low responder group (Table IIc). The association of HLA-
DRB1*01 with inhibitor formation in low responder patients was statistical significant.  
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Table I: Characteristics of inhibitor patients included in this study.  
(A) High titre inhibitor patients.  
Maximum inhibitor titre (BU/ml), number of exposure days (Exp. days) and major inhibitor epitopes are indicated. 
Three of these patients have been described previously.  Patient A has been previously described by Fijnvandraat 
et al (1980) and also by Bril et al (AMC-92, 1999). Patient B has been described by Fijnvandraat et al and patient 
C (AMC-67) has been described by van den Brink et al. Analyis of the epitope specificity of factor VIII inhibitors 
of patient B was not performed (n. p.). 
 
Patient Max. titre 
(BU/ml) 
Exp. days Major inh. 
epitope 
A (1980) 22 10 A2 
A (1999) 2.6 32 A2 
B 9 6 n.p. 
C 400 10 A2 
D 90 25 A2 
 
 
(B) Low titre inhibitor patients.  
Maximum inhibitor titre (BU/ml), number of exposure days (ED) and presence of clinical symptoms are indicated. 
Factor VIII levels during and prior to (in brackets) inhibitor episode are given. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. Epitope mapping of factor VIII inhibitors in patient AMC-118. Binding of anti-factor VIII antibodies 
present in the patient's plasma to recombinant factor VIII light chain, wild-type A2 domain and A2 domain 
containing the Arg593 to Cys mutation (A2-R593C) was assessed by immunoprecipitation. Samples obtained at 
different times of inhibitor development were analyzed; 10/5/2000 (1), 25/5/2000 (2), 05/6/2000 (3), 19/06/02 (4), 
20/07/02 (5), positive control (+), negative control (-).  
 
 
Patient Max. titre 
(BU/ml) 
Exp. days Clinical 
sypmtoms 
Factor 
VIII level 
E 1.2 14 No 8 (19) 
F 0.5 6 Yes 4 (17) 
G 0.2 9 No 5 (27) 
LCh
A2
A2-R593C
+ - 1 2 3 4 5
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Table II Allele frequencies of HLA-DQB1 and DRB1/3/4/5 in inhibitor and non-
inhibitor patients.   
Relative Risks and 95% confidence intervals were calculated as described in the section materials and methods. 
All associations were not significant exept for the association of HLA-DRB1*01 with inhibitor formation in the 
low responder group. (A) Allele frequencies of HLA-DQB1 and DRB1/3/4/5 in 7 inhibitor and 35 non-inhibitor 
patients. Allele frequencies in patients with high inhibitor titres (B) or patients with low inhibitor titres (C) 
compared to non-inhibitor patients. (1): The association of HLA-DRB1*01 with inhibitor formation in the low 
responder group was statistical significant (RR = 5,91, 95% confidence interval = 1,36-25,6 and  p-value = 0.04).  
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HLA-allele Inh. pat.  Non inh. pat. 
 n=7         % n=35       % 
DQB1*     
02 2 28,6 9 25,7 
03 4 57,1 25 71,4 
05 4 57,1 12 34,3 
06 4 57,1 24 68,6 
DRB1*     
01 4 57,1 8 22,9 
03 1 14,3 8 22,9 
04 1 14,3 11 31,4 
07 1 14,3 6 17,1 
09 0 0,00 2 5,71 
10 0 0,00 2 5,71 
11 2 28,6 6 17,1 
12 0 0,00 1 2,86 
13 3 42,9 16 45,7 
14 1 14,3 0 0,00 
15 1 14,3 8 22,9 
16 0 0,00 2 5,71 
DRB3 4 57,1 25 71,4 
DRB4 2 28,6 17 48,6 
DRB5 1 14,3 10 28,6 
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B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.  
Inhibitor neutralization 
by recombinant factor 
VIII fragments.  
Neutralization of anti-
factor VIII antibodies in 
the patients plasma by 
recombinant A2 domain 
(gey bar), A2-R593C 
(black bar) and factor 
VIII light chain (open 
bar). Residual factor VIII 
activity is indicated on 
the x-axis as a percentage 
of the control sample.  
HLA-allele High inh. pat Non inh. pat. 
 n=4         % n=35       % 
DQB1     
05 1 25,0 12 34,3 
06 4 100 24 68,6 
DRB1     
01 1 25,0 8 22,9 
11 2 50,0 6 17,1 
13 3 75,0 16 45,7 
15 1 25,0 8 22,9 
HLA-allele Low inh. pat. Non inh. pat. 
 n=3         % n=35       5 
DQB1     
02 2 66,7 9 25,7   
03 1 33,3 25 71,4 
05 3 100 12 34,3 
DRB1     
01 3 100 8 22,9   (1) 
03 1 33,3 8 22,9 
07 1 33,3 6 17,1 
-25 0 25 50 75 100
LCh
A2 
A2-R593C
Inhibitor neutralization (%  of control)
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Discussion 
 
Over the last few years increasing attention has been directed towards inhibitor 
development in patients with mild haemophilia A. In this study, we describe inhibitor 
formation in a group of previously treated mild haemophilia A patients with the Arg593 to 
Cys genotype. Patient D developed a high titre inhibitor after a period of factor VIII 
replacement therapy. Immunoprecipitation analysis revealed antibodies specific for the 
light chain and the A2 domain of factor VIII. The patient's antibodies recognized both 
exogenous A2 domain and mutated endogenous A2 domain (A2-R593C). Cross-reactive 
antibodies directed to the A2 domain have been observed in three other inhibitor patients 
with the Arg593 to Cys mutation . Interestingly, the predominant inhibitor epitope is 
restricted to the A2 domain in patients with Arg593 to Cys mutation. Only limited reactivity 
of inhibitory antibodies to light chain or C2 fragments has been observed. In general, a 
heterologous mixture of inhibitors is present in inhibitor plasmas. In more than 60% of 
inhibitor patients, antibodies against A2 and/or A3-C1 domains are detected while in over 
80% of inhibitor patients antibodies specific for the C2 domain are detected.14 The 
predominance of anti A2 antibodies in patients with an Arg593 to Cys mutation argues for a 
common mechanism of inhibitor formation in these patients. 
Several observations suggest that inhibitor formation in haemophilia A patients is 
dependent on an adequate T cell response to factor VIII.15-17 Activation of factor VIII-
specific T cells is dependent on appropriate presentation of factor VIII derived peptides by 
HLA molecules present on the surface of antigen presenting cells. In addition, co-
stimulatory signals are required for optimal activation of T cells. Given the nature of the 
antigen, it seems of particular interest to study the role of HLA class II alleles in inhibitor 
formation. So far, the relation between inhibitor formation and HLA class II alleles has 
only been studied in severely affected haemophiliacs. Two studies have shown an increased 
frequency of HLA-DR4 in patients who did not developed an inhibitor whereas others did 
not find a relation between HLA class II alleles and inhibitor development.18-21 Two reports 
describe the role of HLA class II alleles in patients with the same factor VIII.22,23 HLA 
typing was performed in severe haemophilia A patients with intron 22 inversion mutations. 
A statistical significant association of HLA-DQA1*0102 with inhibitor formation has been 
observed by one group.22 The present study shows that one established haplotype (HLA-
DQB1*0501, DRB1*0101) is weakly associated to inhibitor development in mild 
haemophilia A patients with the Arg593 to Cys mutation. The frequencies of HLA-
DQB1*05 and DRB1*01 are raised in patients which developed a low or transient inhibitor 
compared to non-inhibitor patients. In contrast, the frequencies of HLA-DQB1*05 and 
DRB1*01 are not raised in the high responder group (Table IIc). Interestingly, haplotype 
HLA-DQB1*0501, DRB1*0101 also weakly associates with inhibitor development in 
severe haemophilia A patients with an intron 22 inversion.22 Thus, haplotype HLA-
DQB1*0501, DRB1*0101 is associated to a high-level inhibitor in severe haemophilia A 
while this HLA class II may be associated with a low and transient inhibitor titre in mild 
haemophilia A patients which are partially tolerant to factor VIII. In the high responder 
group the frequencies of HLA-DQB1*06 and DRB1*11 or DRB1*13 are raised but a study 
with a larger group of subjects should point out whether this is significant or not (Table 
IIb). We did not observe an association of HLA-DRB1*04 or DRB1*15 with inhibitor 
formation as reported by other groups in severe haemophilia A patients .The development 
of inhibitors in patients with the Arg593 to Cys mutation can be explained by the following 
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series of events. It has been proposed that after uptake and processing of exogenous factor 
VIII by antigen presenting cells, a T cell epitope containing the Arg593 residue may be 
presented by a matching HLA class II molecule. Subsequent T cell activation may result in 
loss of tolerance to both exogenous and endogenous factor VIII and stimulation of factor 
VIII specific B cells to produce antibodies .  
In a recent study the molecular background of inhibitor formation in patients with an 
Arg2150 to His mutation in the C1 domain has been addressed.17 T cell clones generated 
from patients with inhibitors all bound to synthetic peptides overlapping residue Arg2150. 
Interestingly, synthetic peptides encompassing Arg2150 could interact with multiple HLA 
class II molecules. These findings suggest that a restricted number of T cell epitopes that 
promiscuously interacts with HLA class II molecules are involved in initiation of immune 
responses in patients with an Arg2150 to His mutation in factor VIII. Our findings did not 
reveal a strong association of inhibitor formation and HLA class II molecules in patients 
with an Arg593 to Cys mutation. Potentially, this can be explained by a lack of specificity of 
peptides overlapping residue Arg593 for particular HLA class II molecules.  
Additional factors may contribute to the lack of association observed in this study. 
The number of subjects in the inhibitor group is relatively small. Also, about half of the 
patients included have received only limited amounts of factor VIII (< 10 exposure days). 
Inclusion of more patients and follow-up of the patients described in this study is needed to 
assess whether inhibitor formation in mild haemophilia A patients with Arg593 to Cys 
mutation is linked to one or more HLA class II alleles.  
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Appendix 
 
Table III. HLA-DQB1, DRB1, DRB3, DRB4 and DRB5 alleles and inhibitor status of 
42 patients with the Arg593 to Cys mutation. The 42 patients belong to 12 families, which are shown 
in Table III. High titre patients have been described elsewhere: (A) patient A, Fijnvandraat et al 1997 and as 
patient AMC-92, Bril et al 2002; (B) patient B, Fijnvandraat et al 1997; (C) patient AMC-67, van den Brink et al 
1999 and (D) patient AMC-118, this study. 
 
 Pat. DQB1 DRB1 DRB3 DRB4 DRB5   Pat. DQB1 DRB1 DRB3 DRB4 DRB5 
 1 C 06 13 + - + 22 06 15 + - + 
  06 15   03 11   
 2  E 05 01 - - - 23 02 03 + - - 
  03 01   06 13   
 3   06 13 + - + 24 02 03 + - - 
  06 15   03 12   
 4   03 07 + + - 25 02 03 + - - 
  06 13   03 11   
 5   03 07 + + - 26 F 02 03 + - - 
  06 13   05 14   
 6   05 01 - - + 27 G 05 01 - + - 
  06 15   02 07   
 7   03 04 - + + 28 05 01 - + - 
  06 15   03 04   
 8   05 01 + - - 29 02 03 + + - 
  06 13   03 04   
 9   03 07 - + + 30 05 01 - - + 
  06 15   05 16   
 10  05 01 - + - 31 02 07 + + - 
  03 04   03 11   
 11  03 04 - + + 32 03 04 - + - 
  06 15   03 04   
 12  05 10 + - - 33 02 03 + + - 
  06 13   03 04   
 13  06 13 + - - 34 05 01 + - - 
  06 13   06 13   
 14  05 01 + - - 35 03 04 + + - 
  02 03   06 13   
 15  05 10 + - - 36 03 04 - + - 
  06 13   02 07   
 16  05 01 + - - 37 03 04 + + - 
  03 11   03 11   
 17  03 07 + + - 38 06 13 + - - 
  03 03   06 13   
 18 B  03 11 + - - 39 06 13 + - - 
  06 13   06 13   
 19 A 03 11 + - - 40 05 16 - + + 
  06 13   03 09   
 20 D 05 01 - + - 41 06 15 + - + 
  03 04   02 03   
 21  06 15 + - + 42 03 09 + + - 
  06 13   03 11   
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Abstract 
 
Haemophilia A is a bleeding disorder caused by the functional absence of clotting factor 
VIII. A serious complication of replacement therapy is the formation of inhibitory 
antibodies to factor VIII in approximately 25% in patients with severe haemophilia A. 
Although inhibitor formation in mild and moderate haemophilia A is rare, several reports 
have described inhibitor development in patients with mild haemophilia A caused by an 
Arg593 to Cys mutation. At present, it is not clear why some patients with this genetic defect 
develop inhibitors and others do not. To mimic the immune response in these patients, a 
transgenic mouse expressing human factor VIII-R593C was generated (hufVIII-R593C 
mice). Transgenic hufVIII-R593C mice (in a wild type mouse background) receiving 
multiple serial intravenous injections of factor VIII or factor VIII heavy chain did not 
develop anti-factor VIII antibodies. HufVIII-R593C mice were crossed with factor VIII-
deficient mice (E-16 KO mice). Factor VIII-deficient E-16 KO mice develop anti-factor 
VIII antibodies after five serial intravenous injections with human factor VIII while 
hufVIII-R593C/E-16 KO mice did not develop an immune response. Apparently, hufVIII-
R593C mice are tolerant to human factor VIII which is in agreement with the strongly 
reduced incidence of factor VIII inhibitors in patients with mild haemophilia A. However, 
anti-factor VIII antibody development was induced in HufVIII-R593C and hufVIII-
R593C/E-16KO mice by multiple subcutaneous injections of factor VIII with an adjuvant. 
Our data show that hufVIII-R593C/E-16 KO mice provide a valuable model for studies 
directed at the mechanisms underlying inhibitor development in haemophilia A. 
 
 
Introduction 
 
Haemophilia A is an X-linked bleeding disorder caused by a deficiency of coagulation 
factor VIII. Severe haemophilia A patients, whose plasma have less than 1% factor VIII 
activity, suffer from spontaneous joint and muscle bleedings and excessive hemorrhage 
after trauma or surgery.1,2 An inversion of DNA sequence within intron 22 of the factor 
VIII gene is responsible for disruption of the factor VIII gene in almost 50 % of severe 
haemophilia A patients.3 Large or small deletions, missense and nonsense mutations that 
are scattered over the factor VIII gene occur in other patients with severe haemophilia A. 
Recently, a murine model for severe haemophilia A was developed by gene targeting 
techniques. Two strains of mice were generated by insertion of a neo cassette into exon 16 
(E-16 KO) or exon 17 (E-17 KO) of the mouse factor VIII gene. Both the E-16 and E-17 
knock out mice have impaired hemostasis, suffer from spontaneous bleedings and have less 
than 1% factor VIII activity compared to wild type mice.4-6 The murine haemophilia A 
model has been successfully used as a tool for the development of haemophilia gene 
therapy strategies. Phenotypic correction and sustained factor VIII expression has been 
achieved in haemophilic mice.7-10  
Severe haemophilia A patients frequently develop antibodies (so-called factor VIII 
inhibitors) that neutralize factor VIII activity.11 Although progress has been made in 
obtaining information on inhibitors and their epitope specificity, the immunological 
mechanisms underlying the formation of inhibitory antibodies to factor VIII have not been 
elucidated. Much of our current knowledge on the immunobiology of factor VIII inhibitors 
Chapter 7 
 92
has been obtained from the murine haemophilia A model. After repeated intravenous 
injections of human factor VIII, haemophilic mice develop high titres of antibodies which 
resemble inhibitors in haemophilia A patients.12 The antibodies detected in haemophilic 
mice are directed to the heavy chain, light chain and the non-functional B domain of factor 
VIII.13 The anti-factor VIII antibodies are mainly IgG1 (the equivalent of human IgG4) but 
other subclasses are present as well.13,14 The anti-factor VIII response in the haemophilic 
mice has been shown to be T-cell dependent resembling the immune response in 
haemophilia A patients.12,15,17 Inhibition of T-cell co-stimulation via CD40-CD40L has 
been shown to suppress the formation of anti-factor VIII antibodies.18-20 In addition, 
blockade of the CD28-B7 pathway prevented antibody formation in haemophilic mice.12 
Cytokine profiles of factor VIII-specific T cells indicate that the regulation of the anti-
factor VIII antibody response in haemophilic mice involves both Th1- and Th2-type 
cells.14,20 Altogether, these results suggest that factor VIII-deficient mice constitute a 
suitable model for inhibitor formation in haemophilia A. 
Whereas inhibitor development occurs in 25% of patients with severe haemophilia A, 
factor VIII inhibitors are less frequently observed in mild and moderate haemophilia A. 
Inhibitor formation in these patients commonly occurs after extensive factor VIII 
replacement therapy.21,22 Although inhibitor titres are usually low and inhibitors often 
disappear spontaneously, patients can suffer from severe life-threatening bleedings. Most of 
these patients have low amounts of circulating factor VIII, which provides tolerance to 
infused factor VIII. This can explain the lower risk of inhibitor development in 
mild/moderate haemophilia A patients. Interestingly, the risk of inhibitor development is 
higher for patients with missense mutations in the A2 domain or around thee C1/C2 
junction of factor VIII.11,21,22 Besides factor VIII genotype, inhibitor formation is probably 
related to other genetic determinants as well. In addition, different treatment strategies or 
inflammatory conditions can influence inhibitor formation in this group of patients.  
Patients with the missense mutation Arg593 to Cys in the A2 domain of factor VIII 
suffer from mild haemophilia A. Several of these patients have been described who 
developed anti-factor VIII antibodies.23-26 To mimic the immune response in these patients, 
a transgenic mouse expressing human factor VIII with the Arg593 to Cys mutation was 
generated. We evaluated immune responses to administrated factor VIII of transgenic 
hufVIII-R593C mice in wild type and in E-16 KO background. Our results indicate that 
transgenic hufVIII-R593C mice provide a useful model for inhibitor development in 
haemophilia A.   
 
 
Materials and Methods 
 
Generation and characterization of hufVIII-R593C transgenic mice 
Full-length human factor VIII cDNA containing the Arg593 to Cys mutation was assembled 
into pBluescript (Promega, Wisconsin, MI). Subsequently, hufVIII-R593C cDNA was 
cloned into a plasmid containing a mouse albumin promoter sequence and the 3' part of 
human β globin gene which includes downstream polyadenylation signals.27-29 The 
polylinker of the construct was modified and subsequently the plasmid was linearized by 
digestion with NotI. The linearized 12.3 kb fragment, which contains hufVIII-R593C under 
the control of the mouse albumin promoter, was microinjected into pronuclei of fertilized 
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oocytes of FVB or C57BL/6 mice. Offspring was screened by PCR and Southern blot 
analysis for the presence of the transgene. DNA was isolated from a 5 mm piece of mouse-
tail using QIAGEN DNeasy Tissue Kit (Qiagen, Leusden, The Netherlands). For 
genotyping of transgenic hufVIII-R593C mice, 50 to 150 ng of genomic mouse DNA was 
used in one PCR reaction. To confirm the presence of the transgene hufVIII-R593C, the 
forward primer was derived of the human factor VIII exon 14 sequence 
(5'GTGCTCTCAAAACCCACC3') and the backward primer was derived from the human 
factor VIII exon 16 sequence (5'GCCTGATTTCTGAAAGTTACC3'). Amplifications were 
performed in a total volume of 30 µl containing 1 unit Taq polymerase (incubated for 10 
min with Taq start antibodies), reaction buffer, 1.5 mM MgCl2, 0.2 mM each dNTP and 
100 ng each primer. Taq DNA polymerase and Taq start antibodies were purchased from 
Life Technologies (Breda, The Netherlands). Reactions were performed at 94° C for 2 min 
followed by 30 cycles of 10 sec 94° C, 30 sec 58° C and 1 min at 72° C and finally 10 min 
at 72° C. To confirm the presence of the disrupted exon 16 in mouse factor VIII and the 
presence of the undisrupted X-chromosome, two PCR reactions were performed using two 
previously described primer sets.5 Amplifications were performed as described above using 
50 to 150 ng of genomic mouse DNA. Southern blot analysis was performed using genomic 
DNA isolated from a piece of tail of transgenic mice. Following digestion with proteinase 
K and phenol/chloroform extraction, genomic DNA was recovered by ethanol precipitation. 
Twenty microgram of DNA was digested with BamHI and subjected to Southern blot 
analysis. The blots were probed with a 695 bp fragment of human factor A2 domain 
containing the R593C-mutation derived of the plasmid pCLB-GP67-A2-R593C.23 
Digestion of the hufVIII-R593C transgene with BamHI yields a 1929 bp product that is 
complementary to the probe.  
Liver and kidney of heterozygous hufVIII-R593C mice were collected and 
immediately frozen in liquid nitrogen. Total RNA was isolated from the organs and factor 
VIII mRNA levels were measured by RT-PCR essentially as described previously.30 
Primers for amplification of murine factor VIII mRNA have been described elsewhere.30 
Amplification of human mRNA was performed with a different primer set (forward primer: 
5'-GAGGAACCATCGCCAGGCGTCCTT-3', backward primer: 5'-AGGACTGGGACTA 
TGCTCCCTTAG-3'). 
Factor VIII protein levels in plasma of heterozygous hufVIII-R593C mice were 
determined using an ELISA specific for human factor VIII as described previously, except 
that antibody CLB-CAg 12 was used instead of antibody CLB-CAg A.30 The monoclonal 
antibodies CLB-CAg 12 and CLB-CAg 117 against human factor VIII have been described 
previously.31,32 Microtitre plates were coated with monoclonal antibody CLB-CAg-12 (0.5 
µg/well) in 50 mM NaHCO3 pH 9.8 at 4˚ C overnight. After washing with PBS/0.1% 
Tween-20, wells were incubated with plasma samples diluted in 50 mM Tris pH 7.4/0.15 M 
NaCl/2% HSA at 37° C for 2 h. Wells were washed and incubated with horseradish 
peroxidase labelled monoclonal antibody CLB-CAg 117 at 37° C for 2 h. The concentration 
of human factor VIII protein was estimated from a standard curve using a human plasma 
standard.  
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Founder T4 (FVB strain) and offspring were crossed with C57BL/6 mice (Jackson 
Laboratories, Bar Harbor, MN). Adult heterozygous mice from the second to fifth 
generation were used for experiments. The characteristics of the E-16 knock out (E-16 KO) 
strain of haemophilic mice (C57BL/6 mice with a neo cassette in exon 16) have been 
described elsewhere.4,5 Heterozygous transgenic hufVIII-R593C males were bred with 
homozygous E-16 haemophilic females. Male transgenic hufVIII-R593C/E-16 KO mice 
and E-16 KO littermates without the hufVIII-R593C transgene were used in our studies.  
 
Administration of human factor VIII 
To investigate the immune response in transgenic hufVIII-R593C mice we injected 
heterozygous hufVIII-R593C mice and non-transgenic littermates with plasma-derived 
human factor VIII or human factor VIII heavy chain31.33 Serial injections of factor VIII (1 
µg in 100 µl phosphate-buffered saline (PBS)) were administered intravenously (i.v.) every 
week. Plasma samples were obtained before the first injection and subsequently at a two-
weekly interval by retro-orbital bleeding. One week following the last injection mice were 
sacrificed. Blood was collected by cardiac puncture at this time point. Injections of human 
factor VIII heavy chain (1 µg in 100 µl PBS) were performed at a two-weekly interval. 
Plasma samples were obtained before each injection and blood samples were collected by 
cardiac puncture two weeks following the last injections. Immunization of the hufVIII-
R593C/E-16KO and E-16KO mice consisted of five i.v. injections of 1 µg human factor 
VIII at two-weekly intervals. The mice were sacrificed three days after the last injection. 
Spleen cells and plasma samples were collected at this time point.  
To induce loss of tolerance to factor VIII, heterozygous hufVIII-R593C mice and non-
transgenic littermates were subcutaneous injected with factor VIII (1 µg in 100 µl PBS) and 
100 µl Freund's adjuvant (Difco Laboratories, Detroit, Michigan, USA) every week. For the 
first injection, Complete Freund's adjuvant was used whereas subsequent injections were 
performed with Incomplete Freund's adjuvant. Plasma samples were obtained before the 
first injection and subsequently every two weeks by retro-orbital bleeding. One week 
following the sixth injection, mice were sacrificed and blood was collected by cardiac 
puncture. Immunization of hufVIII-R593C/E-16KO and E-16KO mice consisted of four 
s.c. injections with factor VIII and Freund's adjuvant and the mice were bled one week 
following the last injection. 
 
Detection of anti-factor VIII antibodies 
Antibody titres specific for human factor VIII or human factor VIII heavy chain were 
determined by ELISA. Microtitre plates (Nunc, Roskilde, Danmark) were coated with 6 
µg/ml factor VIII or 5 µg/ml human factor VIII heavy chain in 50 mM NaHCO3 pH 9.8 at 
4° C overnight. After washing with PBS/0.1% Tween-20, wells were blocked with 
PBS/0.1% Tween-20/2% gelatin at 37° C for 2 h. After washing, mouse plasma samples 
diluted in 50 mM Tris pH 7.4/0.15 M NaCl/2% HSA at 37° C for 1 h. Subsequently, the 
wells were washed and anti-factor VIII antibodies were detected using polyclonal 
horseradish peroxidase labelled goat anti-mouse immunoglobulin. The concentration of 
anti-factor VIII antibodies was estimated from a standard curve using a mixture of two 
monoclonal antibodies in a 1:1 ratio; CLB-CAg 9  specific for factor VIII heavy chain and 
CLB-CAg 12 specific for the light chain of factor VIII.31,32  
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Factor VIII T cell proliferation assay 
Three days after the last factor VIII injection, mice were sacrificed and spleens were 
isolated. Spleen single-cell suspensions were prepared and after lysis of erythrocytes, the 
cells were washed twice with serum free X-vivo 10 medium supplemented with gentamycin 
(BioWhittaker, Walkersville, Maryland, USA). Cells were subsequently cultured (5 x 105 
cells/well) in six fold in flat-bottom wells in X-vivo medium supplemented with varying 
amounts of purified human factor VIII. Control wells were cultured in six fold with 
medium without factor VIII. Cells were incubated at 37 ºC for 72 hours. Two µCi 3H-
thymidine (0.074MBq) was added to the cultures and the cells were harvested after 20 
hours (Titretek Cell Harvester) and incorporation of  3H-thymidine, expressed in counts per 
minute (cpm), was measured by liquid scintillation. The rate of T cell proliferation is 
expressed as stimulation index (SI), which represents the amount of 3H-thymidine 
incorporated in cultures in the presence of factor VIII divided by the amount of 3H-
thymidine incorporated in the absence of factor VIII. 
 
 
Results 
 
Generation and characterization of hufVIII-R593C transgenic mice 
A single nucleotide substitution that resulted in replacement of Arg593 by a Cys was 
introduced in full-length factor VIII cDNA. This modified human factor VIII cDNA 
(hufVIII-R593C) was placed under control of a mouse albumin enhancer/promoter to direct 
factor VIII expression to the liver. Polyadenylation signals derived of the β globin gene 
were inserted at the 3' end of hufVIII-R593C cDNA (Figure 1A). Injection of the plasmid 
encoding huFVIII-R593C into fertilized oocytes of FVB mice resulted in two founders. 
Founder T4 (FVB strain) was crossed with C57Bl/6 mice for 5 generations and 
heterozygous offspring was further characterized. As expected transgenic mice did not 
show abnormalities in either development or reproduction.  
The presence of the human factor VIII transgene in founder T4 was detected by 
Southern blot analysis (Figure 1B). Offspring was subsequently screened for the presence 
of hufVIII-R593C cDNA by PCR analysis (Figure 1C). The transgene was found in 
roughly 50% of both female and male offspring indicating that the transgene is not linked to 
either the X or Y chromosome. Previously, it has been shown that the albumin 
enhancer/promoter used in this study, directs liver specific expression.28 In wild type mice, 
murine factor VIII mRNA is primarily detected in the liver as well as in the kidney.30 To 
assess liver-specific expression of the human factor VIII transgene, RT-PCR was 
performed on total RNA derived from liver and kidney using primers specific for human 
factor VIII. As expected, human factor VIII mRNA was detected only in de liver whereas 
murine factor VIII mRNA could be detected in both liver and kidney (Figure 2). Expression 
levels of human factor VIIIR593C in murine plasma were measured by using a human 
factor VIII specific ELISA. In plasma of heterozygous transgenic mice hufVIII-R593C, 
protein levels are below the detection limit of our ELISA (i.e. 15 mU/ml) and protein levels 
are consistently negative in wild type C57BL/6 plasma and non-transgenic littermates. 
Similar results were obtained upon analysis of plasma derived of the second founder. 
Overall, our findings show that liver-specific expression of the transgene results in 
undetectable levels of human factor VIII-R593C in the circulation of transgenic mice.  
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Figure 1. Construction and genotyping of transgenic hufVIII-R593C mice. (A) A plasmid with an insert of 
12.3 kb consisting of a mouse albumin enhancer/promoter (Alb Enh/Alb Prom), full-length human factor 
VIIIR593C cDNA (hufVIII-R593C) and β globin polyadenylation signals (βG poly A) was constructed as 
described in Materials and Methods. The insert was separated from the vector sequences by digestion with NotI 
(N) and the linearized fragment was injected into fertilized oocytes of FVB mice. The BamHI (B) restriction 
fragment (B-Fragm) of human factor VIII-R593C DNA  generated by Southern blot analysis is shown. (B) 
Genotyping of the transgenic hufVIII-R593C mouse by Southern blot analysis. Southern blot analysis was 
performed on BamHI digested genomic DNA of founder T4 and a wild type C57Bl/6 control. The blot was 
hybridized with a human factor VIII-specific probe. The 1.9 kb BamHI restriction fragment of human factor 
VIIIR593C DNA that reacts with this probe is indicated by an arrow. (C) Genotyping by detection PCR of 
hufVIII-R593C mice and a wild type C57Bl/6 control mouse. A 432 bp fragment was amplified from genomic 
DNA of founder T4 (indicated by the arrow) using human factor VIII specific primers that are described in 
Materials and Methods. 
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Figure 2. HufVIII-R593C mRNA expression and protein 
expression in the liver. RT-PCR was performed on total RNA of 
liver and kidney to detect factor VIII mRNA.  Primers specific for 
human factor VIII mRNA amplified a 362 bp fragment (left panel). 
Primers specific for murine factor VIII mRNA amplified a 359 bp 
fragment (right panel). Lane 1: RNA isolated from the liver of a 
heterozygous hufVIII-R593C mouse in C57BL/6 background, lane 
2: RNA isolated from the kidney of a heterozygous hufVIII-R593C 
mouse in C57BL/6 background and lane 3: RNA isolated from the 
liver of a C57BL/6 control mouse.  
 
 
 
 
 
 
 
 
Immune response to human factor VIII in transgenic hufVIII-R593C mice 
Previous studies have shown that intravenous injection of human factor VIII in normal 
C57BL/6 mice results in the appearance of inhibitory antibodies.12,13 Therefore, we first 
assessed the effect of the huFVIII-R593C transgene on the immunogenicity of human 
factor VIII in a background of normal mice. HufVIII-R593C mice were injected six times 
with 1 µg of plasma derived factor VIII with one-week interval between injections. Figure 
3A shows the anti-factor VIII antibody response of four transgenic mice and six non-
transgenic controls measured by ELISA. All non-transgenic control mice developed a 
strong antibody response (> 1 µg/ml) after six intravenous injections of factor VIII. In 
contrast, two hufVIII-R593C mice showed a low anti-factor VIII antibody response (< 0.7 
µg/ml) and two hufVIII-R593C mice did not show any antibody response at all. In a second 
series of experiments in which we administered 1 µg of plasma derived human factor VIII 
heavy chain to both wild type and huFVIII-R593C mice at two weekly intervals. The anti-
factor VIII heavy chain antibody concentration in plasma was determined by ELISA 
(Figure 3B). All non-transgenic controls show significant antibody responses after six 
injections whereas most transgenic mice do not develop anti-factor VIII antibodies. Only 
two transgenic mice had a low titre of anti-factor VIII heavy chain antibodies after six and 
eight injections, respectively. Collectively these findings suggest that the humoral immune 
response to injected human factor VIII observed in wild type mice is markedly suppressed 
by the introduction of a transgene encoding human factor VIII with the Arg593 to Cys 
mutation. 
 
          hFVIII             mFVIII
 1  2  3  1  2  3
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Figure 3. Anti-factor VIII antibody response in hufVIII-R593C mice. (A) Anti-factor VIII antibody formation 
measured by ELISA in hufVIII-R593C mice (open squares) and littermate controls (closed triangles) after serial 
i.v. injections of 1 µg of factor VIII every week. Plasma samples were obtained before the first injection and 
subsequently every two weeks. (B) Anti-factor VIII antibody formation measured by ELISA in hufVIII-R593C 
mice (open squares) and littermate controls (closed triangles) after serial i.v. injections of 1 µg of factor VIII heavy 
chain every two weeks. Plasma samples were obtained two weeks after each injection.  
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Immune response to human factor VIII in transgenic hufVIII-R593C/KO mice 
Heterozygous transgenic hufVIII-R593C males were crossed with homozygous E-16 knock 
out females. Breeding of heterozygous hufVIII-R593C males with homozygous E-16 KO 
haemophilic females yielded hufVIII-R593C/E-16 KO or E-16 KO male offspring. These 
males were subjected to five consecutive intravenous injections of factor VIII. Figure 4A 
shows that in most E-16 KO mice considerable levels of anti-factor VIII antibodies are 
present. The concentration of these antibodies varied from 200 ng/ml to 73 µg/ml. 
Remarkably, in none of the four hufVIII-R593C/E-16 KO mice anti-factor VIII antibodies 
were found. Factor VIII specific T cell proliferation was assessed using spleen derived T 
cells of hufVIII-R593C/E-16 KO and E-16 KO males, which were isolated three days after 
the last injection (Figure 4B). The proliferative response of T cells of the E-16 KO mice is 
heterogeneous and dependent on the amount of factor VIII present in the incubation 
mixture. The largest responses were observed at a dose of 10 µg/ml of factor VIII (Figure 
4B). T cell responses were high in mice with high titres of anti-factor VIII antibodies in 
their plasma (Figure 4C). In 2 out of 8 E-16 KO mice tested, only a modest increase in T 
cell proliferation was observed following the addition of factor VIII. In six E-16KO mice, 
significant responses were observed, resulting in stimulation indexes that ranged from 2.5 
until 7.5 (Figure 4B).  The hufVIII-R593C/E-16 KO mice did not show a factor VIII 
specific T cell response after five injections of factor VIII. In none of these mice, a 
stimulation index above 1.2 was observed. Statistical analysis revealed that T cell responses 
in hufVIII-R593C mice were significantly decreased when compared to E-16 KO mice 
(Mann-Whitney U test; p < 0.005). The greatly reduced T and B cell responses suggest that 
hufVIII-R593C/E-16KO mice are tolerant to intravenously administered factor VIII. 
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Figure 4. Characterization of the immune response to factor VIII in hufVIII-R593C mice in E-16 KO 
background. (A) Anti-factor antibody formation measured by ELISA in hufVIII-R593C/E-16 KO mice (open 
squares) and littermate E-16 KO controls (closed triangles) after five i.v. injections of 1 µg of factor VIII at two-
weekly intervals. Plasma samples were obtained three days after the fifth injection. (B) HufVIII-R593CT cell 
proliferative responses to factor VIII in hufVIII-R593C/E-16 KO mice (open squares) and littermate E-16 KO 
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controls (closed triangles) after five i.v. injections of 1 µg of factor VIII. T cell responses were measured at 
different concentration of factor VIII. On the x-axis, the concentration of factor VIII is depicted in µg/ml. On the 
y-axis the average stimulation index (± SD) obtained for hufVIII-R593C mice (open squares) and littermate E-16 
KO controls (closed triangles) is given. (C) Plot of T cell responses versus concentration of anti-factor VIII 
antibodies in plasma. Each symbol represents data obtained for individual hufVIII-R593C/E-16 KO (open squares) 
and littermate E-16 KO mice (closed triangles). 
 
 
Loss of tolerance to human factor VIII in transgenic hufVIII-R593C and hufVIII-R593C/KO 
mice. 
Inhibitor formations in mild haemophilia A patients is rare and frequently occurs following 
a period of extensive factor VIII replacement therapy. Pro-inflammatory conditions and/or 
increased antigen load may contribute to loss of tolerance. To mimic these conditions we 
evaluated whether subcutaneous administration of factor VIII in the presence of Freund's 
adjuvant could evoke an immune response in transgenic hufVIII-R593C mice. Six hufVIII-
R593C mice and six non-transgenic control mice were subcutaneous injected every week 
and anti-factor VIII antibody responses were measured in plasma samples which were 
obtained every two weeks (figure 5A). Two wild type mice died early in this experiment. 
High titre antibodies (> 10 µg/ml) developed in wild type mice after 4-6 subcutaneous 
injections with factor VIII (Figure 5A). Antibody responses were also observed in the 
transgenic hufVIII-R593C mice. Three transgenic mice developed high antibody titres 
similar to the levels observed in wild type mice while three mice developed lower antibody 
titres ranging from 0.5 to 5 µg/ml. These results suggest that partial loss of tolerance in 
hufVIII-R593C mice occurs following subcutaneous administration of factor VIII in the 
presence of an adjuvant. These experiments were repeated with the presence of the hufVIII-
R593C transgene in an E-16 KO background. Four hufVIII-R593C/E-16KO and eight E-
16KO mice received four subcutaneous injections of factor VIII with Freund's adjuvant 
(figure 5B). All E-16KO mice developed a high antibody titre (> 10 µg/ml) whereas only 
two hufVIII-R593C/E-16KO mice developed high titre antibodies to factor VIII (figure 
5B). The other two hufVIII-R593C/E-16KO mice developed low levels of anti-factor VIII 
antibodies. These results show that also in an E-16 KO background partial loss of tolerance 
occurs following subcutaneous injections of factor VIII in the presence of Freund's 
adjuvant. 
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Figure 5. Loss of tolerance in transgenic hufVIII-R593C mice after multiple s.c. injections of factor VIII 
with Freund's adjuvant. (A) Levels of anti-factor antibodies as measured by ELISA in hufVIII-R593C mice 
(open squares) and littermate controls (closed triangles) after serial s.c. injections of 1 µg of factor VIII with 
Freund's adjuvant at a one weekly interval. Plasma samples were obtained before the first injection and 
subsequently every two weeks. (B) Anti-factor antibody formation measured by ELISA in hufVIII-R593C/E-16 
KO mice (open squares) and littermate E-16 KO controls (closed triangles) after four s.c. injections of 1 µg of 
factor VIII with Freund's adjuvant at a one week interval. Plasma samples were obtained one week following the 
last injection. 
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Discussion 
 
The immune response to factor VIII is an important obstacle for treatment of haemophilia 
A patients with factor VIII concentrates. In the majority of the patients with severe 
haemophilia A levels of circulating factor VIII are <1% of normal. Therefore, it is not 
surprising that infused factor VIII is recognized as a foreign substance by the immune 
system. Patients with mild haemophilia A do have circulating levels of factor VIII. It is 
likely that tolerance to factor VIII is maintained in these patients by ignorance or anergy of 
potentially self-reactive T and B cells. Despite the presence of circulating levels of factor 
VIII, a number of reports have suggested that inhibitor formation in mild haemophilia A 
does occur. Apparently, conditions can arise that result in loss of tolerance in this group of 
patients. Although epidemiological studies have not been conducted, it has been suggested 
that missense mutations in the A2 and C1-C2 domain of factor VIII are frequently found in 
mild haemophilia A patients with inhibitors.21  
 Here, we describe the characteristics of a transgenic mouse for human factor VIII 
harboring an Arg593 to Cys mutation that causes mild haemophilia A in humans. Both E-16 
KO mice and huFVIII-R593C/E-16 KO mice have a severe haemophilia phenotype based 
on factor VIII levels in plasma (<1% of normal). We have not performed phenotypic 
analysis of the bleeding tendency in hufVIII-R593C/E-16 KO mice. However, the majority 
of hufVIII-R593C/E-16 KO mice did not survive tail clipping that was initially used for 
purposes of genotyping. This observation suggests that the bleeding tendency of hufVIII-
R593C/E-16 KO mice is similar to that of E-16 KO mice.  
 Multiple factors may contribute to the undetectable levels of huFVIII-R593C in the 
transgenic huFVIII-R593C mice. It is possible that the transgene is integrated at a 
chromosomal location that is flanked by sequences that negatively affect expression of the 
transgene. However, both founders showed equally low amounts of circulating factor VIII. 
In addition, it has been reported that the Arg593 to Cys missense mutation is responsible for 
intracellular accumulation and subsequent degradation of factor VIII.34 The intracellular 
degradation of factor VIII may explain the low levels of circulating factor VIII in both 
patients and transgenic mice carrying this particular genetic defect in the factor VIII gene.  
 Intravenous administration of factor VIII does not result in formation of a high titre of 
anti-factor VIII antibodies in huFVIII-R593C mice whereas in non-transgenic E-16 KO and 
wild type mice an immune response was observed. Apparently, introduction of hufVIII-
R593C gene renders the huFVIII-R593C mice tolerant for human factor VIII. These 
findings are in agreement with a study of Evans and co-workers which describes the 
induction of immune tolerance to human factor VIII in E-17 KO mice by transplantation of 
bone marrow transduced with a retroviral vector expressing huFVIII.35 Although factor 
VIII was undetectable in plasma, 30-50% of the treated E-17 KO mice were tolerant to 
factor VIII. It was suggested that low-level exposure of human factor VIII in bone marrow-
derived antigen-presenting cells induced tolerance in these mice. In our mouse model, 
tolerance to factor VIII may be induced by ignorance or anergy of factor VIII reactive T 
and B cell. Anergic or down-regulated auto-reactive T and B cells are not eliminated from 
the repertoire and can still participate in immune responses but their activation threshold 
has been raised (reviewed by Goodnow).36 Negative selection of factor VIII reactive T and 
B cells by clone elimination in central or peripheral lymphoid tissues is not likely since loss 
of tolerance was observed after subcutaneous injections of factor VIII in the presence of an 
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adjuvant. We are currently investigating whether the observed anti-factor VIII antibody 
response coincides with increased factor VIII dependent T cell responses. It has been 
suggested that central T cell tolerance can be induced by promiscuous gene expression of 
tissue-specific antigens in the thymus.37-40 To investigate whether T cell tolerance is 
achieved in the thymus or in peripheral lymphoid tissues, it would be interesting to 
determine whether the transgene is expressed in the thymus of the hufVIII-R593C mice. 
 The anti-factor VIII immune responses observed in E-16 KO and wild type mice is 
similar to the anti-factor VIII antibody and T cell responses reported by others.12,13,15 In our 
studies we have used highly purified, plasma derived factor VIII whereas other 
investigators have used recombinant factor VIII. Our results suggest that these preparations 
are similar with respect to their immunogenicity. We observed variability in immune 
response within the different groups of animals, for example, not all E-16 KO developed 
high titres of anti-factor VIII antibodies following i.v. injections of factor VIII. This 
variability in antibody titres and T cell proliferation may be due to the heterogeneity of the 
animals used for immunization. HuFVIII-R593C mice have been generated on an FVB 
background. In our experiments, we used mice that were backcrossed to C57BL6 for at 
least two generations. Also, our population of E-16 KO mice was only partially inbred into 
a C57Bl/6 genetic background. This heterogeneity may contribute to a variable anti-factor 
VIII immune response within the different groups of mice. 
 The lack of inhibitor formation in huFVIII-R593C mice after intravenous injections of 
factor VIII is in agreement with the reduced incidence of inhibitor formation in patients 
with mild haemophilia A. In some patients, loss of tolerance is observed following factor 
VIII replacement therapy. Genetic defects in the A2 domain and at the C1-C2 junction have 
been implicated in inhibitor development.21 Inhibitor formation is not observed in all 
patients with these genetic defects, which suggest that other factors contribute to the onset 
of an immune response. Transgenic huFVIII-R593C mice are tolerant to wild-type human 
factor VIII when injected intravenously. However, subcutaneous administration of factor 
VIII in the presence of an adjuvant results in loss of tolerance to infused factor VIII. These 
data suggest that inflammatory conditions and/or antigen presentation are important for 
initiation of immune responses in patients with mild haemophilia A. Collectively, our 
findings indicate that hufVIII-R593C/E-16 KO mice provides a useful model for studies 
directed at mechanisms involved in loss of tolerance in haemophilia A. 
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Introduction 
 
Haemophilia A is a bleeding disorder caused by a decrease or dysfunction of blood 
coagulation factor VIII. Bleeding episodes can be prevented or treated by replacement 
therapy using plasma-derived or recombinant factor VIII. In response to replacement 
therapy, patients can develop an immune response to transfused factor VIII. The formation 
of inhibitory antibodies to factor VIII (factor VIII inhibitors) is one of the most difficult 
problems in treatment of haemophilia A patients.1 
Whereas inhibitor development occurs in 25% of patients with severe haemophilia A, 
inhibitor development in mild and moderate haemophilia A is less frequently observed. It is 
generally believed that the low amount of circulating factor VIII in mild/moderate 
haemophilia A patients explains the lower risk of inhibitor development. Loss of tolerance 
and subsequent inhibitor formation in these patients commonly occurs after extensive factor 
VIII replacement therapy. It has been shown that the risk of inhibitor development is higher 
for patients with missense mutations in the A2, C1 or C2 domain of factor VIII (Table I).2 
However, not all mild haemophilia A patients with these missense mutations develop 
inhibitors after administration of factor VIII. This observation suggests that in addition to 
factor VIII genotype additional factors contribute to inhibitor development in mild 
haemophilia A.  
To investigate the mechanisms underlying inhibitor formation in mild haemophilia A 
patients we have characterized anti-factor VIII antibodies using phage display technology 
and immunoprecipitation analyis. We have evaluated the role of HLA class II molecules in 
inhibitor development in patients with mild haemophilia A caused by an Arg593 to Cys 
mutation. Furthermore, we have developed a small animal model for inhibitor development 
in haemophilia A which enables studies directed at the immunological mechanism 
underlying inhibitor development.  
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Table I. Missense mutations associated with inhibitor development in patients with 
mild or moderate haemophilia A. 
 
Factor VIII 
domain 
Mutation Reports of patients with inhibitors 
A1 domain Leu198 to His Pieneman 1995 
A2 domain Gly420 to Val Liu 1998 
 Arg593 to Cys Pieneman 1995, Fijnvandraat 1997, 
Thompson 1997, Hay 1998, van den Brink 1999, 
Knobe 2000, Bril Chapter 6 this thesis 
 Asn618 to Ser Vlot et al 2002 
 Val663 to Phe Hay 1998 
 Gly701 to Asp Bichandi 1995 
A3 domain Arg1941 to Gln Liu 1998 
 Gly2009 to Arg Hay 1998 
C1 domain Thr2086 to Asn Freson 1998 
 Tyr2105 to Cys Naylor 1993, Hay 1998, Knobe et al, 2000 
 Arg2150 to His Santagostino 1995, Peerlinck 1998, Hay 1998, 
Laprise 1998, Liu 2002 
 Arg2163 to His Hay 1998 (van den Brink et al, 2002: Chapter 2 
this thesis), Waseem 1999 
C2 domain Glu2181 to Asp Hay 1998 
 Arg2209 to Gln Schwaab 1993 
 Trp2229 to Cys Naylor 1991, hay 1998, Cutler 2002 
 Val2232 to Ala Liu 2000 
 Phe2260 to Ile Hay 1998 
 Pro2300 to Leu  Liu 2000 
 Arg2304 to Cys Liu 2000 
 
 
Analysis of anti-C2 antibodies of mild haemophilia A patients using 
phage display 
 
Factor VIII circulates in plasma as a metal-ion linked heterodimer. The heavy chain of 
factor VIII consists of the domains A1-A2-B and the light chain consists of the domains 
A3-C1-C2. Previous studies have demonstrated that inhibitory antibodies detected in both 
severe and mild/moderate haemophilia A patients bind to restricted regions of factor VIII 
(see Figure 1 Chapter 1). Binding sites have been identified in the A2, A3 and C2 domain 
of factor VIII. Binding of antibodies to the A2 domain is localized to amino acid sequence 
Arg484-Ile508 and the major epitope in the A3 domain consists of residues Gln1778-Met1823.3-5 
Inhibitors directed towards the A2 and A3 domain neutralize factor VIII activity by 
interfering with the interaction of factor VIIIa with factor IXa. Residues Glu2181-Val2243 and 
residues Val2248-Ser2312 are involved in antibody binding in the C2 domain.6,7 Inhibitors 
specific for the C2 domain block the binding of factor VIII to the phospholipid surface or 
reduce the release of activated factor VIII from von Willebrand factor.8,9 Usually, a mixture 
of antibodies neutralizes factor VIII function in the patients' plasma.10 
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Previously, anti-C2 antibodies have been studied in a patient with severe acquired 
haemophilia A using phage display technology (patient A in Table II).11 Because the 
majority of the factor VIII inhibitors are of subclass IgG4, a phage display library was 
constructed of the IgG4-specific immunoglobulin heavy chain variable (VH) repertoire of 
the patient.11,12 The patient's VH repertoire was combined with the immunoglobulin light 
chain variable (VL) repertoire of a nonimmune donor. From this library, anti-C2 specific 
single chain variable fragments (scFv's) were isolated and sequence analysis showed that 
their VH gene segments were all derived from the VH1 family. In chapter 2, the isolation of 
19 anti-C2 specific scFv's from a library of a mild haemophilia A patient with a missense 
mutation (Arg2163 to His) in the C1 domain of factor VIII is described (patient B in Table 
II).13 These anti-C2 scFv's were also derived from the VH1 gene family. In two recent 
studies, anti-C2 antibodies encoded by aVH1 derived germline segment were isolated as 
well.14,15 The described anti-C2 antibodies can be divided into two groups derived from two 
different classes of germline genes. The first class of antibodies is derived from germline 
gene segments DP-10 (1-69), DP-14 (1-18) and DP-88 (1-e) and the second class is derived 
from DP-5 (1-24) encoded germline gene segments (see Figure 3 Chapter 3). In chapter 2, 
we show that these two classes of anti-C2 antibodies bind to two different epitopes in the 
C2 domain of factor VIII. ScFv's encoded by DP-10 (1-69), DP-14 (1-18) and DP-88 (1-e) 
compete with monoclonal antibody CLB-CAg 117 for binding to the carboxyl terminal part 
of the C2 domain while scFv's encoded by DP-5 (1-24) bind to an epitope which overlaps 
with the binding site of monoclonal antibody ESH4.16,17 The epitope of the DP-5 (1-24) 
encoded antibodies involved residues at the amino- and carboxyl terminal part of the C2 
domain. 
In chapter 3, the characteristics of the VH domains of scFv's isolated from the 
immunoglobulin repertoire of different patients are analysed in more detail.18 VH domains 
of antibodies specific for the A2 and A3-C1 domains of factor VIII are encoded by 
germline gene segments derived from both VH1 and VH3 family. Anti-A2 and anti-A3-C1 
antibodies are encoded by VH segments, which are commonly used in the normal IgG 
repertoire. In contrast, the anti-C2 antibodies described in chapter 2 are encoded by VH 
gene segments, which are not preferentially expressed in the normal IgG repertoire.19 A 
closer look at the structural elements of de VH domains of the three DP-5 (1-24) encoded 
anti-C2 scFv's, scFv's that bind to the epitope defined by monoclonal antibody ESH4, 
revealed the presence of negatively charged amino acid residues that can react with 
positively charged residues in the C2 domain.13  Recently, the three-dimensional structure 
of a complex of the antibody BO2C11 (a DP-5 (1-24) encoded antibody which has been 
isolated from a patient using Epstein Barr immortalisation) and the C2 domain was 
determined.14,20 Comparison of the three DP-5 (1-24) encoded scFv's with the antibody 
BO2C11 showed that all antibodies have relatively small CDR3 regions and that the 
majority of the negative residues that react with the C2 domain of factor VIII are 
conserved. It is anticipated that more restricted usage of VH germline segments by anti-C2 
antibodies results from a selective recruitment of B cells expressing immunoglobulins with 
negatively charged VH domains upon antigen stimulation. Our results indicate that naive B 
cells expressing immunoglobulins with a negatively charged DP-5 (1-24) encoded VH 
domain are preferentially expanded following exposure tofactor VIII. Subsequent somatic 
hypermutation introduces point mutations in the variable regions, giving rise to high 
affinity antibodies. Selection of these B cells explains why DP-5 (1-24) encoded human 
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antibodies  were isolated from the repertoire of haemophilia A patients while the DP-5 (1-
24) germline gene segment is not dominantly expressed by B cells in the normal repertoire.  
The VH germline gene segment usage by anti-C2 antibodies that compete with 
monoclonal antibody CLB-CAg 117 is less restricted. We show that scFv's binding to the 
carboxyl terminal part of the C2 domain, which were isolated from the repertoire of patient 
A and patient B (Table II) are encoded by the related germline gene segments DP-10 (1-
69), DP-14 (1-18) and DP-88 (1-e).11,13 However, the two scFv's described in chapter 4 are 
derived from different germline gene segments (patient C in Table II). ScFv VK29 is 
derived from DP-25 (1-03), a germline gene segment belonging to the VH1 family that is 
not related to DP-10 (1-69), DP-14 (1-18) and DP-88 (1-e). ScFv VK33 is encoded by DP-
79 (4-39), which belongs to the VH4 gene family (see Figure 1 Chapter 3). A striking 
feature of all anti-C2 scFv's, which bind to the epitope defined by monoclonal antibody 
CLB-CAg 117 is the presence of a long CDR3 region (18-23 aa). Whereas the negatively 
charged residues in the VH domain determines the epitope specificity of the monoclonal 
antibody ESH4 competing anti-C2 antibodies, the exceptionally large CDR3 region may 
determine the epitope specificity of the monoclonal antibody CLB-CAg 117 competing 
anti-C2 antibodies. It has been postulated that factor VIII inhibitors may originate from the 
expansion of pre-existing natural anti-factor VIII B cell clones.21-23 Natural autoantibodies 
are immunoglobulins reactive with self-antigens and the majority of natural autoantibodies 
are polyspecific. Because most natural autoantibodies are reactive with a variety of self-
antigens, natural autoantibodies might provide the template for specific high-affinity 
autoantibodies or antigen-induced antibodies in patients with autoimmune diseases. It has 
also been suggested that polyreactive antibodies have long CDR3 regions in the heavy 
chain.24 Aguilera et al. described the characteristics of eight polyreactive autoantibodies 
with long CDR3 regions in the heavy chains (9-20 aa).24 These observations suggest that 
the anti-C2 antibodies specific for the epitope of CLB-CAg 117 may originate from natural 
anti-factor VIII antibodies with long CDR3 regions. 
 
 
Table II Overview of the anti-C2 antibodies isolated from the IgG4 repertoire of three 
haemophilia A patients using phage display.  
1) Patient A has been previously described as patient AMC-174. Anti-C2 scFv's isolated from the repertoire of this 
acquired haemophilia patient have been described by Van den Brink et al.11 
2) Patient B is a mild haemophilia A patient with an Arg2163 to His mutation. Anti-C2 scFv's isolated from the 
repertoire of patient B are described in chapter 2.133) Patient C is also known as patient AMC-67, a mild 
haemophilia A patient with the Arg593 to Cys mutation described by Van den Brink et al. (see also chapter 6 this 
thesis).25 Anti-C2 scFv's isolated from the repertoire of this patient are described in chapter 4.  
 
 Patient A 1) Patient B 2) Patient C 3) 
Plasma:    
Percentage of inhibitory anti-C2 
antibodies of total inhibitors 
20% 80% 10% 
    
Isolated scFv's using phage 
display: 
   
VH germline gene segment DP-10 (1-69)  DP-5 (1-24)  DP-25 (1-03) 
 DP-14 (1-18) DP-88 (1-e) DP-79 (4-39) 
 DP-88 (1-e)   
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Analysis of anti-A2 antibodies of mild haemophilia A patients using 
phage display  
 
In chapter 5, we describe  inhibitor development in a patient with mild haemophilia A 
caused by the Arg593 to Cys mutation.26 Two previous studies have shown that inhibitory 
antibodies arising in patients with the same mutation were directed towards Arg484-Ile508, a 
major binding site for factor VIII inhibitors.27,28 In patient AMC-92, a low level of 
antibodies with a different specificity was detected fifteen years after the onset of the first 
inhibitor.29 The patient's antibodies were directed at residue Arg593 and could discriminate 
between exogenous and endogenous factor VIII. However, our analysis of the 
immunoglobulin repertoire reveals antibodies specific for residues Arg484-Ile508 (chapter 
5).26 Surprisingly, antibodies reactive with Arg593 were not isolated from the repertoire of 
patient AMC-92 by phage display. Peripheral B cells expressing this specificity may be 
absent in the blood sample of 1993 that was used for construction of the library. However, 
we cannot exclude that limitations in our experimental protocol have precluded isolation of 
antibody fragments specific for Arg593. For instance, we have used a variable 
immunoglobulin light chain repertoire of non-immune source for construction of our phage 
display libraries. Assembly of human antibodies reactive with residue Arg593 may require 
the presence of a particular immunoglobulin light chain that is not represented in the 
repertoire we have used.  
The isolated scFv's specific for Arg484-Ile508 and analysis of antibodies present in the 
plasma of patient AMC-92 during a second high titre inhibitor period indicated the presence 
of cross-reactive antibodies specific for residues Arg484-Ile508 (chapter 5).26 Cross-reactive 
antibodies recognize both administrated (exogenous) factor VIII and the patient's mutated 
(endogenous) factor VIII. Our immunoprecipitation data suggest that cross-reactive 
antibodies co-exist with a persisting level of 'true' alloantibodies that selectively recognise a 
B cell epitope overlapping with amino acid Arg593 in patient AMC-92. The latter population 
of antibodies was not detected in two other unrelated inhibitor patients with the same 
genetic defect.27,28 We propose that the region Arg484-Ile508 constitutes an immunodominant 
epitope that may obscure B cell epitopes overlapping Arg593. This may explain the rare 
occurrence of antibodies reactive with Arg593 in patients with the Arg593 to Cys mutation. 
Interestingly, antibodies reacting exclusively with exogenous factor VIII have until now 
been observed in three patients with the Arg2150 to His mutation.30,31 Apparently, B cell 
clones reactive with Arg2150 dominate the anti-factor VIII repertoire of this group of 
patients. At present it is not clear why in some patients with mild haemophilia A true 
alloantibodies exist whereas in plasma of most patients cross-reactive antibodies against the 
major inhibitor epitopes on factor VIII are found.  
We proposed the following mechanism of inhibitor development in patient AMC-92. 
Fifteen years after the onset of the first inhibitor in patient AMC-92, a low level of 
antibodies directed against Arg593 are still present in the patient's plasma. Our analysis of 
the immunoglobulin repertoire expressed by peripheral B cells reveals antibodies specific 
for residues Arg484-Ile508 (Figure 1, upper panel). These cross-reactive antibodies are not 
observed in plasma at this time point but were probably present at the onset of the first 
inhibitor when the patient had a high inhibitor titre and reduced factor VIII levels. The 
antibody titre decreased which coincided with a increase of plasma factor VIII levels. 
However, a low level of antibodies directed against the Arg593 epitope present on 
exogenous factor VIII peristed for an extended period of time. Following a second period of 
Chapter 8 
 114
factor VIII replacement therapy, cross-reactive antibodies, directed against Arg484-Ile508, are 
present in plasma  (Figure 1, lower panel). We suggest that memory B cells expressing 
antibodies directed against Arg484-Ile508 differentiate into antibody-secreting plasma cells 
upon treatment with factor VIII. This explains the rapid appearance of anti-A2 antibodies 
and decrease of factor VIII levels in patient AMC-92. The VH gene library of patient AMC-
92 originates from RNA isolated from peripheral blood lymphocytes. The B cell pool in 
peripheral blood consists of naive B cells (60%) and memory B cells (40%). Peripheral 
memory B cells are defined by expression of the CD27 surface antigen and the presence of 
somatic hypermutations.32 Memory B cells can differentiate into antibody-secreting plasma 
cells upon stimulation with antigen.33-35 We suggest that scFv's reactive with residues 
Arg484-Ile508 of patient AMC-92 were isolated from peripheral memory B cells. Further 
studies should address whether the phage display repertoire of factor VIII inhibitors indeed 
originates from peripheral memory B cells. The analysis of inhibitor development of patient 
AMC-92 could be relevant for treatment of other haemophilia A patients. Knowledge on 
the presence of peripheral factor VIII-specific memory B cells can be helpful in predicting 
whether an anamnestic response will occur in haemophilia A patients with a history of 
inhibitor development.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Proposed mechanism of inhibitor development in patient AMC-92.  
Factor VIII replacement therapy stimulates the differentiation of peripheral memory B cells expressing surface 
immunoglobulins directed against Arg484-Ile508 into plasma cells that rapidly produce cross-reactive antibodies 
(indicated in gray). Memory B cells expressing antibodies reactive with Arg484-Ile508 are mainly present in 
secundary lymphoid organs (LO). Plasma cells secreting antibodies directed against Arg593 (indicated in white) are 
present in bone marrow (BM) and spleen (SP) for extended periods (> 8 years). In the right panel, the results from 
immunoprecipitation analysis (Antibodies present in plasma) and the results from phage display analysis (Phage 
display of peripheral B cells) are summarized. Phage display analysis after factor VIII treatment was not 
performed (N.P.). 
Memory B cells 
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ScFv's reactive with Arg484-Ile508 have been isolated from the immunoglobulin 
repertoire of patient AMC-92 using phage display.26 Two different clones reactive with 
Arg484-Ile508 were isolated from the patient’s IgG4-specific repertoire. The majority of 
scFv's, represented by scFv 92-102, were derived from heavy chain gene segment DP-47 
(3-23), belonging to the VH3 family (Table III). The same VH segment was observed for 
scFv VK41, an anti-A2 antibody that was derived from a phage library of a different patient  
(11)with the Arg593 to Cys mutation (patient AMC-67).28 ScFv VK41 is directed against 
amino acid residues Asp712-Ala736 a binding site in the acidic region following the A2 
domain. Despite the common of VH segment DP-47, scFv 92-102 and scFv VK41 recognise 
distinct antigenic sites in the A2 domain of factor VIII. Inspection of the pattern of somatic 
hypermutation of the VH domain of scFv 92-102 reveals a deletion of three amino acids in 
the CDR2 region (Table III). Small deletions and/or insertions are observed in 
approximately 6% of the human B cell repertoire.36 The CDR2 region is a common site for 
deletions/insertions of amino acids although deletions of three amino acids are infrequently 
observed.32,37 Modelling studies suggest that sequence variations in this part of the CDR2 
changes the surface properties, however, they may not alter the main-chain structure of the 
antibody molecule.38 Only one isolated scFv was encoded by VH segment DP-58 (clone 92-
137). VH gene segment DP-58 is infrequently used in the immunoglobulin repertoire and 
Matsuda and co-workers have not mapped this segment to a functional locus.32,39,40 
However, the sequence of clone 92-137 shows several amino acid mutations from the 
germline DP-58 and is therefore likely to be derived from an antigen stimulated B cell. 
Previously, another scFv specific for the major epitope Arg484-Ile508 was isolated from mild 
haemophilia A patient AMC-67.28 This scFv (VK34) was encoded by germline gene 
segment DP-10 (1-69), belonging to the VH1 family (Table III). Anti-A2 antibodies in these 
two inhibitor patients are derived of VH1 and VH3 gene segments, which are present in 70% 
of peripheral IgG+ B cells in the normal repertoire.19 Apparently, anti-A2 antibodies in 
mild haemophilia A patients with the Arg593 to Cys mutation are encoded by VH gene 
segments which are commonly used in the normal repertoire. 
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Table III. Comparison of deduced protein sequence of the heavy chains of anti-A2 
specific human antibodies with variable heavy chain germline gene segments.  
FR, framework region; CDR, complementarity-determining region. Dashes indicate sequence identity to variable 
heavy chain germline gene segments. Lower case indicates amino acid substitution encoded by the PCR primers. 
Sequences are available from Genbank under accession numbers: AY052530 (VH 92-102); AF217790 (VH VK41); 
AY052532 (VH 92-137); AF217789 (VH VK34). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HLA genotype and factor VIII inhibitors in mild haemophilia A 
patients with an Arg593 to Cys mutation 
 
We have studied the inhibitor development in a cohort of 42 patients with mild haemophilia 
A. All these patients have a missense mutation in the A2 domain of the heavy chain of 
factor VIII that causes a substitution of an arginine at position 593 to a cysteine. In this 
cohort, four patients developed a high titre of inhibitor following factor VIII replacement 
therapy. Inhibitor development of two high responder patients from our cohort and one high 
responder patient with the Arg593 to Cys mutation from a different study have been 
described previously.25-29 In chapter 6, we describe the epitope specificity of the anti-factor 
VIII antibodies of another high responder patient (patient D). Remarkably, all high 
responder patients with the Arg593 to Cys mutation develop antibodies directed against the 
A2 domain and three patients develop antibodies specific for the light chain as well (Table 
IV). The predominant inhibitors in these patients are cross-reactive A2 antibodies, most 
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likely directed against the major inhibitor epitope Arg484-Ile508, whereas only a minor 
contribution of anti-light chain antibodies is observed. These data suggest that patients with 
a missense mutation in the heavy chain of factor VIII are less tolerant for the heavy chain 
compared to the light chain. One explanation for this phenomenon can be that when 
exposed to wild-type factor VIII, the patient's immune system recognises the heavy chain as 
non-self while whereas the light chain is recognised as self. Factor VIII-specific T cells will 
recognize that portion of factor VIII carrying the Arg593 residue and will provide T help for 
antibody formation predominantly targeting the non-self part of the factor VIII protein. 
Another explanation can be that after initiation of the immune response to factor VIII, light 
chain-specific T cells and/or light-chain specific B cells become anergic because of 
circulating levels of wild-type factor VIII light chain. At present it is not fully understood 
why high responder patients with the Arg593 to Cys develop inhibitory antibodies that 
predominantly target the  A2 domain of factor VIII. 
 
 
Table IV. Epitope specificities in high responder patients with the Arg593 to Cys 
mutation.  
High titre patients have been described elsewhere: 1) patient AMC-67: van den Brink et al 1999 and as patient C in 
chapter 6 this thesis; 2) patient F: Thompson et al 1997; 3) patient D: chapter 6 this thesis; 4) as patient A: 
Fijnvandraat et al 1997 and as patient AMC-92:, Bril et al 2002 (chapter 5, this thesis) and also as patient A in 
chapter 6 in this thesis.25-27,29  
 
Patient Antibody epitope specifities Major inhibitor epitope 
AMC-67 (C) 1) cross-reactive A2, LCh, C2 A2 
F 2) cross-reactive A2, LCh, C2 A2 
D 3) cross-reactive A2, LCh A2 
AMC-92 (A) 4) wild-type reactive A2, cross-
reactive A2 
A2 
 
 
Several studies have provided evidence that inhibitor development in haemophilia A 
patients is T-cell dependent. Anti-factor VIII antibodies are usually extensively 
hypermutated and of IgG4 subtype which points at a  role for  T cells in inhibitor 
formation.11-14,26.28,41 It has been shown that factor VIII-reactive T cells are present in the 
circulation of haemophilia A patients with inhibitors.42 Also, the disappearance of factor 
VIII inhibitors in haemophilia A patient with declining CD4+ T cell counts caused by HIV 
infection indicate that inhibitor formation in T cell dependent.43 Reding et al. observed anti-
factor VIII CD4+ T cells in congenital and acquired haemophilia A patients but also in 
healthy individuals.44 Recently, three factor VIII-specific T cell clones were isolated from a 
mild haemophilia A patient.45 Several studies in haemophilic mice have shown that the 
antibody response in murine haemophilia A is T cell dependent as well.46-48 We hypothesize 
that in patients with the Arg593 to Cys mutation the immune response to infused factor VIII 
is initiated by factor VIII-specific T cells that recognize a factor VIII peptide containing the 
residue Arg593 as non-self (Figure 2). Following factor VIII infusion, antigen presenting 
cells (APC's) will endocytose and degrade the factor VIII protein. Antigen-derived peptides  
are bound by HLA class II alleles and presented to CD4+ T cells. As peptides containing the 
Arg593 residues will only bind to the T cell receptor (TCR) in the context of a matching 
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HLA class II molecule, we investigated whether the presence of a particular HLA class II 
allele is related to inhibitor development patients with the Arg593 to Cys mutation. We 
observed in three (out of four) high responder patients the presence of haplotype HLA-
DQB1*06, DRB1*13. However, it should be noted that two of these patients are twin 
brothers. In the fourth high responder patient haplotype HLA-DQB1*05, DRB1*01 was 
found. Interestingly, haplotype HLA-DQB1*05, DRB1*01 was raised in the low responder 
group compared to non inhibitor patients in our study and has also been associated with 
inhibitor development in patients with severe haemophilia A.49  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.    Antigen presentation of a factor VIII peptide bound to an HLA class II 
allele on the surface of an antigen-presenting cell (APC) to the T cell receptor (TCR) 
on the surface of a CD4+ T cell.  
 
 
 
Analysis of the amino acid sequence of factor VIII reveals that peptide fragments 
containing residue Arg593 are likely to bind to relevant HLA class II molecules in the high 
responder patients from our study (Figure 3). Peptides encompassing Arg593 were predicted 
to bind to HLA-DRB1*0101, 1101, 1302 and 1501 by an HLA class II binding peptide 
prediction server based on quantitative matrices.50 These results indicate that antigenic 
peptides containing Arg593 can be presented to T cells in the context of multiple HLA class 
II molecules.  
Recently, Jacquemin and co-workers have characterised three factor VIII-specific T 
cell clones from a mild haemophilia A patient with an Arg2150 to His mutation in the C1 
domain of factor VIII.45 This patient developed a high titre of inhibitory antibodies specific 
for wild type and not self factor VIII. The T cell clones recognized a peptide containing 
residue Arg2150 and did not recognize the mutated peptide containing His2150. Interestingly, 
the peptide encompassing Arg2150 was able to bind to a large array of HLA-DR molecules. 
Binding of antigenic peptides to multiple HLA class II alleles can explain the increased 
frequency of inhibitor development in patients with the Arg2150 to His and Arg593 to Cys 
mutation and can also explain the weak associations observed between inhibitor 
development and HLA class II alleles. 
 
APC CD4+ T 
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Figure 3.  Peptide prediction of wild type factor VIII to HLA-DR alleles present in 
high responder patients with the Arg593 to Cys mutation by the MHC class II binding 
peptide prediction server ProPred.50  
Peptide prediction of factor VIII peptides to HLA-DRB1*04, which is present in one high responder patient was 
not determined because this allele was not subtyped. 
 
 
 
A murine model for inhibitor development in haemophilia A patients 
 
In chapter 7 we present a new murine model for inhibitor development in haemophilia A 
patients. We have created a mouse transgenic for human factor VIII harbouring the Arg593 
to Cys mutation, which causes mild haemophilia A in humans. Liver -specific expression of 
the transgene was directed by the murine albumin promotor. Nevertheless we could not 
detect human factor VIII in plasma by sensitive ELISA and western blotting techniques. 
The transgenic hufVIII-R593C mice were crossed with the murine factor VIII knock out 
mice (E-16 KO) generated by Bi and co-workers.50,51 E-16 KO mice have less than 1 % 
factor VIII activity in plasma and display a severe bleeding tendency. Although we did not 
study the phenotype in detail, we observed that hufVIII-R593C/E-16 KO have an impaired 
hemostasis and bleed to death after tail clipping as well. Introduction of the hufVIII-R593C 
gene did not reduce the severe phenotype of the E-16 KO strain in hufVIII-R593C/E-16 
KO mice. Injections experiments performed in chapter 7 clearly show that transgenic 
hufVIII-R593C/E-16 KO mice are tolerant for i.v. injected human factor VIII in contrast to 
E-16 KO mice, which develop anti-factor VIII antibodies following injections of factor 
VIII. We show in chapter 7 that hufVIII-R593C/E-16 KO do not develop anti-factor VIII 
antibodies and have no factor VIII-specific T cell proliferation following serial i.v. 
injections of human factor VIII. The observed tolerance to factor VIII in transgenic 
HufVIII-R593C/E-16 KO mice is in agreement with the low inhibitor incidence in mild 
haemophilia A patients. 
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Following factor VIII replacement therapy, inhibitor development has been observed 
in some mild haemophilia A patients with the Arg593 to Cys mutation.25-27,29 We 
investigated whether our transgenic mouse model can be used as a model for inhibitor 
development in haemophilia A patients. We increased pro-inflammatory conditions by 
injecting factor VIII s.c. in the presence of an adjuvant to provoke an immune response to 
factor VIII. We observed significant anti-factor VIII antibody responses in transgenic 
hufVIII-R593C mice in both wild type and E-16 KO background. These results show that 
an anti-factor VIII immune response can be evoked in our transgenic model and we 
therefore conclude that hufVIII-R593C mice are a valuable model for inhibitor 
development in haemophilia A. 
Inhibitors which arise in haemophilia A patients, bind factor VIII at restricted regions 
in the A2, A3 and C2 domain of factor VIII.3-7 In a previous study, a first attempt has been 
made to investigate whether factor VIII knock out mice exhibit an anti-factor VIII antibody 
response with epitope specificities similar to that observed in patients53. Antibodies 
obtained from immunized E-17 KO mice (another factor VIII knock out strain) were tested 
for their reactivity with thrombin cleavages products of recombinant human factor VIII. 
The antibodies were directed to the heavy chain, light chain and the non-functional B 
domain of factor VIII.53 We have investigated the epitope specificity of anti-factor VIII 
antibodies in immunized E-16 KO mice by immunoprecipitation analysis with radiolabelled 
recombinant human factor VIII constructs. Preliminary data show that the antibodies were 
predominantly directed to the light chain whereas limited reactivity was observed with the 
A2 and C2 domain of factor VIII. Since these results were obtained from one single 
experiment, we cannot exclude that we underestimate the binding to A2 and C2 due to 
limitations in our experimental protocol. Both factor VIII knock out strains have been 
constructed by targeted disruption of part of the  factor VIII gene that encodes factor VIII 
light chain. Surprisingly, both the E-16KO and E-17KO mice do produce some amounts of 
non-functional factor VIII heavy chain.54 Despite the presence of circulating murine factor 
VIII heavy chain, both knock out strains can develop antibodies directed to the heavy chain 
of human factor VIII. Overall, it can be concluded that the antibody specificities of factor 
VIII knock out mice resemble the immune response in haemophilia A patients. Future 
studies will have to address whether the antibody specificities observed in transgenic 
hufVIII-R593C mice resemble the antibody specificities of mild haemophilia A patients 
with the Arg593 to Cys mutation. 
Factor VIII-specific CD4+ T cells which drive the synthesis of inhibitors have been 
detected in haemophilia A patients as well as in the factor VIII knock out mice.42,44-48 
Classically, CD4+ T cells are divided in Th1 and Th2 cells. Th1 cells secrete pro-
inflammatory cytokines such as IFN-γ and IL-2 whereas Th2 cells secrete IL-4 and IL-10. 
Both CD4+ T cell populations secrete cytokines that drive B cell differentiation and 
antibody synthesis. Th1 cells mediate the synthesis of IgG subclasses that bind complement 
(IgG1 and IgG2 in humans) and Th2 cells drive the synthesis of IgG4 antibodies which are 
associated with inhibitor development in humans.12 Recently, the distribution of Th1- and 
Th2-induced anti-factor VIII IgG subclasses in severe haemophilia A patients has been 
studied.55 The results from this study indicate that Th1 driven antibody synthesis may be 
more important than previously appreciated. The authors suggested that Th2-driven 
synthesis of inhibitors occurs when the anti-factor VIII antibody response in high and 
intense, while Th1-driven synthesis of inhibitors occurs when the antibody response is low. 
It was suggested that Th1 cells might be involved in long-term maintenance of anti-factor  
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VIII antibody synthesis. These observations are in agreement with the observed immune 
responses in the factor VIII knock out mice. Haemophilic mice developed both Th1 and 
Th2 cell responses following immunization with factor VIII. Factor VIII dependent  T cells 
produce both Th1- and Th2-specific cytokines. Also, anti-factor VIII antibodies are  of 
subclass IgG1 (Th2-driven) and IgG2 (Th1-driven).47,48,56 It is of interest to determine 
cytokine profiles and IgG subclass distribution in transgenic huFVIII-R593C/E-16 KO 
mice following immunization with human factor VIII.  
Tolerance to factor VIII is likely maintained by ignorance or anergy of auto-reactive T 
and B cells in the hufVIII-R593C/E-16 KO mice and mild haemophilia A patients. Anergic 
T and B cells are tuned down but are still capable of participating in an immune response 
(reviewed by Goodnow).57 Following subcutaneous injections of factor VIII with an 
adjuvant, an anti-factor VIII antibody response was observed in our mouse model which 
suggests activation of anergic factor VIII reactive T and B cells. The activation threshold of 
anergic T and B cells is raised and a strong immunogenic stimulus is required to activate 
anergic T and B cells. Apparently, subcutaneous immunization with factor VIII in the 
presence of an adjuvant provided a strong stimulus for anergic T and B cells and partial loss 
of tolerance to factor VIII was observed. In some mild haemophilia patients loss of 
tolerance to factor VIII is observed following peri-operative factor VIII treatment. Pro-
inflammatory conditions and a high antigen load may provide a strong stimulus for anergic 
factor VIII reactive T and B cells in humans. Besides inflammatory conditions, HLA class 
II profile may be related to loss of tolerance to factor VIII.50,58 In chapter 6, we evaluated 
the role of HLA class II alleles in inhibitor development in mild haemophilia A patients 
with the Arg593 to Cys mutation. We observed a weak association but more patients should 
be studied to link a particular HLA class II allele with inhibitor formation in patients with 
the Arg593 to Cys mutation. It is interesting to investigate the role of HLA class II alleles 
and loss of tolerance to factor VIII in our mouse model. Chimeric human/mouse MHC class 
II molecules containing the antigen-binding region of HLA-DR alleles found in inhibitor 
patients can be introduced in the hufVIII-R593C/E-16 KO mice.59-61 HufVIII-R593C/E-16 
KO mice transgenic for chimeric human/mouse MHC class II alleles would provide a 
powerful tool to study the role of HLA class II alleles in inhibitor development. It is likely 
that both inflammatory conditions and immune response genes like HLA class II alleles 
contribute to inhibitor development in mild haemophilia A. 
 
 
Future directions 
 
The  studies presented in this thesis aim at a better understanding of the immunobiology of 
inhibitor development in mild haemophilia A. Detailed knowledge of the characteristics 
and epitope specificities of anti-factor VIII antibodies can be applied for the construction of 
recombinant factor VIII variants with reduced immunogenicity. Recent studies that employ 
human-porcine hybrids suggest that it is indeed possible to decrease the antigenicity of 
factor VIII.62 However, factor VIII is a large molecule with multiple potential T cell and B 
cell epitopes. At present it is not clear whether elimination of immunodominant regions will 
result in factor VIII variants with a decreased immunogenicity. Studies directed at the 
interactions of factor VIII specific B and T cells are perhaps more promising. Prevention of 
immune responses to factor VIII by interfering with co-stimulatory signals has already been 
achieved in haemophilic mice. Despite these promising results long-lasting tolerance to 
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factor VIII could not be established in a reproducible manner. Obviously, there is a need for 
alternative protocols for downregulation and modulation of inhibitor formation in 
haemophilia. The results presented in this thesis have provided detailed insight into the 
molecular characteristics of factor VIII inhibitors. Furthermore, several determinants 
potentially contributing to loss of tolerance in haemophilia A have been explored both in 
humans and a newly developed murine model for haemophilia A. Ultimately, a 
combination of these two approaches will help to identify candidate genes and treatment-
related factors that are involved in inhibitor development in patients with haemophilia A. 
At the same time, it should be emphasized that despite regular treatment the majority of 
haemophilia A patients do not mount an immune response to factor VIII. Little information 
is present on (genetic and non-genetic) determinants that prevent immune responses to 
intravenously administered factor VIII in this group of patients. Clearly, this is an area of 
interest that given the availability of well-characterized cohorts of patients with identical 
genetic defects in the factor VIII gene should be actively pursued.  
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The X-linked bleeding disorder haemophilia A is due to a deficiency or functional defect of 
coagulation factor VIII. The bleeding tendency can be corrected by administration of factor 
VIII concentrates. A serious complication of factor VIII replacement therapy is the 
development of anti-factor VIII antibodies (inhibitors) that neutralize factor VIII activity. In 
recent years, the epitope-specifities and the inhibitory mechanisms of factor VIII inhibitors 
have gained increasing interest. The generation of factor VIII knock-out mice has opened 
the possibility of studying the immunobiology of inhibitor formation in murine models of 
haemophilia A. In spite of these recent developments however, the immunological 
mechanisms underlying the anti-factor VIII immune response have remained poorly 
understood so far. Most of our current knowledge is based on studies on inhibitor formation 
in the severe form of haemophilia. However, inhibitors also occur in patients with mild 
haemophilia A, in particular after a period of extensive factor VIII replacement therapy. 
These patients differ from severe haemophiliacs in that they have low levels of circulating 
factor VIII activity (5-25% of normal). The presence of endogenous factor VIII may have 
major impact on the immune response to exogenous factor VIII during replacement 
therapy.  The studies presented in this thesis were performed to obtain a better 
understanding of the immunobiology of inhibitor development in mild haemophilia A.  
In the introduction (chapter 1), recent studies on the immunobiology of factor VIII 
inhibitors in haemophilia A patients are summarized and discussed. While factor VIII is a 
large protein comprising multiple domains (A1-A2-B-A3-C1-C2), the majority of factor 
VIII inhibitors bind to a few restricted regions in the A2, A3 and C2 domain and their 
inhibitory mechanism is well characterized. Several studies have addressed the T cell 
dependence of the immune response to factor VIII. Recent studies in a murine model for 
severe haemophilia A suggest that inhibition of T cell responses by co-stimulatory blockade 
provides a potentially promising approach for treatment and/or prevention of inhibitor 
formation. 
We have characterized the anti-factor VIII antibodies in patients with mild 
haemophilia A employing phage display technology. In chapter 2, anti-C2 antibodies were 
isolated and characterized from the repertoire of a mild haemophilia A patient. Our results 
provide evidence for the presence of two classes of anti-C2 antibodies that recognize 
distinct antigenic sites in factor VIII. The characteristics of the anti-C2 antibodies were 
further analysed in chapter 3, and compared to the epitopes of previously described murine 
monoclonal antibodies. The first class of anti-C2 antibodies bind to the epitope defined by 
monoclonal antibody ESH4 and these antibodies are encoded by germline gene segment 
DP-5 (1-24). The second class of antibodies bind to the epitope defined by monoclonal 
antibody CLB-CAg 117. Antibodies belonging to this second class of antibodies were also 
isolated from a different patient with mild haemophilia A (chapter 4). The VH gene 
segment usage of the antibodies directed at the epitope defined by CLB-CAg 117 is less 
restricted compared to the first class of anti-C2 antibodies. This second class of anti-C2 
antibodies is striking in that its CDR3 region, which is one of the antigen binding loops in 
the antibody molecule, is exceptionally large. Based on this property we argue that this 
class of anti-C2 antibodies originates from a pool of polyreactive human antibodies.  
In chapter 5, we describe the inhibitor development of a patient with mild 
haemophilia A caused by an Arg593 to Cys mutation. We have isolated and characterized 
anti-A2 antibodies using phage display and we have performed epitope-mapping studies of 
anti-factor VIII antibodies in plasma using immunoprecipitation analysis. We show that in 
this patient cross-reactive antibodies specific for a major epitope in the A2 domain of factor 
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VIII co-exist with a persisting level of antibodies exclusively recognizing wild-type (and 
not endogenous) factor VIII. The data presented in chapter 5 provide a possible explanation 
for anamnestic responses observed in patients with a history of inhibitor development. We 
propose that activation of a quiescent pool of memory B cells underlies the rise in inhibitor 
titre observed in haemophilia A patients with a history of inhibitor development.  
Chapter 6 describes the epitope specificities of anti-factor VIII antibodies in another 
patient from our cohort of mild haemophilia A patients with the Arg593 to Cys mutation. 
Results from this chapter and previous studies show that high responder patients with the 
Arg593 to Cys substitution develop inhibitory antibodies predominantly directed at the A2 
domain of factor VIII. This suggests that inhibitor formation proceeds via a common 
mechanism in these patients. The role of HLA class II alleles in inhibitor formation was 
investigated by HLA genotyping of 42 patients with the Arg593 to Cys mutation. We 
observed in three (out of four) high responder patients the presence of haplotype HLA-
DQB1*06, DRB1*13. In the low responder group, a weak association of haplotype HLA-
DQB1*05, DRB1*01 with inhibitor formation was observed. These data suggest a weak 
association between inhibitor development and HLA class II alleles in mild haemophilia A 
patients with the Arg593 to Cys mutation. 
In Chapter 7, we present the characteristics of a mouse transgenic for human factor 
VIII with the Arg593 to Cys mutation (hufVIII-R593C mouse). The anti-factor VIII immune 
response was analysed in transgenic hufVIII-R593C mice crossed with factor VIII-deficient 
mice (exon 16 knock out, or E-16 KO mice). Serial intravenous injections of human factor 
VIII do not evoke an immune response in hufVIII-R593C/E-16 KO mice. The introduction 
of the human factor VIII–R593C transgene renders the mice tolerant to human factor VIII. 
However, when hufVIII-R593C/E-16 KO mice were subcutaneously injected with factor 
VIII in the presence of an adjuvant, loss of tolerance to factor VIII was observed. The 
results of chapter 7 demonstrate that hufVIII-R593C/E-16 KO mice provide a valuable 
model for studies directed at the mechanisms underlying inhibitor development in 
haemophilia A. 
Finally, chapter 8 provides a general overview that discusses the implications of our 
findings. 
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Hemofilie A is een bloederziekte die wordt veroorzaakt door een tekort aan stollingsfactor 
VIII. Bloedingen bij patiënten met hemofilie A worden behandeld met het toedienen van 
factor VIII preparaten. Een ernstige en soms levensbedreigende complicatie bij deze 
behandeling is het ontstaan van antistoffen die de activiteit van factor VIII remmen. De 
afgelopen jaren hebben onderzoekers zich gericht op het ontdekken van de bindingsplaatsen  
van deze remmende antistoffen op factor VIII en ook de manier waarop antistoffen factor 
VIII kunnen remmen. De ontwikkeling van een factor VIII-deficiënte muis heeft het tevens 
mogelijk gemaakt om de immunologische aspecten van het ontstaan van remmende 
antistoffen tegen factor VIII te onderzoeken. Desondanks is onze kennis over het ontstaan 
van remmende antistoffen nog beperkt. De meeste studies zijn gericht op het ontstaan van 
remmende antistoffen bij patiënten met de ernstige vorm van hemofilie A maar remmende 
antistoffen komen soms ook bij milde hemofilie A patiënten voor. Remmende antistoffen 
kunnen bij milde hemofilie patiënten ontstaan na een periode van intensieve behandeling 
met factor VIII. Milde hemofilie A patiënten hebben een laag gehalte factor VIII in hun 
bloed (5-25 % ten opzichte van gezonde personen). De kleine hoeveelheid factor VIII in het 
bloed verklaart waarschijnlijk waarom het ontstaan van remmende antistoffen bij milde 
hemofilie patiënten minder vaak voorkomt vergeleken met ernstige hemofilie patiënten.  
Het onderzoek beschreven in dit proefschrift richt zich op de immunologische achtergrond 
van het ontstaan van remmende antistoffen tegen factor VIII bij milde hemofilie A 
patiënten. 
 In de inleiding (hoofdstuk 1) worden recente studies over het ontstaan van remmende 
antistoffen bij hemofilie A patiënten beschreven. Factor VIII is een groot eiwit en is 
opgebouwd uit verschillende domeinen (A1-A2-B-A3-C1-C2). Het is echter gebleken dat 
remmende antistoffen maar op een beperkt aantal plaatsen aan factor VIII binden (A2, A3 
en C2 domein) en de manier waarop antistoffen de functie van factor VIII remmen is 
aangetoond. Andere onderzoekers hebben in een diermodel voor hemofilie A aangetoond 
dat de remming van de anti-factor VIII T cel response wellicht een mogelijkheid biedt om 
antistof ontwikkeling te voorkomen. 
Met behulp van de faag display techniek worden remmende antistoffen tegen factor 
VIII geïsoleerd uit het gehele antistof repertoire van patiënten. In hoofdstuk 2 wordt de 
isolatie van  remmende anti-C2 antistoffen van een patiënt met milde hemofilie A 
beschreven. De resultaten wijzen erop dat er twee groepen van anti-C2 antistoffen zijn die 
op verschillende plaatsen aan factor VIII binden. De eigenschappen van de anti-C2 
antistoffen worden verder geanalyseerd en vergeleken met monoklonale muizen antistoffen  
in hoofdstuk 3.  Antistoffen in de eerste groep hebben dezelfde bindingsplaats als de 
monoklonale antistof ESH4 en de VH domeinen van deze antistoffen zijn afkomstig van 
kiemlijn gen segment DP-5 (1-24). Antistoffen in de tweede groep hebben dezelfde 
bindingsplaats als de monoklonale antistof CLB-CAg 117. Antistoffen behorende bij deze 
tweede groep werden ook geïsoleerd uit het antistof repertoire van een andere milde 
hemofilie A patiënt (hoofdstuk 4). Het VH domein van deze groep antistoffen is niet 
afkomstig van één specifiek kiemlijn gen segment maar van verschillende gen segmenten. 
Een opvallende eigenschap van deze antistoffen is dat ze een uitzonderlijk lang CDR3 
gebied bevatten. Deze laatste eigenschap doet vermoeden dat anti-C2 antistoffen ontstaan 
uit poly-reactieve antistoffen. 
In hoofdstuk 5 wordt het ontstaan van remmende antistoffen beschreven bij een milde 
hemofilie A patiënt. Bij deze patiënt is een Arg593- Cys substitutie in het A2 domein van 
factor VIII de oorzaak van milde hemofilie A. Met behulp van de faag display techniek 
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werden anti-A2 antistoffen geïsoleerd en verder werden de anti-factor VIII antistoffen die 
aanwezig waren in het bloed van de patiënt gekarakteriseerd. De resultaten van hoofdstuk 5 
geven een mogelijke verklaring voor de snelle ontwikkeling van remmende antistoffen bij 
patiënten die al eerder remmende antistoffen in hun bloed hadden.  
Hoofdstuk 6 beschrijft de karakterisering van anti-factor VIII antistoffen in een andere 
milde patiënt met de Arg593- Cys mutatie.  Resultaten van deze analyse en resultaten van 
andere onderzoekers wijzen erop dat patiënten die deze mutatie hebben en die een hoge 
antistof titer ontwikkelen, remmende antistoffen ontwikkelen die binden aan het A2 
domein. Deze bevinding suggereert dat de ontwikkeling van remmende antistoffen bij 
patiënten  met de Arg593- Cys substitutie op dezelfde manier gebeurd. De invloed van HLA 
klasse II allelen op de ontwikkeling van remmende antistoffen werd onderzocht in een grote 
groep milde hemofilie patiënten met de Arg593- Cys mutatie. Bij drie (van de vier) patiënten 
met een hoge antistof titer werd haplotype HLA-DQB1*06, DRB1*13 gevonden en bij 
patiënten met een lage antistof titer werd een zwakke associatie gevonden met haplotype 
HLA-DQB1*05, DRB1*01. De gegevens van de HLA-typering suggereren een zwakke 
associatie van HLA genen met het ontstaan van remmende antistoffen bij deze groep van 
milde hemofilie patiënten. 
De karakterisering van een muis transgeen voor humaan factor VIII met de Arg593- 
Cys substitutie (hufVIII-R593C muis) wordt in hoofdstuk 7 beschreven. Het ontstaan van 
anti-factor VIII antistoffen werd geanalyseerd in transgene hufVIII-R593C muizen gekruist 
met factor VIII-deficiënte muizen (exon 16 knock-out, of E-16 KO muizen). Intraveneuze 
injecties met (humaan) factor VIII geven geen antistof ontwikkeling in de hufVIII-
R593C/E-16 KO muizen. Dit geeft aan dat de transgene muis tolerant is voor humaan factor 
VIII. Deze tolerantie wordt doorbroken wanneer de injectie subcutaan worden toegediend 
en in aanwezigheid van Freund's adjuvant. Deze resultaten geven aan dat de hufVIII-
R593C/E-16 KO muis een waardevol instrument zal zijn in verder onderzoek naar het 
ontstaan van remmende antistoffen bij hemofilie A patiënten. 
 Hoofdstuk 8 is een algemene discussie over het onderzoek beschreven in dit 
proefschrift. 
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